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Abstract
Diseases spread by the Aedes genus of mosquitoes are some of the fastest growing and
fastest spreading viral pathogens in the world. Large dengue virus (DENV) epidemics
have emerged in Fiji since the Second World War and there was widespread transmission
of Zika virus (ZIKV) throughout the Pacific between 2013 and 2017. However, very
few ZIKV cases were confirmed in Fiji. I conducted a serological survey in Fiji in 2017
and used these serological data, combined with mathematical modelling, to analyse
transmission dynamics of arboviruses in Fiji.
I found evidence for ZIKV circulation in Fiji between 2013 and 2015 followed by low
ZIKV seroprevalence in 2017. I used paired serum samples to analyse the immunological
response to ZIKV following outbreaks in Fiji and French Polynesia and found that
neutralising antibodies declined in adults within two years of the outbreak in each
country. I combined serological data with surveillance and molecular data to model
unobserved ZIKV transmission and compare ZIKV and DENV transmission dynamics
in Fiji. I found that the introduction time of a virus in Fiji could explain different
transmission dynamics and concluded that ZIKV was likely introduced to Fiji in late
2014.
I found high seroprevalence for all four DENV serotypes. I used a mathematical model
of DENV transmission to analyse a DENV outbreak in 2017 to predict the duration and
peak of the outbreak in real-time. I found that jointly fitting the model to a historic
outbreak as well as the emerging outbreak improved the accuracy of the predictions
from the model.
ii
Mathematical Modelling of Arbovirus Outbreak Dynamics in Fiji and the Wider Pacific
Overall, I combined multiple data sources with mathematical modelling to reveal a
diverse range of outbreak dynamics and serological responses to outbreaks of closely
related viruses in the same location. I found that ZIKV and DENV do not necessarily
generate a similar immune response in the same population and that both can cause
low level multi-year outbreaks as well as large single season epidemics. Despite these
challenges, mathematical modelling can improve our understanding of arbovirus out-
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Diseases spread by the Aedes genus of mosquitoes are responsible for millions of viral
infections globally (James et al., 2018). This doctoral thesis focuses on dengue virus
(DENV) and Zika virus (ZIKV) which are two viruses that share the same primary
vector of transmission, the Aedes aegypti mosquito. The public health burden of DENV
and ZIKV is increasing annually as temperatures increase and the viable range of Aedes
mosquitoes expands (Kraemer et al., 2019). The devastating impact of these arboviruses
means that more needs to be understood about how these viruses transmit.
This PhD thesis investigates the transmission dynamics of DENV, ZIKV and other
related arboviruses in Fiji and the wider Pacific. This thesis describes a population-
representative longitudinal serological data collection study I led in Fiji in 2017. These
data have been used to understand serological dynamics following arbovirus outbreaks
and, combined with mathematical modelling, I have developed transmission dynamic
models for ZIKV and DENV in Fiji. The overall aims of this research are (i) to improve
understanding of population immune dynamics following arbovirus outbreaks and (ii)
identify the determinants of arbovirus transmission dynamics in island outbreaks. This
introduction will introduce the three main topics in the thesis title in turn: ‘arbovirus
outbreaks’, ‘Fiji and the wider Pacific’ and ‘mathematical modelling’.
1.1.1 Dengue virus and Zika virus outbreaks
DENV and ZIKV are two closely related members of the virus family Flaviviridae,
genus flavivirus. Both are arboviruses, a contraction of arthropod-borne viruses, and
therefore exist in nature because of transmission between a susceptible vertebrate host
– in this case, humans – and a hematophagous arthropod – in this case, mosquitoes
(Gubler, 1998; Musso and Gubler, 2016).
ZIKV is a positive-sense, single-stranded RNA virus that can cause mild, acute febrile
illness in humans (Musso and Gubler, 2016). The flavivirus ZIKV was first isolated
in a sentinel Rhesus Macaque in the Zika forest, near the East African Virus Research
2
Mathematical Modelling of Arbovirus Outbreak Dynamics in Fiji and the Wider Pacific
Institute in Entebbe, Uganda in 1947 (Dick, 1952). The first phylogenetic study of ZIKV
based on the full genome found two distinct lineages, African and Asian. Haddow et al.
(2012), found evidence that the ZIKV that caused outbreaks in the Pacific was the
Asian lineage.
DENV is another flavivirus and has four antigenically distinct serotypes. DENV-1
was first isolated in 1943 in Japan (Hotta, 1952) and 1945 in Calcutta (Sabin and
Walter Schlesinger, 1945), and the first full sequence was published in 1987 (Mason
et al., 1987). DENV-2 was first isolated in Trinidad in 1954 (Anderson et al., 1956)
and the full sequence published in 1988 (Hahn et al., 1988). DENV-3 was isolated
and sequenced in 1963 and 1988 respectively (Osatomi et al., 1988; Russell et al.,
1966). Finally, DENV-4 was isolated in 1981 and sequenced in 1987 (Lanciotti et al.,
1997; Mackow et al., 1987). There is considerable genetic variation between these
serotypes. The genomes of the four DENV serotypes share approximately 60% sequence
identity (Blok, 1985; Holmes and Burch, 2000; Yap et al., 2007). Even within serotypes,
distinct genotypes have been identified (Rico-Hesse, 1990) and the serotypes are not
antigenically homogeneous (Katzelnick et al., 2015). Despite this genetic variation the
disease and clinical symptoms caused by infection with any serotype are consistent.
Virus infection and vectors
The primary route of transmission of ZIKV and DENV is through the bite of an infected
female Aedes mosquitoes but other transmission routes are possible (Epelboin et al.,
2017). Other mosquito species, including from genera Anopheles and Mansonia, carried
detectable ZIKV in Senegal in 2011 (Diallo et al., 2014). Similarly, DENV is transmitted
to humans by the Aedes genus of mosquitoes (Halstead, 2008; Simmons et al., 2012).
The main mosquito species for ZIKV and DENV transmission in Fiji and the wider
Pacific is Aedes aegypti because it is an urban-adapted mosquito and thrives in close
proximity to humans (Gubler, 1998). Aedes aegypti are day-biting mosquitoes and
propagate when the female mosquito lays eggs in standing water, often near human-
inhabited dwellings (Gubler, 1987; Kraemer et al., 2015). Transmission of ZIKV and
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DENV is almost always seasonal and is affected by temperature and rainfall. Trans-
mission increases in warmer and wetter seasons (Halstead, 2008). Notable effects of
increased temperature are the shortening of the extrinsic incubation period and in-
creased biting rate (Mordecai et al., 2017). Aedes aegypti mosquitoes are the most
efficient arbovirus vector in Fiji. However, there are 26 known species of mosquitoes
in Fiji of which several are recognised as vectors of DENV including Aedes albopictus,
Aedes polynesiensis and Aedes pseudoscutellaris (Prakash et al., 2001).
ZIKV virus can also persist in semen and there are reports of sexual transmission of
ZIKV (Foy et al., 2011; Musso et al., 2015a). There is also evidence of perinatal trans-
mission of ZIKV from mother to child and through transfusion of infected blood (Musso
et al., 2014). The evidence on transmission through breastfeeding is not conclusive (Colt
et al., 2016). Mosquito-borne transmission remains the primary route of transmission
(Althaus and Low, 2016; Yakob et al., 2016).
Disease burden and epidemiology
Between 1947 and 2007 there were only 14 documented cases of ZIKV infection in
humans. The first ZIKV epidemic was recorded in the Yap islands of the Federated
States of Micronesia in 2007 (Duffy et al., 2009) and outbreaks followed across the
Pacific from 2013 (Baud et al., 2017; Musso and Gubler, 2016) then the Americas where
over 750,000 cases were confirmed or suspected (Pan American Health Organization,
2018b).
DENV virus outbreaks have a longer recorded history and are ubiquitous in tropical
regions where Aedes species of mosquitoes thrive. An estimated 2.5 billion people live
in DENV endemic countries (World Health Organisation, 2009). DENV-like epidemics
have been recorded for centuries (Henchal and Putnak, 1990) and DENV incidence has
increased 30-fold since the middle of the 20th century (World Health Organisation,
2009). This rapid increase in transmission is attributed to a combination of increasing
urbanisation within tropical countries, increased travel between countries and ineffective
control strategies (Simmons et al., 2012). Another key factor in the increase of DENV
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incidence is the expanding geographical range of Aedes mosquitoes because of increasing
global temperatures, attributed to climate change (Messina et al., 2014).
In 2009, the World Health Organisation (WHO) reported an estimated annual incidence
of DENV of 50-100 million (Rigau-Pérez et al., 1998; World Health Organisation, 2009).
Over the past decade, methods to estimate and map the annual incidence of DENV have
improved. Bhatt et al. (2013), estimated that there were 390 million DENV infections
per year in 2013. This estimate was based on risk maps which have since been updated
with global climate projections (Messina et al., 2019). The authors estimate that, in
2015, approximately half the world’s population lived in areas that are environmentally
suitable for DENV transmission and by 2080 this will increase to 62% of the world’s
population.
Clinical presentation and complications
The first clinical description of ZIKV is from a human challenge study conducted in
1956 and the patient reported a fever and slight headache (McFadzean and Tsang,
1956). During the first ZIKV epidemics in Yap and French Polynesia the most common
clinical symptoms reported were fever, rash, arthritis and/or arthralgia and/or myalgia,
conjunctivitis and fatigue (Musso and Gubler, 2016).
Analysis of blood samples after the French Polynesia outbreak estimated that 50-66% of
the population experienced a ZIKV infection (Aubry et al., 2015). During the outbreak
an estimated 11.5% of the population reported with symptoms (Musso et al., 2014),
which suggests that approximately 10-20% of ZIKV infections were symptomatic dur-
ing this outbreak. The proportion of asymptomatic infections is likely to be highly
dependent on setting due to the variety of laboratory tests used for case definition and
cross-reactivity in serum samples from variable levels of other circulating flaviviruses.
A systematic review of the prevalence of asymptomatic ZIKV infections found that a
pooled estimate would not be robust due to the large heterogeneity in estimates, which
ranged from 29% to 82% (Haby et al., 2018). Causes for this heterogeneity could include
the representativeness of sampled individuals, different case definitions and different age
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structures in studied populations (Burger-Calderon et al., 2020; Haby et al., 2018).
ZIKV can also cause severe neurological and neonatal complications. Microcephaly is a
severe congenital malformation in neonates where the head circumference is smaller than
normal because the brain has not developed properly. In Brazil there was evidence that
an increase in microcephaly cases was causally associated with ZIKV (Schuler-Faccini
et al., 2016) and a study of babies born during the ZIKV epidemic found that 14%
had severe developmental problems (Elisabeth Lopes Moreira et al., 2018). In French
Polynesia, ZIKV infection in the first trimester dramatically increased the rate of micro-
cephaly cases (Cauchemez et al., 2016). Another neurological complication potentially
associated with ZIKV is Guillain-Barré syndrome (GBS), an autoimmune disease caus-
ing acute, or subacute flaccid paralysis. No clear etiologies were found for a cluster of
nine GBS cases in Fiji in 2014 (Pastula et al., 2016). However, a larger cluster of 42
GBS cases during the French Polynesia outbreak was associated with the circulating
ZIKV (Cao-Lormeau et al., 2016). A systematic review of evidence was conducted by
Krauer et al. (2017), and concluded that ZIKV is a cause of congenital brain abnormal-
ities including microcephaly and that ZIKV is a trigger for, but insufficient to cause,
GBS.
DENV infection leads to a wide range of clinical presentations. The majority of DENV
infections are subclinical (Gubler, 1998) and 300 million of the estimated 390 million
annual infections are subclinical or mildly symptomatic (Bhatt et al., 2013). There
is strong evidence that human hosts with asymptomatic infection can still transmit
DENV to mosquitoes (Duong et al., 2015).
In those that become symptomatic, these symptoms follow an incubation period of 3-7
days. Symptom onset after the incubation period is acute, typically a fever accompa-
nied by headache (Henchal and Putnak, 1990; Rigau-Pérez et al., 1998). A generalised
muscular rash may be seen during the first 1-2 days of fever, followed by anorexia,
nausea and vomiting and the fever typically persists for 4-6 days (Henchal and Putnak,
1990). A small proportion of patients will progress to a critical phase that results in the
severe form of the disease, dengue hemorrhagic fever (DHF) (Gubler, 1998; Rigau-Pérez
et al., 1998; Stephenson, 2005).
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Non-pharmaceutical interventions
The most common method to attempt to reduce the burden of these arboviruses is
through management of the main vector, Aedes mosquitoes. The increase of DENV
transmission and the emergence of a ZIKV pandemic is evidence that current control
strategies are insufficient to slow the spread of these arboviruses. However, they re-
main the most effective means of control until a vaccine becomes available. Integrated
vector management (IVM) is “a rational decision-making process for the optimal use
of resources for vector control” and recommended by WHO (Pan American Health
Organization, 2018a; World Health Organisation, 2009). Strategies for controlling the
Aedes aegypti population can be broadly split into three categories: strategies to stop
mosquito propagation, strategies to kill adult mosquitoes and strategies to change in-
dividual human behaviour and risk of exposure.
Environmental management is a principal strategy to stop mosquito propagation through
the elimination of non-essential containers that provide larval habitats for Aedes mosquitoes
(Buhler et al., 2019). Long-term strategies may include improved sanitation and water
access, which would remove the need for water tanks at dwellings. In the short-term
it is often the physical removal of breeding sites and collection of waste (Vanlerberghe
et al., 2009). Another strategy to stop mosquito propagation is larviciding, chemical
treatment of potential breeding sites to kill mosquito larvae (Kroeger et al., 2006). The
WHO instructions state that this is to be considered complimentary to environmental
management, not a primary means of reducing mosquito propagation.
A second technique for reducing mosquito density is adulticides, which are insecticides
that are targeted to kill adult mosquitoes. These can be applied as either residual
surface treatments or as space treatments, fogging areas with adulticide to reduce adult
mosquito density. Residual surface application is challenging with Aedes aegypti since
these female mosquitoes lay a small number of eggs at multiple cites (Reiter, 2007,
2016). Space spraying is used in emergency situations and is designed to rapidly and




Finally, the interactions between humans and mosquitoes can be minimised through
guidance and individual behavioural change (Parks and Lloyd, 2004). In response to
the emergence of ZIKV in the Americas, the Pan-American Health Organisation out-
lined “personal prevention measures” to be promoted alongside IVM (Pan American
Health Organization, 2018a). These included sleeping under mosquito nets, wearing
long sleeves and application of repellents containing DEET, IR3535 or Icaridin (Pan
American Health Organization, 2018a).
The evidence for the effectiveness of IVM and personal prevention measures in reducing
arbovirus transmission is sparse and weak. Buhler et al. (2019), reviewed studies on
environmental management and found some evidence of effectiveness in reducing larval
and pupal densities of Aedes mosquitoes. Bowman et al. (2016), conducted a systematic
review of studies that evaluated vector control against Aedes aegypti or Aedes albopictus
for a period of at least three months. The authors concluded that their review and
analysis “demonstrate the remarkable paucity of reliable evidence for the effectiveness
of any dengue vector control method”. Heintze et al. (2007), similarly concluded that
“evidence that community-based dengue control programmes alone and in combination
with other control activities can enhance the effectiveness of dengue control programmes
is weak”. Reiter (2016), stated that “there are very few published studies and even
fewer studies that formally assess the impact of existing insecticide-based strategies
on dengue”. Studies have even shown that vector control can create a false sense of
security that exacerbates transmission (Bouzid et al., 2016).
Investigating the impact of vector control on epidemics is challenging because out-
breaks can end due to a combination of several factors, including population immunity,
seasonal factors and human movement. Until the point that future pharmaceutical
interventions prove effective, and several are being developed (Pang et al., 2017; Yakob
et al., 2016), the effectiveness of vector control in the prevention of DENV, ZIKV and
related arbovirus transmission remains a major gap in our understanding.
Finally, a novel non-pharmaceutical intervention against arbovirus transmission is the
use of Wolbachia in mosquitoes which blocks the transmission of many important human
pathogens. There is research that shows introduction of Wolbachia in a mosquito
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population reduces R0 by 66-75% (Ferguson et al., 2015). Ndii et al. (2015), show that
the effect of Wolbachia on DENV transmission can be via multiple routes such as a
reduction in lifespan and cytoplasmic incompatibility which gives Wolbachia carrying
females a competitive advantage in mating. Research also shows that this intervention
is effective against ZIKV transmission (Dutra et al., 2016). Introduction of Wolbachia
needs to be combined with a broader integrated vector control programme for their
release to be effective (Yakob et al., 2017).
Pharmaceutical interventions
There are no specific anti-viral treatments available for either DENV or ZIKV. There is
one licensed vaccine available for DENV, a recombinant, live-attenuated DENV vaccine
(Dengvaxia) that was approved in several countries in 2016. However, due to the
complexity in DENV pathogenicity, this vaccine is only recommended in specific settings
(Ferguson et al., 2016b; Flasche et al., 2016) and is not distributed in Fiji or other Pacific
countries studied in this doctoral project. There is no vaccine currently available for
ZIKV.
1.1.2 Diagnosis, serology and cross-reaction of DENV and ZIKV
Laboratory diagnosis of DENV or ZIKV can be performed either directly or indirectly.
Direct methods involve detection of viral components in serum. Indirect methods in-
volve detection of short-term immunoglobulin class M (IgM) or long-term immunoglob-
ulin class G (IgG) antibodies against the virus. The choice of method depends on
the duration of the illness in the patient with the suspected infection and affects the
sensitivity of the diagnosis (Peeling et al., 2010) (Figure 1.1). In the case of DENV,
during the febrile phase of infection viral nucleic acid can be detected by means of
reverse transcription polymerase chain reaction (RT-PCR). After the onset of illness,
the virus can be detected in serum, plasma, circulating blood cells and other tissues for
4–5 days (Gubler, 1998; World Health Organisation, 2009). Alternatively, detection of
the virus-expressed soluble nonstructural protein 1 (NS1) by means of enzyme-linked
9
Chapter 1. Introduction
immunosorbent assay (ELISA) or the lateral-flow rapid test is sufficient to confirm a
diagnosis of DENV (Simmons et al., 2012). The RT-PCR is very sensitive but NS1
detection by ELISA is less so with approximately 60 to 80% sensitivity in secondary
infections, but sensitivity exceeds 90% in primary infections (Simmons et al., 2012).
Diagnosis of ZIKV is also ideally performed with detection of viral nucleic acid by
RT-PCR. A rapid NS1 detection diagnostic test is not currently available (Musso and
Gubler, 2016). ZIKV is also detectable in saliva samples and filter papers spotted
with dried blood that can be shipped to reference laboratories if local facilities cannot
perform these diagnostic tests, as has been done in the Pacific (Musso and Gubler, 2016;














Figure 1.1: Antibody dynamics following suspected ZIKV or DENV infection (adapted from
Peeling et al. (2010)). The earliest opportunity to detect DENV is through reverse transcrip-
tion polymerase chain reaction to detect viral nucleic acid during the febrile phase of infection.
Non-structural protein 1 (NS1) antigen and short-term immunoglobulin class M (IgM) anti-
bodies are detectable with serology shortly after. Long-term antibodies immunoglobulin class
G (IgG) antibodies are detectable for the rest of the patient’s life
At the end of the acute phase of infection, serology is the method of choice for diagnosis
of DENV (Gubler, 1998; Innis et al., 1989; Peeling et al., 2010). Antibody response
to infection is not consistent and depends on the immune status of the host includ-
ing previous flavivirus infections and vaccinations against tick-borne encephalitis virus
(TBEV), Japanese encephalitis virus (JEV) and yellow fever virus (YFV) (Mansfield
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et al., 2011). IgM are the first antibodies to appear following DENV infection and are
detectable in 50% of patients by days 3-5 after onset of illness, increasing to 80% by
day 5 and 99% by day 10 (Innis et al., 1989; World Health Organisation, 2009).
Serological diagnosis can be used for ZIKV as well, as was done during the 2007 Yap
outbreak with IgG and IgM ZIKV ELISA. A post-outbreak review of diagnostic testing
for ZIKV found that IgM antibodies to ZIKV were detectable approximately 1 week
following infection. In over 80% of individuals however, IgM antibodies were still de-
tectable more than 2 months following infection. Using detection of IgM antibodies as
evidence of recent ZIKV infection could therefore be misleading since the individual
could have been infected several months prior to sample collection (Theel and Jane
Hata, 2018).
In Fiji, DENV outbreaks are confirmed through non-structural protein 1 (NS1) antigen
detection or IgM ELISA. This laboratory reporting switches to clinical-based report-
ing during outbreaks when laboratory capacity is exceeded (Kucharski et al., 2018).
Clinical-based reporting relies on a standard case definition for DENV. Clinical cases
are defined as suspected cases if they presented to health practitioners with rash and/or
mild fever and at least two of the following signs: conjunctivitis, arthralgia, or oedema
(Kucharski et al., 2018). ZIKV diagnosis of suspected cases in Fiji are performed at
Institut Louis Malardé in French Polynesia. Serum samples blotted on filter paper
cards and saliva samples collected on dry oral swabs from suspected cases are tested by
real-time RT-PCR for the presence of RNA from the four DENV serotypes, ZIKV and
chikungunya virus (CHIKV) (Aubry et al., 2012; Kama et al., 2019).
The consequences of cross-reaction between DENV and ZIKV
Cross-reactivity is the reaction between an antibody raised against one virus recognising
another virus. Cross-reactivity between flaviviruses has been well documented (Calisher
et al., 1989; Mansfield et al., 2011; Scott et al., 1983). The window to diagnose flavivirus
infection through detection of viraemia is short and is often missed so serological di-
agnosis is necessary. However, differential classification in serological diagnosis is more
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challenging because of cross-reactivity (Kerkhof et al., 2020). The main problem when
using serological detection – for either recent or historical flavivirus infection – is that
it increases the probability of a false positive result (Hirota et al., 2010). For example,
vaccination for another flavivirus, yellow fever virus, can result in false DENV positive
results by enzyme ELISA (Houghton-Triviño et al., 2008). It was apparent following
the ZIKV outbreak in Yap island in 2007 that cross-reaction could complicate ZIKV
diagnostics (Duffy et al., 2009; Lanciotti et al., 2008). Antibodies generated following
DENV and ZIKV infections are highly cross-reactive (Balmaseda et al., 2017; Musso
and Gubler, 2016; Priyamvada et al., 2016; Speer and Pierson, 2016; Van Meer et al.,
2017), which can affect results from commercially available test kits (Felix et al., 2017;
Kikuti et al., 2018). In the absence of a perfect diagnostic test, serological studies in
settings where flaviviruses co-circulate must be accompanied with sensitivity analyses
to validate findings from any one assay because of this cross-reactivity.
Cross-reactivity can complicate serological testing, but it can also lead to complex
immune responses to repeat infections. There is evidence that previous infection with
a DENV serotype or ZIKV can both suppress and enhance subsequent infection with
a heterologous DENV serotype or ZIKV. I will introduce the evidence of the impact of
cross-reactivity as follows: the effect of prior DENV infection on subsequent heterotypic
DENV infection, prior DENV infection on subsequent ZIKV infection, finally prior
ZIKV infection on subsequent DENV infection.
Human infection with one DENV serotype confers long-term immunity to that serotype
(Halstead, 1974; Simmons et al., 2012). It is well established that infection with a
single DENV serotype confers a strong cross-protective immunity against heterologous
serotypes but that this protection is temporary (months) (Montoya et al., 2013; Reich
et al., 2013; Sabin, 1952; Snow et al., 2014). Clapham et al. (2016), found that antibody
titres increased from convalescence to 6 months following DENV infection. After this
period of cross-protection prior DENV infection may be a significant risk factor for
more severe disease from a secondary heterotypic DENV infection (Burke et al., 1988;
Cummings et al., 2005; Dejnirattisai et al., 2010; Halstead et al., 1970; Kliks et al.,
1988; Simmons et al., 2012). This phenomenon – antibody-dependent enhancement
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(ADE) – is one in which pre-existing DENV antibodies bind to the virus particles but
are non-neutralising and subsequently enhance the growth of the virus. Salje et al.
(2018), characterised antibody dynamics in a cohort in Thailand and found that one
year after infection individuals with moderate antibody titres (≤ 1:40) were at much
greater risk of the more severe dengue hemorrhagic fever than those with high titres
(>1:40) or DENV näıve individuals. Post-secondary infections are rarely reported and
appear to reduce, but not eliminate, the risk of disease (Gibbons et al., 2007; Olkowski
et al., 2013; Wikramaratna et al., 2010).
Secondly, prior DENV infection could affect future ZIKV infection. ZIKV outbreaks
spread rapidly from 2013 in the Pacific and in the Americas which are both areas with
a high burden of DENV infection. Urgent research was therefore necessary to assess
whether prior DENV immunity would enhance the severity of ZIKV disease as it could
for heterotypic DENV infections. Experimental evidence demonstrated enhanced ZIKV
infection in the presence of DENV antibodies (Bardina et al., 2017; Dejnirattisai et al.,
2016; Paul et al., 2016; Priyamvada et al., 2016). However, other in vivo experiments
have shown no evidence that prior flavivirus immunity had a detrimental effect on
ZIKV infection (Castanha et al., 2016; McCracken et al., 2017; Pantoja et al., 2017).
Conversely, experimental evidence that a previous DENV infection can cross-neutralise
and protect from ZIKV infection has been supported in studies of longitudinal seroepi-
demiological cohorts. In Salvador, northeast Brazil, a cohort of 1436 urban residents
were followed and pre-existing high antibody titres to DENV were associated with re-
duced risk of ZIKV infection and symptoms (Rodriguez-Barraquer et al., 2019). Within
a large paediatric cohort in Nicaragua, prior DENV infection was protective against
ZIKV (Gordon et al., 2019). Montoya et al. (2018), analysed antibody dynamics in this
cohort with others from Latin America and Asia. The authors found that neutralising
antibody titres can distinguish ZIKV from the DENV serocomplex and did not enhance
ZIKV infection. Evidence from Brazil shows that multitypic DENV infection may pro-
tect from development of more severe ZIKV disease (Pedroso et al., 2019). These results
support a large body of experimental evidence (Barba-Spaeth et al., 2016; Swanstrom
et al., 2016; Wen et al., 2017). The duration of cross-neutralising antibodies from
DENV infection is less certain. It has also been shown in vitro that cross-neutralising
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antibodies are not present in the late DENV convalescent stage of infection (≥ 6 months
after infection) (Collins et al., 2017).
There is less evidence about the effect of ZIKV on subsequent DENV infection be-
cause the ZIKV epidemic was so recent. Models in nonhuman primates (NHP) have
demonstrated that cross-reactive antibodies generated from ZIKV infection enhanced
a subsequent DENV infection (George et al., 2017; Valiant et al., 2018). However, an-
other NHP model showed no evidence of enhanced DENV infection following ZIKV
(Pérez-Guzmán et al., 2019). It has been hypothesised that the DENV season following
the ZIKV epidemic in many locations across the Americas was less severe because of
protection from ZIKV (Borchering et al., 2019; Perez et al., 2019; Ribeiro et al., 2018).
Cross-reactivity between DENV and ZIKV is unquestionably a limitation in serological
studies. However, the impact it has on outbreak dynamics when both viruses can
circulate in the same location at the same time is less clear and needs further study
(Culshaw et al., 2017; Langerak et al., 2019). Fiji and the wider Pacific are locations
where such studies are appropriate because of the presence of Aedes aegypti mosquitoes
on many islands which can transmit both DENV and ZIKV.
1.1.3 Fiji and the wider Pacific
This doctoral project analysed data from two countries from the South Pacific: Fiji and
French Polynesia. Fiji is an island country in the South Pacific, situated approximately
2,000 kilometres northeast of New Zealand. The country is made up of over 330 islands,
approximately one third of which are permanently inhabited. It is an economically
developing country and is classified as “upper middle income” by the World Bank
(World Health Organisation Western Pacific Region, 2011).
There are two major islands in Fiji in terms of population and economic activity. Vanua
Levu, in the Northern Division, and Viti Levu which is split between the Central and
Western Divisions (Figure 1.2). Approximately 80% of the Fijian population of 884,887
people live in Central and Western Division. The capital city, Suva, is in the southeast
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Figure 1.2: Map of Divisions within Fiji
corner of Viti Levu and is home to 94,088 Fijians (Fiji Bureau of Statistics, 2018a).
French Polynesia is the other country with data presented in this doctoral project.
It is of particular interest because, like Fiji, it has a long history of DENV epidemics
(Teissier et al., 2020) and a recent ZIKV epidemic (Cao-Lormeau et al., 2014b). French
Polynesia is to the east of Fiji and the other side of the international date line. French
Polynesia is a collection of 118 dispersed islands split into five archipelagos. The largest
of these are the Society Islands, including French Polynesia’s largest island Tahiti and
capital city Pape’ete. The population of French Polynesia recorded in 2017 is smaller
than Fiji at 281,764 (United Nations, 2019).
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Age has been shown to be an important risk factor for the severity of DENV clinical
presentation since older people are more likely to have experienced DENV infection
even in endemic settings (Flasche et al., 2016; Simmons et al., 2012). The mean age
of a confirmed or suspected DENV-3 case during the 2013-14 epidemic was 27.7 years
old (IQR: 16-38) (Kucharski et al., 2018). Consideration of the age distribution of a
population is therefore important when studying arbovirus transmission. The median
age in the Fijian population as recorded in the 2017 census was 27.5 years and 20% of the
population are children younger than 10 (Fiji Bureau of Statistics, 2018b) (Figure 1.3).
The population in French Polynesia has fewer young children (15.7% of the population)
but similar levels of people aged over 50 (20.5% in French Polynesia and 19/3% in Fiji)



























Figure 1.3: Age pyramid of Fiji from census data collected in 2017 (Fiji Bureau of Statistics,
2018b)
Urbanisation is another important consideration in the study of DENV and ZIKV. The
primary vector of these flaviviruses, and therefore the burden of disease, are typically
concentrated in urban areas with dense populations. Fiji has seen increased urbanisa-
tion between censuses conducted in 2007 and 2017. The proportion of the population
living in urban areas increased from 50% in 2007 to 56% in 2017. The population
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Figure 1.4: Age pyramid of French Polynesia from census data collected in 2012 (Institut
de la statistique de la Polynésie française, 2020)
of Rewa province – which includes Suva – increased by 7% from 100,995 to 108,016
between 2007 and 2017 (Fiji Bureau of Statistics, 2018b). By contrast, the popula-
tion in French Polynesia is dispersed over five separate archipelagos with fewer urban
centres. However, the capital city Pape’ete is comparable to Suva, as each houses ap-
proximately 10% of that country’s total population (25,763 people in Pape’ete) (Institut
de la statistique de la Polynésie française, 2020).
Temperature is another critical factor in arbovirus transmission. Fiji and French Poly-
nesia are both tropical countries with warm climates that suit virus transmission by
Aedes mosquitoes (Mordecai et al., 2017; Nishiura et al., 2016a; Richard et al., 2016;
Roth et al., 2014). Average temperatures are very similar in both countries, at 26.4°C
in Fiji and 27°C in French Polynesia (Fiji Meteorological Service, 2017; Institut de la
statistique de la Polynésie française, 2020). However, French Polynesia is closer to the
equator and, as a result, temperature is less variable over a year compared to Fiji where




















Country Fiji French Polynesia
Figure 1.5: Average monthly temperature (°C) in Fiji and French Polynesia (Fiji Meteoro-
logical Service, 2017) (Institut de la statistique de la Polynésie française, 2020)
Arboviruses in the Pacific
Island populations are isolated and typically have smaller populations so are therefore
less likely to sustain endemic transmission (Black, 1966; Keeling and Grenfell, 1997).
This is especially true of diseases that have a seasonal pattern of transmission – such as
DENV and ZIKV – with a low-transmission period through which an epidemic cannot
easily persist. This generates a pattern of self-contained single serotype epidemics in
the South Pacific with reintroduction from outside sources after an interval period of
several years (Cao-Lormeau et al., 2014a). DENV circulation in Pacific island countries
and territories (PICTs) in the 20th century began with the first recorded major outbreak
of DENV-1 towards the end of the Second World War (Imrie et al., 2007; Rosen, 1958).
Decades later, there was a DENV-2 outbreak in 1971 (Maguire et al., 1974) which was
closely followed by DENV-1 in Fiji in 1975 (Reed et al., 1977) and DENV-4 in 1979 in
French Polynesia (Chungue et al., 1999).
A pattern emerged of a single large outbreak invading a country with no transmission
for several years afterwards. This pattern can be clearly seen in data from French
Polynesia between 1978 and 2014 that has been collated by Teissier et al. (2020) (Figure
1.6). The authors defined eight epidemic periods and six inter-epidemic periods over
the 35 year time frame. Multiple serotypes were reported in two of these epidemic
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periods but most were monotypic or primarily single-serotype outbreaks. This pattern
of intermittent epidemics is observable at the regional level as well. Following DENV-4
in 1979, the next large regional outbreak was in 1989-90 (Chungue et al., 1999; Fagbami
et al., 1995; Taleo et al., 2000). This was followed in 1996-1999 with DENV-2 cases in
French Polynesia (Deparis et al., 1998) and Fiji (Prakash et al., 2001).








Figure 1.6: Timing and serotype of DENV outbreaks in French Polynesia between 1978 and
2014, using data from Teissier et al. (2020)
Since 2000, DENV outbreaks have become more frequent (Kiedrzynski et al., 1996;
Singh et al., 2005). Taking Fiji as a case study, a large DENV-1 epidemic in 2001-04
(Singh et al., 2005) was followed by DENV-4 circulation in 2007 (Li et al., 2010; War-
rilow et al., 2012). DENV-3 then spread in 2013-2014 (Cao-Lormeau et al., 2014a) and
most recently, the Fiji Ministry of Health declared a DENV-2 outbreak in April 2017
(Fijivillage, 2017). Increased birth and immigration rates may be creating enough sus-
ceptible hosts for DENV to circulate every 3-4 years with a single serotype reappearing
every 10-12 years (Cao-Lormeau et al., 2014a). However, the relative contribution of
these causes remain poorly understood.
The first recorded outbreak of ZIKV occurred on the Pacific island of Yap, part of the
Federated States of Micronesia in 2007 (Duffy et al., 2009; Hayes, 2009). This was a
large and quick outbreak with an estimated 73% of the residents of Yap state infected
with ZIKV between April and July 2007 (Duffy et al., 2009). ZIKV next emerged in
French Polynesia in October 2013. The outbreak was short as well, lasting 21 weeks
and peaking at the end of February 2014 (Musso and Gubler, 2016). By the end of the
outbreak an estimated 11.5% of the population had ZIKV fever (Musso et al., 2014). A
serological survey conducted in 2015 in the general population estimated an infection
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rate of 50 to 66% (Aubry et al., 2015).
Following the French Polynesia outbreak ZIKV spread quickly through the Pacific
(Musso and Gubler, 2016; Roth et al., 2014). In 2014 ZIKV outbreaks were confirmed
in New Caledonia, Cook Islands and Easter Island. In New Caledonia, less than 1% of
the population reported as confirmed ZIKV compared to 11.5% in the French Polyne-
sia outbreak (Musso and Gubler, 2016; Musso et al., 2018). The cause of this smaller
outbreak is still unknown but could be related to mosquito species, different popula-
tions, or the lack of a “cold season” in French Polynesia (Musso and Gubler, 2016).
The outbreak in the Cook Islands was small, with 905 cases reported and there were
50 suspected ZIKV cases reported in Easter Islands (Musso and Gubler, 2016). In
2015 ZIKV continued to spread through the Pacific as local transmission of ZIKV was
confirmed in Vanuatu, Solomon Islands, Samoa and Fiji. DENV has spread in all of
these countries and there were reports of concurrent circulation of DENV, ZIKV and
chikungunya virus (CHIKV) throughout the Pacific (Roth et al., 2014).
It is probable that the virus spread from the Pacific Islands to Brazil with some evidence
from molecular data and phylogenetics that ZIKV was introduced to Brazil from French
Polynesia and Easter Island around the same time (Delatorre et al., 2018). Once ZIKV
emerged in northeast Brazil, likely introduced between August 2013 and April 2014
(Faria et al., 2016), it spread through the Americas and was declared a Public Health
Emergency of International Concern by WHO (World Health Organisation, 2016).
Disease monitoring in the Pacific was enhanced in 2010 with the launch of the Pacific
Syndromic Surveillance System (PSSS). This is a sentinel surveillance system with 121
sentinel surveillance sites across twenty-one countries in the Pacific that report weekly
on five syndromes: (i) diarrhoea, (ii) influenza-like illness, (iii) prolonged fever, (iv)
acute fever and rash, and (v) dengue-like illness (Craig et al., 2016). However, most
countries in the PSSS are small and adapting to emerging diseases can be challenging.
Craig et al. (2016), found that existing reporting on acute flaccid paralysis (AFP) for
Polio eradication programmes was insufficient for the identification of ZIKV emergence
in the Pacific.
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Arboviruses in Fiji
There have been regular outbreaks of DENV in Fiji since the virus emerged after World
War II (Kiedrzynski et al., 1996; Kucharski et al., 2018; Singh et al., 2005). Fiji has
regular epidemics but has no evidence of sustained endemic DENV transmission. Most
of these outbreaks record thousands of cases which is consistent with a large monotypic
epidemic. Such outbreaks can deplete the susceptible population and prevent any other
DENV serotype from emerging for half a decade, and the same serotype from emerging
for 10-12 years (Cao-Lormeau et al., 2014a). Figure 1.7 shows a schematic of reported
DENV outbreaks in Fiji since 1970 and demonstrates this pattern of intermittent mono-
typic epidemics.






DENV-1DENV-2DENV-4 DENV-4 DENV-3DENV-2 DENV-2
Figure 1.7: Timing and serotype of DENV outbreaks in Fiji between 1970 and 2017, using
data from Kucharski et al. (2018). Blue region highlights the main study period for this
doctoral project
Details on these outbreaks are shown in Table 1.1, adapted from Kucharski et al.
(2018) and demonstrate the diverse range of dynamics of these individual outbreaks,
with some very large outbreaks and some much smaller. There is a limited amount of
post-outbreak serological data to validate the size of these outbreaks in the population.
As reported elsewhere in the Pacific (Roth et al., 2014), there were concurrent outbreaks
of DENV, ZIKV and CHIKV between 2013 and 2018. This six-year window is the focus
of this doctoral project and includes four notable outbreaks of arboviruses in Fiji (Figure
1.8). Firstly a large DENV-3 outbreak in 2013-14 (Cao-Lormeau et al., 2014a). There
were a small number of confirmed locally-acquired ZIKV and CHIKV cases between
2015 and 2016 (Kama et al., 2019). Finally, a DENV-2 epidemic emerged in 2017
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Table 1.1: Reported arbovirus outbreaks in Fiji between 1930-2017. Adapted from Kucharski
et al. (2018)
Year Main virus Reported cases Seroprevalence Source
1930 ? Thousands (Maguire et al., 1971)
1944-5 DENV-1 Thousands (Reed et al., 1977)
1971-3 DENV-2 3,413 25%* (Maguire et al., 1974)
1974-5 DENV-1 16,203 (Reed et al., 1977)
1980 DENV-4 127 (Fagbami et al., 1995)
1981 DENV-1 18 (Kiedrzynski et al., 1996)
1982 DENV-2 676 (Kiedrzynski et al., 1996)
1984-6 DENV-? 490 (Fagbami et al., 1995)
1988 DENV-? 22 (Fagbami et al., 1995)
1989-90 DENV-1° 3,686 54%* (Fagbami et al., 1995; Waterman
et al., 1993)
1997-8 DENV-2 24,780 (World Health Organisation,
2015)
2001-3 DENV-1 ? (Halstead, 2008)
2008 DENV-4 1,306 (Pacnet Report, 2008; ProMED-
mail, 2008)
2013-14 DENV-3 25,496 53.2%** (Kucharski et al., 2018)
2015-17 ZIKV 16** 21.9%** (Kama et al., 2019)
2015-17 CHIKV 93** (Aubry et al., 2019; Kama et al.,
2019)
2017 DENV-2 755* Fiji MOH data
* Suva
** Central Division
°There is also evidence of DENV-3 circulation during this period (Singh et al., 2005) .
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(Fijivillage, 2017).
Previous serological surveys in Fiji
This thesis uses data from two previous serological surveys conducted in Fiji. In 2013,
Watson et al. (2017), collected 1,781 samples from across mainland Fiji; 695 of them
in Central Division. Watson et al. (2017), characterised the epidemiology of typhoid
fever and Lau et al. (2016), used the samples to analyse risk factors for leptospirosis
transmission in Fiji. The authors conducted a representative, clustered, cross-sectional
seroepidemiological survey of the two main Fijian islands. A follow-up study was con-
ducted in November 2015 in Central Division after the DENV-3 epidemic. 333 of the
same participants were resampled in 2015 to collect a data set of pre- and post-outbreak
serology (Kama et al., 2019; Kucharski et al., 2018).
Data from these serological surveys showed evidence of increased DENV-3 infections,
concentrated in DENV näıve children, as expected given the large reported outbreak.
Analysis of serology also showed that a large proportion of the population in Fiji had
seroconverted to ZIKV between 2013 and 2015, which is before cases were reported
(Figure 1.9). Kama et al. (2019), found evidence of undetected circulation of ZIKV
and CHIKV in Fiji using these data.
1.1.4 Mathematical modelling of arboviruses
Mathematical modelling of an infectious disease – shortened to ‘mathematical mod-
elling’ from this point – is an abstract simplification of reality that uses mathematical
language to describe the behaviour of a disease transmission system. The dynamics
of disease transmission can be complex at an individual level and fields of study such
as medicine, genomics and microbiology inform our understanding of these dynam-
ics. At a population level, however, the dynamics often conform to simple processes
which can be modelled mathematically. These models of infectious diseases include the
mechanisms driving transmission in a population and can therefore be differentiated
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Figure 1.8: Recent arbovirus outbreaks in Fiji between 2013 and 2018. Reported cases for
DENV-3. Confirmed cases for DENV-1, DENV-2, DENV-4, CHIKV and ZIKV
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DENV3 ZIKV


















Figure 1.9: Change in DENV-3 and ZIKV seroprevalence in Fiji between 2013 and 2015.
Circles show estimated seroprevalence for ZIKV and DENV-3 in the corresponding age group.
Vertical lines show 95% confidence intervals. The majority of the increase in seroprevalence
between 2013 and 2015 was in the youngest age group, but for ZIKV there was an increase in
seroprevalence across all age groups
from ‘statistical models’ that describe the relationship between observed quantities and
independent variables, common across the study of non-communicable diseases. By in-
cluding these mechanisms explicitly in the model we can ask more interesting questions
about an epidemic: When did the disease emerge? How quickly did it spread? When
did transmission peak, and why did it end?
Models are simplified representations of reality and as such there is trade-off between
the ‘detail’ and ‘transparency’ of the model. A model is usually simplified by making
more assumptions and omitting details that are deemed unimportant. This can make
the model easier to understand but conclusions from this model are only valid if these
assumptions hold. The choice of model complexity and the balance of this trade-off
will depend on the purpose of the model and what hypothesis is being tested.
A popular mathematical modelling approach is to use compartmental models. A popu-
lation is divided up into compartments based on their infectious status. An example of
compartmental modelling was first proposed by Ross and Hudson (Ross and Hudson,
1917) and expanded in the 1920s and 30s by Kermack and McKendrick (Kermack et al.,
1927, 1932, 1933). For a disease that confers lifelong immunity, a basic compartmental
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model has three compartments: all individuals in a population (N) are either suscep-
tible (S) to the virus, are infectious (I), or have recovered (R). The rate of transition
between these compartments determines the dynamics of an epidemic in this model,
which is typically expressed as a system of ordinary differential equations (Equations
1.1-1.3). These equations express the change in compartments for each time step t
(where t is small).
dS
dt









Individuals move between the S and I compartment following infection at a rate known
as the ‘force of infection’ (λ). The force of infection is the product of transmission prob-




remain infectious for a fixed period of time so transition to the R compartment occurs at
a constant rate (γ) (Figure 1.10). This simple model makes several assumptions about
how the disease spreads. Everyone mixes evenly and therefore has an equal probability




Figure 1.10: Schematic of compartmental framework of an SIR model
The parameters in this model can be used to calculate important epidemiological quanti-
ties. The basic reproduction number (R0) is the average number of secondary infections
generated by a typical infectious individual in an entirely susceptible population. In
this basic SIR model R0 is equal to the ratio
β
γ
(Keeling and Rohani, 2011).
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DENV and ZIKV are vector-borne diseases, viruses that are transmitted between hu-
mans by vectors. In the case of DENV and ZIKV the intermediary host is a mosquito.
Modelling of vector-borne diseases is based on the work of Ronald Ross studying malaria
in the early 20th century (Ross, 1908, 1911). After the Second World War George Mac-
donald continued the work of Ross and focused on applied theory to support the WHO
Global Malaria Eradication Programme (Macdonald, 1956a,b, 1957; Macdonald and
Goeckel, 1964; WHO, 1956). This class of models has been refined but still carries a
common set of assumptions: mosquito bites are distributed randomly and evenly among
single vertebrate host populations, mosquito mortality is independent of age, both the
pathogen latent period and fraction of mosquitoes that blood feed on the host are con-
stant and there is only one mosquito vector species (Smith et al., 2012). A systematic
review conducted in 2013 found that even recent models were still largely dependent
on the same assumptions set out in Ross-Macdonald models (Reiner et al., 2013).
Compartmental modelling of DENV has a long history (Andraud et al., 2012; Reiner
et al., 2013). Newton and Reiter (1992), produced a compartment vector-host model
to estimate the R0 of DENV as 1.9. Other early modelling estimates for the DENV
R0 were 1.33 from serological data in Mexico (Koopman et al., 1991) and 2.03 from an
analysis of the early growth of a 1990-91 epidemic in Brazil (Marques et al., 1994). By
1995 researchers were comparing model outputs with data to validate their simulations
(Focks et al., 1995). Esteva and Vargas (1998) developed a compartmental model for
DENV to define the global stability of the endemic equilibrium and then extended it
to include demographic changes (Esteva and Vargas, 1999).
As these models developed they were targeted at increasingly complex areas of DENV
epidemiology. Compartmental models that included multiple serotypes were developed
to analyse the effects of ADE and cross-protection between DENV serotypes. Ferguson
et al. (1999), developed a DENV model with multiple serotypes to demonstrate that
ADE acts to generate complex and persistent cyclical or chaotic epidemic behaviour.
Cummings et al. (2005), used a two-serotype model to describe the effect of ADE on
the evolutionary dynamics of DENV. Adams et al. (2006), used a compartmental two-
serotype model for DENV transmission in Bangkok and found evidence that infection
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with one serotype must be moderately cross-protective to recreate the observed epi-
demiological data. The importance of a temporary period of cross-serotype protection
have been shown in models of DENV compared to data from Thailand (Nagao and
Koelle, 2008; Wearing and Rohani, 2006). DENV models have advanced to the point
of informing pivotal public health planning. The proven efficacy in phase III trials of
a DENV vaccine, Dengvaxia, led to the licensing of the vaccine in several countries.
Dynamic modelling of DENV and the effect of the vaccine informed WHO guidance
on optimal use of the vaccine only in settings with high DENV endemicity (Ferguson
et al., 2016b; Flasche et al., 2016).
Mathematical models can then be fitted to available data from infectious disease out-
breaks. Such data can include surveillance data on the number, location and timing
of cases as well as serological data on the proportion people infected. Outputs from
mathematical models can then be formally compared to observed data under the as-
sumption that these data follow a defined statistical distribution. Parameters from
the model can then be estimated and compared between diseases, between different
outbreaks and between locations. Further details are available in Chapter 2.
Modelling island outbreaks and models of DENV and ZIKV
Islands and remote settings have been a considerable source for epidemiological studies
of infectious diseases since the mid 20th century (Panum and Petersen, 1940). The
isolated nature of Pacific islands in particular led to several findings in the study of
measles. Black (1966), found that measles could probably not persist in dispersed island
communities with a population under 200,000. Cliff and Haggett (1984), used data
from Iceland to demonstrate that measles spread in a hierarchical pattern depending
on population size. Gould et al. (1971), studied the epidemiology of measles outbreaks
in Ponane (now part of the Federated States of Micronesia) and Rosen (1962), studied
a measles outbreak in 1951 in Tahiti using pre- and post-outbreak seroprevalence data.
Mathematical models of infectious diseases have similarly been used to great effect in
island settings. Camacho et al. (2011), modelled an influenza outbreak with multiple
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peaks on the remote island of Tristan da Cunha. The authors were able to characterise
a rapid rate of reinfection in their model by using the remoteness of the island as a justi-
fication that the second wave of infections could not have been caused by reintroduction
of the virus. The authors concluded that the second wave of infection was caused by
either a delayed or deficient immune response to the primary wave of infections in the
population. This insight into influenza transmission dynamics was facilitated by study-
ing the ‘natural experiment’ of the remote island outbreak. Mathematical models have
also been applied in island settings to design optimal pandemic preparedness strategies
(Nishiura et al., 2009) and to provide estimates of R0 for emerging diseases (Yakob and
Clements, 2013).
Small island outbreaks of DENV have been used to study the effect of seasonal cli-
mate variation on DENV transmission with statistical models including the association
between El Niño southern oscillations and DENV incidence (Hales et al., 1996) and
a characterisation of 40 years of DENV outbreaks in New Caledonia (Descloux et al.,
2012). However, the use of compartmental models to study DENV outbreaks on small
islands is limited. Chowell et al. (2013), used a compartmental model for a DENV
outbreak on Easter island and estimated a very high R0 for the outbreak assumed to
be linked to the high level of susceptibility in the population. Lourenço and Recker
(2014), modelled the first European DENV outbreak showing significant and prolonged
autochthonous transmission in Madeira in 2012, and defined a period of high epidemic
risk based on the climate in Madeira. Rodrigues et al. (2015), subsequently modelled
the effect of control measures on this same outbreak. More recently Funk et al. (2016),
used the dynamics of island outbreaks to compare DENV and ZIKV epidemics in is-
land settings. The authors found greater similarity between the reproduction number
of DENV and ZIKV in the same location, than between DENV outbreaks in separate
locations, suggesting that location is pivotal to outbreak dynamics.
The initial spread of ZIKV through the Pacific led to several mathematical models of
arboviruses in island settings. Kucharski et al. (2016), modelled the French Polynesia
epidemic and estimated that the majority of French Polynesia was infected during
the outbreak despite only 11.5% of the population reporting as cases (Cao-Lormeau
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et al., 2014a). Champagne et al. (2016), compared two compartmental model structures
to model ZIKV epidemics on several Pacific islands: Yap (Micronesia), Tahiti and
Moorea (French Polynesia), and New Caledonia. They estimated a range of R0 across
these islands between 1.5 and 4.1, with smaller islands displaying higher and more
variable values. Nishiura et al. (2016a), used a different modelling method to estimate
R0 for ZIKV based on the early exponential growth of the ZIKV epidemic in French
Polynesia and estimated R0 to between 1.8 and 2. Riou et al. (2017), analysed ZIKV
and CHIKV outbreaks across the Pacific with a time-dependent SIR model and found
similar transmission potential for both viruses in the same territory. Lourenço et al.
(2018), were able to model an outbreak of ZIKV in Africa on the island of Cabo Verde
and found similar characteristics to outbreaks in the Americas and Pacific. Finally,
Cousien et al. (2019), used a household model with the ZIKV outbreak on the island of
Martinique in the Caribbean to estimate that approximately one fifth of ZIKV infections
occurred in the household setting.
Following these initial island outbreaks of ZIKV, the virus spread to large countries
in the Americas. Here, mathematical models were important to characterise these
emerging outbreaks, including initial estimates of R0 (Nishiura et al., 2016b; Shutt et al.,
2017) and of the contribution of sexual transmission to outbreak dynamics (Gao et al.,
2016; Towers et al., 2016). Modelling also made a valuable contribution to outbreak
response. Ferguson et al. (2016a), modelled the spread of ZIKV in the Americas to
inform control strategies in real-time and Perkins et al. (2016), projected the number
of child-bearing age women at risk of ZIKV infection. After the epidemic Lourenço
et al. (2017), used a climate driven transmission model to characterise the determinants
of high attack rates of ZIKV transmission in urban settings in Brazil. Netto et al.
(2017), also used a compartmental model for the spread of ZIKV in one of the worst
affected regions during the pandemic, Salvador in northeast Brazil. The authors used
opportunistically sampled sera from blood donors and HIV registers to constrain their
model alongside the available case data and estimated ZIKV R0 was 2.1 (95% CI 1.8-2.5)
at the onset of the outbreak.
In summary, mathematical modelling is a useful tool in analysing transmission dynam-
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ics and is particularly valuable in island settings where outbreak periods, circulating
viruses, and pre-outbreak immunity can be more clearly defined. Available data from
Fiji shows regular DENV outbreaks of differing severity and silent circulation of ZIKV.
This thesis includes an analysis of serological data and development of mathematical
models of outbreak dynamics in the setting of Fiji and the wider Pacific.
1.2 Aims
The overall aim of this research is to better understand the transmission of DENV and
ZIKV by using serological data and mathematical modelling. Specifically (i) to improve
understanding of population immune dynamics following arbovirus outbreaks and (ii)
identify the determinants of arbovirus transmission dynamics in island outbreaks.
1.2.1 Objectives
This aim will be met by fulfilling the following objectives:
1. Conduct a serological survey in Fiji, resampling as many participants of previous
surveys in Central Division as possible
2. Analyse longitudinal serological data to determine the burden of ZIKV infection
in Fiji between 2013 and 2017
3. Evaluate the population level immune response to ZIKV from serological data
following outbreaks in Fiji and French Polynesia
4. Develop a mathematical model of arbovirus transmission and use it to explain
different transmission dynamics of recent arbovirus outbreaks in Fiji
5. Inform control strategies for DENV outbreaks in Fiji by estimating the effect of




This is a research paper style thesis consisting of four chapters written in the style of
a journal article, preceded with this introduction chapter and followed by a discussion
of the research. This opening chapter provides background on arboviruses, serological
analysis of DENV and ZIKV and the principles of mathematical modelling to analyse
arbovirus outbreak dynamics. The results chapters are as follows:
1. Materials & Methods. This chapter details methods used in this doctoral
project. Methods are described for the data collection with a seroepidemiological
survey in Fiji in 2017, serological testing on samples collected from this survey
and mathematical modelling methods used in Chapters 5 and 6.
2. A longitudinal seroepidemiological survey of arbovirus burden in Fiji.
This chapter details the serological survey I led in Fiji 2017. This chapter describes
and discusses results about the burden of DENV, ZIKV and related arboviruses
in Fiji between 2013 and 2017.
3. Zika seroprevalence declines and neutralising antibodies wane in adults
following outbreaks in French Polynesia and Fiji. This is the only chapter
that is currently published, in eLife in 2020 (Henderson et al., 2020). This chapter
presents an analysis of eight serological survey across Fiji and French Polynesia
to analyse the long-term immune response to ZIKV in a population following an
outbreak.
4. Interactions between timing and transmissibility explain diverse fla-
vivirus dynamics in Fiji. This is the main modelling chapter of the thesis and
has been submitted for publication. This chapter presents a mathematical model
I developed to explain differing transmission dynamics of ZIKV and DENV in
Fiji since 2013.
5. Modelling dengue virus transmission in Fiji and assessing the contri-
bution of vector control interventions in ending DENV epidemics. The
final chapter presents a model of DENV transmission that I used in real-time
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in Fiji in 2017 to forecast the dynamics of a DENV outbreak. Post-outbreak, I
used this model to estimate the contribution of vector control to the outbreak
dynamics.
The thesis concludes with discussion of the findings, the strengths and limitations of the
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Chapter 2. Materials & Methods
This Chapter describes the methods used in this doctoral project: the design and im-
plementation of a seroepidemiological study from 2017, the serological testing methods
used to test for antibodies against specific viral infections and the mathematical model
that is used to analyse trends in outbreak dynamics in Fiji between 2013 and 2017.
2.1 Data collection
2.1.1 Study design
Two previous serological studies have been conducted in Fiji. A nationally representa-
tive cross-sectional seroepidemiological study was conducted in 2013 (Lau et al., 2016;
Watson et al., 2017). In 2015, participants from Central Division were contacted and
another serum sample was collected. I led a third serological survey in the same area
between May and June 2017 to recontact and sample participants from previous sero-
logical surveys who had given consent to being recontacted. A sample of longitudinal
sera from the same individual is preferable to cross-sectional sampling because of the
variation between individual’s immune responses. By sampling repeatedly from the
same individuals we were able to control for this within-host variation as well as pre-
existing immunity. In addition, by successfully sampling a large proportion of these
original participants I could ensure that our sample remained nationally representa-
tive and would therefore provide better information on population immune response to
circulating arboviruses, compared to convenience sampling for instance.
This follow-up study, like the study performed in 2015 (Kama et al., 2019; Kucharski
et al., 2018), restricted the geographic coverage from the whole of Fiji to Central Di-
vision only. This restriction was made because the 2013-14 DENV-3 outbreak was
concentrated in Central Division. The reference laboratory for communicable diseases
in Fiji is based at Mataika House in Suva, Central Division, so collected samples from
Central Division could instantly be processed and stored. Central Division is the largest
Division in Fiji and includes a broad distribution of rurality – how urbanised an area is.
Sampling from Central Division could therefore potentially be generalised to the rest
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of Fiji. We planned to compare existing pre-epidemic serum collected from volunteers
in areas affected by arbovirus transmission with serum from another round of data
collection.
Between September and December 2013, serum samples were collected from 2,000
randomly-selected people across Fiji for a combined typhoid and leptospirosis study
by the Fijian Ministry of Health, LSHTM, the University of Queensland and World
Health Organisation (LSHTM ethics ref 6344, Fiji national research ethics review com-
mittee ref 2013 04) (Watson et al., 2017). 695 of the study participants were in Central
Division and 455 of these have available data for arboviruses. Between October and
November 2015 (LSHTM ethics ref 10207, Fiji national research ethics review com-
mittee ref 2015.111.C.D) (Kucharski et al., 2018), 390 participants were followed up
(56%). The 2017 study, which took place between May and June 2017, followed the
same protocol as the 2015 project and aimed to revisit up to 400 of the original 2013
participants.
2.1.2 Sample size and exclusion criteria
We aimed to follow up 350 participants as this was approximately 50% of the original
2013 study participants in 2017. We assumed that approximately 15% of these paired
samples would seroconvert between 2015 and 2017. Allowing for 5% seroreversion,
assuming no cross-reactivity and a probability of type-1 error of 0.05, with a sample
size of 350 we would be able to detect a 15% change in ZIKV seroprevalence between
2015 and 2017 with 88% power using McNemar’s test, and a 20% change with 98%
power.
Participants were eligible for inclusion if they were aged 12 months or older during the
first study in 2013. The youngest possible participants for inclusion would be at least
3 by May 2017. Exclusion criteria were clotting disorders, such as haemophilia and
other coagulopathies, concurrent medical anticoagulation such as through administra-
tion of warfarin or heparin, or the presence of severe underlying medical conditions
or significant acute illness. Non-medical exclusion criteria were needlephobia or other
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unwillingness to participate, inability to consent to treatment through lack of insight,
understanding, and for children, the refusal of, or inability to attain parental consent.
There were no additional exclusion criteria. These criteria were checked again in 2017
to confirm that the potential participant was still eligible.
2.1.3 Funding and ethical approval
The field work and serological analysis were funded by a grant from the Enhancing Re-
search Activity in Epidemic Situations (ERAES) programme, funded by the Wellcome
Trust. This grant covered all project costs, including consumables, staff, transport,
shipping and laboratory testing.
Ethical approval was obtained from the LSHTM ethics committee in February 2017
(ref: 12007) conditional on local ethics approval. I submitted our ethics application in
March 2017. I received a request for justification of our sampling method, storage of
samples in Fiji and testing of samples outside of Fiji. I sent my response on 23 May
2017 and received ethical approval for the study on 29 May 2017 (ref: 2017.20.MC).
2.1.4 Field team
Field team – recruitment
Working with Dr. Adam Kucharski, we developed a budget based on the experience
from the 2015 serological survey. We budgeted for recruitment of six operational field
workers for a period of twenty-eight working days. We established two working field
teams, each with a qualified phlebotomist and two field workers.
One field worker in each team would represent the team on field visits and was in
charge of coordinating field visits, administering questionnaires and reporting on data
and any problems in the field. Two such field workers were recruited through contacts
of the surveillance department at the Ministry of Health. Jessica Paka and Amele
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Ratevono were recruited to perform this role. Jessica and Amele both had a certificate in
public health at Fiji National University (FNU). Mosese Ligani and Jonetani Bola were
recruited as the second field workers for each team and were responsible for transport
and maintenance of the vehicles during field work. Both had good knowledge of Suva
and Central Division and were well recommended. Additionally, they were able to
represent the field team effectively at iTaukei villages where it is important that a male
performs rituals during a sevusevu ceremony to greet a village official. Finally, newly
qualified phlebotomists Warren Fong and Manisha Prakash were recruited and were
solely responsible for collecting venous blood samples and storage of samples until they
could be processed at Mataika House the same day. I also budgeted for 112 hours of
overtime laboratory work by an existing member of the laboratory staff at Mataika
House, Taina Naivalu.
Field team – training and risk management
The six members of the field teams came to Mataika House for a full day of training
and planning before the data collection began. I conducted training giving the team
a background to the study and setting out the aims and objectives of this 2017 study.
Formal training was then given in three key areas. Firstly, the plan to recontact partic-
ipants which would be led by Jessica and Amele. Secondly, the process and importance
of obtaining informed consent. Both Jessica and Amele were bilingual so could explain
the purpose of the study and the process of data collection in English or iTaukei accord-
ing to the preference of the participant. Finally, we covered the process of dealing with
adverse events – most likely a sharps injury in this study – and detailed the standard
operating procedures in the case of such events. The phlebotomists in the field teams
reviewed the equipment that had been provided and additional pharmaceutical supplies
were purchased to meet their requests.
I updated the standard operating procedures (SOPs) used in the previous serological
surveys in Fiji for this study in 2017. These SOPs covered sharps injuries management
and reporting, adverse event reporting, collection and transport of blood samples, ob-
taining informed consent, telephone follow up and processing and storage of blood
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samples.
Field team – equipment
The majority of fieldwork supplies were purchased in the UK and I brought them to
Fiji myself. We purchased enough phlebotomy and sample storage consumables for
400 samples. These included shielded needles, vacutainers, alcohol wipes and gel, first
aid kits and hygienic products for phlebotomists. I also carried pipettes, cryovials,
cryolabels, boxes and biohazard waste bags for the processing of samples at Mataika
House.
2.1.5 Field work
Field work – plan
Potential participants (or the parents of child participants) were first contacted by
telephone by a field worker, where phone details were provided. The field team explained
the details of the proposed study explained and answered any questions from potential
participants. Where a telephone number was not given or was no longer active, a visit
was made to the village or house to seek permission for further involvement in the
study. Address records, village governance systems, community nurses or community
health workers, local knowledge and previous GPS mapping were also used to help
locate participants.
Samples were collected in clusters in 2013. In Central Division these clusters all had
25 participants in the original 2013 study so in 2017, different clusters were targeted
each day depending on their location. The majority of clusters were located in Suva
so it was possible to visit several in a day. Others were very remote and took a whole
day to visit (Figure 2.1). As a result, I kept track of samples collected and the age
distribution of samples throughout the study and adapted where teams targeted their
data collection in the limited available time.
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Figure 2.1: Map of clusters of participants in serological surveys in Central Division, Fiji.
Blue circles show the centroid of a cluster of 25 participants originally recruited in 2013. The
red diamond shows the location of Suva, the capital and most populous city in Fiji
Once contact had been made, a blood sample was collected and questionnaire completed
at that time. In most cases however, permission was sought for a return visit at a
convenient time to complete the data collection.
Field work – permissions and consent
I initially met with the Divisional Medical Officer Central (DMOC), Dr. Dave Whippy,
to discuss plans for this study. I also presented the study plan to the National Task-
force for the Control of Outbreak Prone Diseases (NTCOPD) during my third week
in Fiji while setting-up the study. These meetings along with continued support from
established collaborators at the Ministry of Health ensured that we had administrative
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support to conduct the study. The DMOC also helpfully supplied me with regional and
local contacts across Central Division.
When visiting participants, essential information was provided in the form of written
information sheets, which were retained by the participants. Information was also
communicated by the field workers. Information sheets contained information on the
purpose of the study and answered potential questions from participants. The study
staff member who obtained the informed consent also signed the form.
For children age 12-17, study information was provided to the parent and the child.
Written consent was obtained from both the parent and the child. If either lacked the
capacity to give consent, or declined consent, then the child was not included in the
study.
For children aged 1 to 11, written consent was obtained from the parent only, though
information was provided to both. If the parent was unable to give consent, the child
was not included in the study. Appropriate age-based professional judgement was used
for children in this age range who indicated unwillingness or distress in participating in
the study.
Several of the clusters of participants were located in traditional iTaukei villages. In
these locations, local customs and traditions were respected and permission to enter
a village was sought from a village official. This was informal acceptance in some
locations but more typically it involved a sevusevu ceremony. A gift of dried yaqana
roots was presented and the purpose of the study was presented. Yaqana is pounded
into a powder and mixed with water to make a kava drink, a putative sedative drink
which is has strong social significance in Fijian culture. Once permission was obtained
from the village official, arrangements were made to come back to the village and sample
as many participants as possible. These close knit village social structures often meant
that many participants were located and could be sampled when we returned to the
village.
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Field work – implementation
We proceeded with the data collection as planned. The primary challenge was that
people rarely keep the same phone number in Fiji beyond 12 months so most of our
telephone records were obsolete. This increased the need to visit areas in person and
work with local nurses to locate last known addresses of participants.
Another challenge was that names were often passed down over generations in the same
family, especially down the male line, so cousins could often have the same name. This
meant that field workers asked extra questions of participants to ensure that we were
sampling the correct individual.
These serological studies were not originally designed to be longitudinal cohort stud-
ies. Permission from participants to be recontacted and followed up for further health
research was obtained in both 2013 and 2015, however several participants wanted to
learn about how their previous samples had helped inform health research. As a result,
I outlined previous successful research with the field teams so they could communicate
to participants that samples had been essential to the analysis of risk factors for typhoid
fever (Watson et al., 2017) and leptospirosis (Lau et al., 2016) transmission in Fiji and
quantifying dengue transmission during a large outbreak in 2013-14 (Kucharski et al.,
2018).
The majority of field visits were easily accessible and recruitment within Suva was
most efficiently done on foot. Other clusters of participants could only be reached on
rural roads so a four-wheeled drive vehicle was hired for the duration of the study.
More complicated still were clusters that could only be accessed by boat. Local boat
transport was hired to reach these sites as shown in Figure 2.2.
Recontacting participants was the largest challenge in this study and data collection
was routine once contact had been made. The study purpose was outlined and the
questionnaire completed before a blood sample was collected (details below). A short
questionnaire asked for details of fever and rash and healthcare-seeking behaviour during
the outbreak period.
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Figure 2.2: (Left) One of the study phlebotomists is led to a village field site in rural Central
Division. (Right) One study team travels by boat to reach a remote cluster of participants to
the East of Suva
Completed questionnaires and fieldwork operational management paperwork were kept
on paper in opaque folders or fold-over clipboards to protect confidentiality. Ques-
tionnaire data was entered using password-protected Microsoft Excel to a password
protected computer and encrypted before external transfer.
Data will be kept for at least 10 years in line with LSHTM policy. Paper records will
be kept at the national communicable disease surveillance centre at Mataika House.
Electronic records will be kept at LSHTM, the National Data Repository at Mataika
House. Mataika House records will be managed as per national surveillance data.
Access to the full data set at LSHTM will be limited to the research team. Data
are de-identified if shared with other researchers by removal of participant names and
demographic information.
Field work – sample collection
Approximately 2ml of blood was collected using conventional clinical practices. A ve-
nous blood sample was collected using a needle & holder system or luer needle system,
into the required vacutainer, as per manufacturer’s directions and WHO best practice
guidelines. All needles were disposed of in a designated ‘sharps’ bin. If the partici-
pant had veins that were difficult to palpate, or collapsed on the first fill attempt, the
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phlebotomist had the option to use a 10ml syringe attached to a 23G or 25G needle.
After collection, the vacutainer was inverted gently five times to mix the blood with
the tube content and left upright for 30 minutes to allow the clot to form.
Field work – sample management
Samples were transported to the laboratory at Mataika House, Suva, on the same day
as collection. The sample was centrifuged for 10 to 15 minutes at 1000 to 1300 Relative
Centrifugal Force (RCF) using a powered centrifuge. The samples were pipetted using
aseptic technique into screw top cryovials, pre-labelled with the participant ID and
participant initials according to the SOP. Two aliquots were pipetted in the following
quantities: 1ml to Institut Louis Malardé (ILM), Tahiti and the remainder (approxi-
mately 1ml) to remain at Mataika House, Fiji.
Aliquoted samples were stored in freezer boxes at Mataika House before half of the
samples were shipped to ILM in July 2017. The samples retained at Mataika House
are to be stored for at least 10 years as a public health research serum bank. The
information sheet informs participants that their samples and information may be used
for other health research as determined by the Ministry of Health, as per the original
survey.
2.1.6 Dissemination and follow up reporting
Preliminary results were shared with Dr. Mike Kama and his team at the Fiji Centre
for Disease Control. I travelled with Dr. Adam Kucharski to Institut Louis Malardé
to work directly with Dr. Van-Mai Cao-Lormeau, Dr. Maite Aubry and their team in
French Polynesia. We spent two weeks combining data from Fiji and data from French
Polynesia to analyse serological dynamics following ZIKV outbreaks which was later
published (Henderson et al., 2020) and is presented in chapter 4.
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2.2 Serological testing
Serological analysis of prior DENV and ZIKV infection
There are three serological tests for previous infection with arboviruses discussed in
this doctoral project: ELISA for detection of IgG antibodies, microsphere immunoassay
(MIA) for IgG antibodies and plaque reduction neutralisation assays (PRNTs) for the
detection of neutralising antibodies (NAbs) (Figure 2.3).







Figure 2.3: Schematic of serological assays for detection of previous DENV and ZIKV infec-
tion used in this thesis. The ELISA test shows the process of generating a fluorescent signal if
the patient’s sera contains the primary antibody of interest. The higher the concentration of
primary antibody in a serum sample, the stronger the fluorescent signal. The microsphere im-
munoassay follows a similar process but for several antigens simultaneously with colour coded
fluorescent signals. The neutralisation assay uses a two-fold serial dilution of sera which
is then incubated with the antigen of interest. Serum samples with higher concentrations of
neutralising antibodies will prevent plaque formation at weaker dilutions
ELISAs can detect for anti-DENV or -ZIKV IgG antibodies. Most antibodies generated
following DENV or ZIKV infection are directed against the envelope (E) protein, which
is composed of three domains: EDI, EDII and EDIII. EDIII mediates virus attachment
to the cell membrane (Beck et al., 2015; Bhardwaj et al., 2001). For ELISAs, the EDIII
protein for DENV-specific antigens is bound to anti-DENV IgG antibodies in a patient’s
serum, blood on filter paper, or saliva. These antibodies are then bound to monoclonal
or polyclonal antibodies which are conjugated with an enzyme. This enzymic reaction
can transform a non-coloured substrate into coloured products that can be read using
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colorimetric readout (Aubry et al., 2015; Fernández and Vázquez, 1990). In general,
IgG ELISA lacks specificity within the flavivirus serocomplex group generating positive
reactions for closely related flaviviruses (Beck et al., 2015). This is especially true
following secondary infections as newly produced antibodies have stronger avidity than
antibodies produced months or years after infection (Midgley et al., 2011; Rothman,
2011). Theiler and Casals (1958), demonstrated that a secondary flavivirus infection
resulted in an increase in heterologous antibodies to other viruses of the same group.
Microsphere immunoassays (MIAs) use similar principles to the ELISA but are far more
efficient and increasingly popular (Anderson et al., 2011; Beck et al., 2015; Johnson
et al., 2005; van der Wal et al., 2012; Wong et al., 2003, 2004, 2017; Wynwood et al.,
2015). The need to detect a specific colour in assays has complicated the ability to
read multiple test results in a single sample volume. MIAs use technology based on
the covalent bonding of antigen or antibody to microspheres or beads (Mandy et al.,
2001). By colour-coding the beads into several spectrally distinct sects, each bead can
be coated with different recombinant antigens and it is possible to capture multiple
binding antibodies in a single sample. This tool retains the ease and rapidity of ELISA
with improved precision (Beck et al., 2015). The binding of secondary antibodies and
subsequent enzyme reactions follows, as before, except that the enzyme reactions are
spectrally distinct for each of the antigens included in the assay. This technology allows
for efficient testing of multiple viruses simultaneously as it only requires a small quantity
of sample and is very quick (<3 hours compared to 3–6 days for flavivirus neutralisation
tests) (Beck et al., 2015).
For this doctoral project, the detection of IgG antibodies against ZIKV, DENV and
CHIKV was performed using an MIA adapted from Beck et al. (2015). Sera were
diluted 1/400 and incubated with a mix of microspheres coupled with recombinant
antigens for CHIKV, DENV-1, -2, -3, -4, RRV and ZIKV. Recombinant antigens used
in both assays comprised domain III of the envelope glycoprotein of ZIKV, DENV-1,
DENV-2, DENV-3, or DENV-4 strains (respective GenBank accession no. KJ776791,
AF226686.1, FM986654, FJ44740.1, FM986672.1). Antigens were produced using the
Drosophila S2 expression system (Life Technologies, USA) as previously detailed (Aubry
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et al., 2015). The median fluorescence intensity was read on a MagPix instrument (Bio-
Rad Laboratories). The cut-off of the MIA was determined by colleagues at ILM using
ROC curve analysis for all the antigens with positive and negative control sera. The
positive control sera for DENV were collected within 3 months of an RT-PCR confirmed
infection, or confirmed positive for all DENV serotypes by neutralisation test. The
positive control sera for CHIKV and ZIKV were collected within one year of RT-PCR
confirmed infection. The sensitivity and specificity of the MIA assay were respectively
100% and 100% for CHIKV, DENV-1, and DENV-3, 89.5% and 97.1% for DENV-2,
96.9% and 100% for DENV-4, and 79.6% and 94.9% for ZIKV (Cao-Lormeau et al.,
2016).
The third serological test studied in this thesis is the virus neutralisation test (VNT).
These tests are often used as validation of results from quicker diagnostic methods such
as ELISA and MIA (Beck et al., 2015; Dauphin and Zientara, 2007). The purpose
of a VNT is to test for the ability of a patient’s sera to neutralise a virus. Plaque
reduction neutralisation assays (PRNTs) are a form of VNT (Roehrig et al., 2008;
Russell et al., 1967; Schmidt et al., 1976) and are the gold standard for determining
previous DENV exposure (Raafat et al., 2019). Briefly, cell cultures are inoculated with
serum that has been previously incubated with a specific antigen at serial dilutions (1:10,
1:20, ... , 1:1280). The cells are incubated for one week and if there are insufficient
neutralising antibodies in the diluted sera the viral particles will enter and kill the
cells creating a “plaque” of dead cells which can be counted (Salje et al., 2014). The
weakest dilution of sera that results in a 50% reduction in the number of plaques
compared to a serum free virus was used to determine the PRNT value of a sample.
The concentration of plaques can be measured by microscopic observation, fluorescent
antibodies (with an ELISA) or specific dyes that react with infected cells depending
on the virus (Schmidt et al., 1976). This alternative process means the assay is less
specific than ELISA based methods (Beck et al., 2015). However, VNTs do provide a
key measure of immunity to a virus given that they test the ability to neutralise the
virus (Salje et al., 2014), which also makes VNTs an excellent validation of previous
ELISA results. Katzelnick et al. (2016), found that neutralising antibody titres against
DENV correlated with protection from symptomatic infection in a cohort of Nicaraguan
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children. Venturi et al. (2006), used PRNTs to monitor protective immunity against
tick-borne encephalitis. PRNTs can also be used to analyse antibody dynamics in
longitudinal sera (Clapham et al., 2016). However, the variability in PRNT values is
poorly understood and potentially important. Salje et al. (2014), recommend repeated
testing of samples to obtain a measure of variability in the assay. The main limitation
with this approach, and therefore this test, is that it is very time consuming and
therefore expensive (Beck et al., 2015; Shan et al., 2017).
Detection of neutralising antibodies against ZIKV and each of the four DENV serotypes
was performed for all serum samples in 2017 and a subset of samples in 2015 and 2013.
Vero cells cultured on 96-well plates were inoculated with serial dilutions of each serum
previously incubated with titrated ZIKV [PF13-251013-18], DENV-1 [PF15-080108-
88], DENV-2 [PF96-300896-243/158], DENV-3 [PF90-300190-30/56] or DENV-4 [PF09-
290509-104]. One week later, infected cells were detected by ELISA using primary
mouse pan-flavivirus E mAb 4G2 which reacts with ZIKV E protein (Hamel et al.,
2015) and a secondary goat anti-mouse IgG HRP-conjugated antibody (Santa Cruz).
The neutralising antibody titre was defined as the inverse of the latest serum dilution
that inhibited the virus (Cao-Lormeau et al., 2016).
2.3 Mathematical modelling
A deterministic compartmental SEIR model is used throughout this thesis and is intro-
duced here. An SEIR model is an extension of the SIR model that includes a latency
period for those that are ‘exposed’ or ‘pre-infectious’ (E). The intrinsic incubation
period (IIP) is the duration between a human host being infected but before they are
infectious. A key distinction in model structure when using compartmental models
for vector-borne diseases is whether to explicitly model the mosquito population. A
vector-host model is a compartmental model with additional compartments to include
mosquito transmission dynamics explicitly, however this comes at the cost of estimating
more parameter values in the model. Pandey et al. (2013), compared the performance
of a vector-host model with a simple SIR model structure to estimate DENV incidence
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data from Thailand. The authors found that both model structures fit the data well,
but a comparison of model performance using Akaike’s information criterion strongly
selected the simpler SIR model. However, it may still be preferable to explicitly model
the vector population, especially if the model includes interventions that are directly
targeted at reducing mosquito density. In a systematic review of models of mosquito-
borne pathogens, Reiner et al. (2013), found that 62% of models in the review explicitly
modelled the mosquito population.
Two versions of an SEIR model are used in this thesis. In Chapter 5 an SEIR model
with only a human population is used and described in full. Here, I will introduce the
extension of this model which is used in Chapter 6 and includes a mosquito population.
This model allows for two latent periods: the intrinsic incubation periods (IIP) (αH)
and the extrinsic incubation period (EIP) is the equivalent period in mosquitoes (αM).
The length of the extrinsic and intrinsic incubation period differ (Chan and Johansson,
2012) and the EIP is dependent on seasonal climate factors (McLean et al., 1974; Watts
et al., 1987). The transmission rate from humans to mosquitoes, βM, is equal to cpM
where c is the mean rate of bites per female mosquito per unit of time and pM is the
human-to-mosquito transmission probability. The transmission rate from mosquitoes
to humans, βH = mcpH, where pM is the mosquito-to-human transmission probability
and m is the number of female mosquitoes per person (m) (Chitnis et al., 2006; Funk
et al., 2016; Manore et al., 2014; Pandey et al., 2013). By explicitly modelling these
rates separately we can allow for differences in transmission probability from human-
to-mosquito and vice versa. In this model, mosquitoes are born and die in the model at
a constant rate (δ) so the mosquito population size remains constant. These additional
complexities require additional parameters, which in turn require more data to estimate
accurately. This model is simplified by assuming that the total mosquito population
size is unknown so the proportion of susceptible (sm), exposed (em) and infectious (im)
mosquitoes are used in the model, hence the lower case characters in the compartments.
It is also assumed that mosquitoes do not recover from infection so there is no recovered
compartment for mosquitoes.
The basic reproduction number from this model is equal to the product of the average
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Figure 2.4: Schematic of a vector-borne disease model. The disease spread between a human
population (blue) and a vector population (orange). Humans move from being susceptible
(SH), to pre-infection (EH), to infectious (IH), then recover (RH). The vector population
follows the same process without a recovered compartment (sM , eM , iM )
number of mosquitoes infected by the typical infectious human and the average number
of humans infected by the typical infectious mosquito (Equation 2.1) (Diekmann et al.,









An important consideration in the modelling of DENV and ZIKV epidemics is the
effect of seasonal changes in climate on the spread of these viruses. It has been well
documented that temperature affects the vector biology of Aedes mosquitoes such that
the transmission of viruses such as DENV and ZIKV changes (Brady et al., 2014;
Lourenço and Recker, 2014; McLean et al., 1974; Mordecai et al., 2017; Watts et al.,
1987; Winokur et al., 2020). Mordecai et al. (2017), modelled the effect of temperature
on mechanisms driving Aedes aegypti and Aedes albopictus transmission of DENV,
ZIKV and CHIKV. The authors found non-linear relationships between temperature
and several factors, including the extrinsic incubation period, mosquito lifespan and
mosquito development rate. When combined, these effects show that transmission
occurs between 18-34°C with maximal transmission occurring in a range from 26-29°C
(Mordecai et al., 2017).
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Seasonal forcing is an important consideration in the modelling of a range of diseases
and a variety of methods exist to vary transmission rates over time (Altizer et al.,
2006; Bjørnstad, 2018; Keeling and Rohani, 2011). In Fiji and the wider Pacific the
temperature fluctuations over a year follow a sine wave-like pattern, therefore we can
capture the corresponding fluctuations in transmission by using a sine function. This
seasonal forcing function is characterised by a parameter for the amplitude (βamp) and
midpoint (βmid) (Equation 2.2). Again, the model has become more complicated and
a single transmission rate is not appropriate, but the model now better represents the
reality of arbovirus transmission.
β(t) = β0 (1 + βamp sin (2π (t+ βmid))) (2.2)
Several additional simplifying assumptions have been made in the model introduced
here as well as those assumptions previously outlined in all Ross-Macdonald models.
However, several of these assumptions are valid because of the advantages of the study
setting. Epidemics in Fiji are typically self-limiting after introduction from external
sources (Cao-Lormeau et al., 2014; Roth et al., 2014). This is likely because small,
centralised and geographically isolated populations are less likely to sustain endemic
transmission compared to a large populations (Black, 1966; Keeling and Grenfell, 1997).
Greater heterogeneities in age structure, spatial dispersion and movement patterns in
larger populations will decrease the probability of epidemic fade-out in the troughs
between epidemics (Grenfell et al., 1995; Keeling and Grenfell, 1997). Outbreaks of
DENV in the Pacific have also typically been monotypic – caused by one virus or
serotype of DENV – which simplifies models by removing the need to model several
serotypes simultaneously (Feng and Velasco-Hernández, 1997; Ferguson et al., 1999).
Island settings also make it easier to characterise the level of susceptibility at the start
of an outbreak (Camacho et al., 2011).
The time frame also has implications for the structure of the model. This model is
used for analysis of single outbreaks in this thesis and I do not include human births
since the mean human lifespan is much longer than the outbreak duration. I have
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also ignored disease induced mortality in the model because it is small (Arima and
Matsui, 2011; Burattini et al., 2008). I have assumed a simple homogeneously mixing
human population with no age structure for simplicity. Age structure can be included
by creating age-specific compartments in the model however this increases the number
of parameters and complexity in the model (Kucharski et al., 2018; Pongsumpun and
Tang, 2003; Supriatna et al., 2008). The small area and isolated nature of the Pacific
islands meant that I ignored international travel during outbreaks, though this is an
important consideration for studies over longer time periods (Bhatt et al., 2013; Messina
et al., 2019). Finally, I have removed human-to-human transmission from this model
because transmission of the arboviruses being studied is dominated by mosquito-borne
transmission, even though sexual transmission of ZIKV is possible (Althaus and Low,
2016; Foy et al., 2011; Yakob et al., 2016).
Fitting mathematical models to data
A model output for a given set of parameter values can be compared to observed data
to validate the model as well as provide estimates of unknown model parameters. We
can then use these estimates to answer hypotheses or the parameters themselves might
be of interest, for example estimating R0. There are many frameworks under which
models can be fit to data but this thesis will focus on Monte Carlo Markov Chains
(MCMC) under a Bayesian framework. MCMC is an efficient method to sample from a
posterior distribution when that distribution is unknown (Chan, 2013), which is often
the case with epidemiological parameters of infectious disease transmission.
I want to generate samples of the parameter set of my model (θ = {β, γ, ...}) from
the posterior distribution p(θ|data). Using Bayes theorem we know that this poste-
rior distribution is proportionate to the product of the likelihood of the data given θ
(p(data|θ)) and prior information on θ (p(θ)) (Equation 2.3). The posterior distribution
(p(θ|data)) is a probability distribution that represents our uncertainty about θ after
seeing the data. The posterior is not analytically tractable but the likelihood and prior
distributions can be obtained in closed form.
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p(θ|data) ∝ p(data|θ)p(θ) (2.3)
The likelihood can also be flexible enough to combine multiple data sets. This is
particularly valuable if data come from different sources and provide complimentary
information, for example surveillance data of the number of cases during an outbreak
and serological data of the proportion of the population infected (Birrell et al., 2011;
Goubar et al., 2008). We know something about the observation process for these data
and can define the probability of observing the data in data set 1 and data set 2 at








Throughout this thesis surveillance data are assumed to follow a negative binomial dis-
tribution. The negative binomial (NB) distribution is a discrete probability distribution
for count data that relaxes the assumption in the Poisson distribution that the mean
and variance of the distribution are equal (Lloyd-Smith, 2007). The NB distribution
has been used in several other disease modelling studies including severe acute respi-
ratory syndrome (Lloyd-Smith et al., 2005), Middle East respiratory syndrome-related
coronavirus (Kucharski and Althaus, 2015) and DENV (Padmanabha et al., 2012). The
additional parameter in the NB distribution, the ‘dispersion’ parameter, gives greater
flexibility to captures the skew in the transmission distribution because of individual
variation in infectiousness. The NB distribution is preferable therefore to reflect both
under- or over-reporting of case data. When fitting models to seroprevalence data I
assumed that these data were binomially distributed as the result of n independent
experiments with a binary outcome with probability p =
x
n
where x is the positive
results from a sample size n.
The prior information facilitates formal inclusion of information from previous studies
in our estimation of the parameters. The prior, p(θ) quantifies our belief about the
parameter via a probability distribution before comparing the model output to data.
With the likelihood and prior defined, we can use Monte Carlo methods to draw de-
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pendent samples from a Markov chain with p(θ|data) as its equilibrium distribution.
There are several algorithms available to design a Markov chain with the required equi-
librium distribution but I used the popular Metropolis-Hastings algorithm throughout
this doctoral project (Hastings, 1970; Metropolis et al., 1953).
The Metropolis-Hastings algorithm uses MCMC to sample from the posterior distribu-
tion. An initial value of θ is chosen (θ0 = θt−1) as the ‘current’ sample. A ‘candidate’
sample, θ′, is chosen randomly from a proposal distribution g(θ′|θt−1), for example a
Gaussian distribution: θ′ ∼ N(θt−1, σ). The next sample in the chain (θt) is selected
as either the candidate θ′ or current value θt−1 with probability as defined in Equation
2.5. This process is repeated a large number of times to obtain a large sample of θ and
in the long-run this chain will converge towards the target distribution.








The parameter set from arbovirus transmission models can be large so this process can
be made more efficient by sampling all of θ from a multivariate Gaussian distribution.
The performance of this MCMC sampler can be improved by adapting the proposal
distribution. If the proposal distribution is too narrow the chain will be slow to reach
the target distribution as it takes longer to explore the parameter space. If the proposal
distribution is too broad then the chain will reject a lot of samples and ‘stick’ in the
same place for many steps. Roberts and Rosenthal (2009), showed that mixing of the
chain can be most efficient if the variance of the proposal distribution is tuned to a
target acceptance rate of 0.234.
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Cao-Lormeau, V.M. et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in
French Polynesia: A case-control study. The Lancet, 387(10027):1531–1539, 2016. ISSN 1474547X.
doi: 10.1016/S0140-6736(16)00562-6.
Chan, M. and Johansson, M.A. The Incubation Periods of Dengue Viruses. PLoS ONE, 7(11), 2012.
ISSN 19326203. doi: 10.1371/journal.pone.0050972.
Chan, W. Statistical methods in medical research, volume 8. 2013. ISBN 0-632-05257-0. doi: 10.3233/
MAS-130255.
Chitnis, N., Cushing, J.M. and Hyman, J.M. Bifurcation analysis of a mathematical model for malaria
transmission. SIAM Journal on Applied Mathematics, 67(1):24–45, 2006. ISSN 00361399. doi:
10.1137/050638941.
Clapham, H.E. et al. Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children after Symp-
tomatic Primary and Postprimary DENV Infection. Journal of Infectious Diseases, 213(9):1428–
1435, 2016. ISSN 15376613. doi: 10.1093/infdis/jiv759.
Dauphin, G. and Zientara, S. West Nile virus: Recent trends in diagnosis and vaccine development.
Vaccine, 25(30 SPEC. ISS.):5563–5576, 2007. ISSN 0264410X. doi: 10.1016/j.vaccine.2006.12.005.
Diekmann, O., Heesterbeek, J.a.P. and Roberts, M.G. The construction of next-generation matrices
for compartmental epidemic models. Journal of the Royal Society, Interface / the Royal Society, 7
(47):873–885, 2010. ISSN 1742-5689. doi: 10.1098/rsif.2009.0386.
Feng, Z. and Velasco-Hernández, J.X. Competitive exclusion in a vector-host model for the dengue
fever. Journal of Mathematical Biology, 35(5):523–544, 1997. ISSN 0303-6812. doi: 10.1007/
s002850050064.
Ferguson, N., Anderson, R. and Gupta, S. The effect of antibody-dependent enhancement on the
transmission dynamics and persistence of multiple-strain pathogens. Proceedings of the National
Academy of Sciences of the United States of America, 96(2):790–794, 1999. ISSN 0027-8424. doi:
10.1073/pnas.96.2.790.
Fernández, R.J. and Vázquez, S. Serological diagnosis of dengue by an ELISA inhibition method
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Abstract
Mosquito-borne diseases such as dengue (DENV), Zika (ZIKV) and chikungunya (CHIKV)
carry a large public health burden globally. However, understanding of these viruses is
limited because a large proportion of infections are subclinical so are not detected by
surveillance systems. Longitudinal serological data can therefore help our understand-
ing of the quantity and timing of infections. In 2017 we collected 320 serum samples
from a population-representative sample of participants from Central Division, Fiji, to
combine with previous samples collected in 2013 and 2015. We found high levels of
seroprevalence for all four dengue serotypes in 2017 but low levels of seroprevalence for
ZIKV and CHIKV despite recent reports of transmission of these viruses. Analysis of
serological data between 2013 and 2017 revealed a diverse range of serological patterns.
CHIKV increased slightly 2015-17 in a predominantly näıve population. DENV-1 sero-
prevalence continued to increase despite an absence of recent case reports. DENV-3 and
DENV-2 seroprevalence increased rapidly following an outbreak and ZIKV increased
slightly then declined rapidly between 2013 and 2017. Given the challenge of accu-
rately recording infections with these closely related viruses, longitudinal serological
data reveals the diverse range of underlying outbreak dynamics.
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3.1 Background
3.1.1 Arbovirus burden globally
This chapter presents details and results of a serological study of arbovirus burden in Fiji
in 2017. Arboviruses such as dengue virus (DENV), Zika virus (ZIKV), chikungunya
virus (CHIKV) and Ross River virus (RRV) present a large global health burden. Our
understanding and ability to quantify how widely these viruses transmit, and interact
with each other, can be improved through the collection of serological data.
DENV and ZIKV are two flaviviruses primarily transmitted by the Aedes genus of
mosquito. The incidence of DENV transmission has increased 30-fold in the past 50
years (World Health Organisation, 2009). There is evidence that infection with one
of the four DENV serotypes provides lifelong immunity for that serotype (Halstead,
1974) and temporary heterogeneous immunity against all serotypes (Sabin, 1952). An
estimated 20-50% of cases are symptomatic (Bhatt et al., 2013; Endy et al., 2002; Funk
et al., 2016) so surveillance and modelling of the virus is complicated.
ZIKV is related to other flaviviruses such as DENV (Hayes, 2009; Priyamvada et al.,
2016). Symptoms of ZIKV infection include low grade fever, rash and conjunctivitis
(Heukelbach et al., 2016). ZIKV has additionally been associated with birth defects
and neurological complications such as microcephaly (Cauchemez et al., 2016; Schuler-
Faccini et al., 2016) and Guillain-Barré Syndrome (GBS) (Cao-Lormeau et al., 2016).
ZIKV spread throughout the Pacific between 2007 and 2016 (Craig et al., 2016; Musso
and Gubler, 2016) and the largest outbreak was in French Polynesia in 2013 (Cao-
Lormeau et al., 2014b). ZIKV spread to the Americas and was declared a Public
Health Emergency of International Concern in 2016 (World Health Organisation, 2016).
Between 2015 and 2017 there were fewer than one million confirmed or suspected ZIKV
cases reported (Pan American Health Organization, 2018) but over 100 million people
were estimated to have been infected (Moore et al., 2019).
CHIKV can also be transmitted by the Aedes genus of mosquito, primarily Aedes ae-
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gypti. Unlike ZIKV and DENV, which are flaviviruses, CHIKV is an alphavirus that
causes an acute febrile syndrome and severe, debilitating rheumatic disorders in hu-
mans that may persist for months (Wimalasiri-Yapa et al., 2019). Reports from the
Americas demonstrate that all three of these arboviruses – CHIKV, DENV and ZIKV
– are able to cocirculate in the same location (Carrillo-Hernández et al., 2018).
Finally, RRV is an arbovirus and alphavirus like CHIKV. Infection with RRV may
cause disease in humans, typically presenting as peripheral polyarthralgia or arthritis,
sometimes with fever and rash (Harley et al., 2001). There have been sporadic reports of
RRV outbreaks in Pacific islands countries and territories (PICTs) along with evidence
of silent circulation of RRV in French Polynesia (Aubry et al., 2015b).
There is an urgent need to better understand arbovirus transmission dynamics and
island populations present a unique opportunity to do this. Small populations are less
likely to sustain endemic transmission so the timing of outbreaks can be well defined
(Black, 1966; Keeling and Grenfell, 1997). Island populations are currently less likely
to sustain endemic transmission. However it is important to understand whether these
viruses will continue to pass through island populations as large but brief epidemics, or
exhibit longer-term ‘slow burn’ dynamics and become endemic as DENV has in areas of
Southeast Asia (Bhatt et al., 2013; Jentes et al., 2016; Salje et al., 2019; Shepard et al.,
2016). In particular it is not well understood how infection with multiple arboviruses
can affect the immune response to a novel but closely related virus in individuals and
in populations.
To better understand the burden of different diseases in the Pacific there are multiple
sources of data available. Surveillance data provides data on the number of people in-
fected with a particular disease and when they presented with symptoms. A syndromic
surveillance system is used in the Pacific to rapidly detect and assess infectious disease
outbreaks (Craig et al., 2016; Kool et al., 2012). This system is implemented across
twenty-one countries in the Pacific. Surveillance data provides important information
on the cause, timing and size of disease outbreaks. However, surveillance data for these
arboviruses are incomplete because some people will never show symptoms, some will
never report at a health centre especially if symptoms are mild and data can be entered
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incorrectly.
Individuals who are infected with these arboviruses develop specific and cross-reactive
neutralising antibodies to the virus that can be detected years later (Gubler, 2004;
Halstead et al., 1983; Imrie et al., 2007; Tesh et al., 1975). Serological surveys can
be used to detect antibodies against different viruses in serum samples and therefore
characterise the proportion of the population that has likely been exposed to the virus
at some point, regardless of whether the host experienced symptoms. These estimates
can be used to estimate the true burden of viral infections after an arbovirus outbreak
and to estimate the potential for that virus to emerge in a population (Aubry et al.,
2018; Rosen, 1958; Salje et al., 2018; Succo et al., 2018). Serological data can be used
to monitor risks to public health by estimating population immunity, for example with
ZIKV in Kenya where serum collected between 2007 and 2014 showed no evidence of
prior exposure to ZIKV (Kisuya et al., 2019). In the case of ZIKV the case definition
has been shown to miss the majority of ZIKV infections. Evidence from longitudinal
serological data collected in child participants in Managua, Nicaragua, showed evidence
that the majority of ZIKV infections would not be recorded as ZIKV cases under the
WHO case definition (Burger-Calderon et al., 2020). This is a demonstration of the
potential to study serological data to better understand the epidemiology of arboviruses.
3.1.2 Previous serological surveys of arboviruses in Fiji
This chapter presents results from a serological survey I led in 2017. This study built
on two recent serological studies conducted in Fiji and aimed to sample repeated mea-
surements from previous participants to estimate arbovirus burden and transmission
dynamics in Fiji. In 2013 Watson et al. (2017) collected 1,781 samples from across
the two main islands of Fiji with 695 of them collected from Central Division. They
characterised the epidemiology of typhoid fever and Lau et al. (2016), used the samples
to analyse risk factors for leptospirosis transmission in Fiji.
In 2013, the study team conducted a representative, clustered, cross-sectional seroepi-
demiological survey of the Fijian mainland. Population density sampling methods were
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used and in Central Division samples were collected in clusters of twenty-five partici-
pants. The age of the sampled participants ranged from 1 to 85 years old. To ensure
the sample was population representative nursing zones serving approximately 1,000
to 10,000 people were selected with probability proportional to population size (Ben-
nett et al., 1991). Random number generation using Ministry of Health administrative
records was used. Households were randomly selected and an occupant aged ≥1 year
was randomly selected. In Central Division, age-stratified sampling was used for repre-
sentativeness across age groups. This original study was not focused on arboviruses but
the serum samples collected were subsequently tested for evidence of previous infection
with chikungunya virus (CHIKV), dengue viruses serotypes 1, 2, 3, 4 (DENV-1, -2, -3,
-4), Ross River virus (RRV) and Zika virus (ZIKV).
A large DENV-3 outbreak began after this original serosurvey with suspected cases
reported between October 2013 and August 2014. To better understand the outbreak
dynamics a follow-up serological study was conducted in November 2015. 333 or the
same participants were resampled in 2015 to collect a data set of pre- and post-outbreak
serology. Between May and June 2017, I led a team of public health researchers and
phlebotomists to collect paired samples from the same individuals sampled in 2013, or
tripled samples if the individual was also sampled in 2015.
The two studies conducted in 2013 and 2015 add to a limited evidence base on post-
outbreak seroprevalence for DENV (Kucharski et al., 2018). There were two historic
seroprevalence estimates available but these studies estimated dramatically different
post-outbreak seroprevalence of 25% in 1971-3 following a DENV-2 epidemic (Maguire
et al., 1974) and 54% in 1989-90 after a predominantly DENV-1 epidemic (Water-
man et al., 1993) despite similar numbers of cases in both outbreaks, 3,413 and 3,686
respectively.
A modelling analysis of serum samples collected in 2015 showed evidence that herd
immunity alone was not sufficient for a DENV-3 outbreak to end. Kucharski et al.
(2018), found that seasonal variation and vector control measures contributed to the
end of the 2013-14 DENV-3 outbreak. This demonstrates the potential for serological
data to be used to infer transmission dynamics of a disease, as well as estimating the
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burden of the disease.
Another key contribution from these previous serological surveys was the identification
of low-level ZIKV circulation. ZIKV was first recorded in surveillance data in July
2015 (Kama et al., 2019) and 16 cases were confirmed in total between 2015 and 2017
in Central Division. An outbreak of ZIKV was never declared in Fiji. However, there
was evidence in serological data in 2015 that ZIKV transmission was widespread in Fiji
because an estimated 21.9% of the population were seropositive for ZIKV in 2015 and
phylogenetic analysis found evidence that ZIKV was introduced to Central Division in
late 2013 (Kama et al., 2019). Serological data can provide insight into outbreaks that
are not possible with surveillance data alone.
3.1.3 Expanding uses of serology
Serological data are a vital tool in epidemiological research. When only a single sample
is available for an individual, a threshold titre is often used as evidence of prior exposure
or protection or both. For example seroprevalence estimates of ZIKV in Fiji in 2015
(Kama et al., 2019) and RRV in French Polynesia between 2011 and 2013 (Aubry et al.,
2015b) both showed evidence of silent circulation of these viruses. Salje et al. (2016),
reconstructed sixty years of CHIKV transmission in the Philippines from serological
data. Age stratified serological data can be useful to analyse previous exposure in a
location and if we assume that low seroprevalence is equivalent to high susceptibility
in a certain age group, they can be used to detect potential future outbreaks (Aubry
et al., 2017).
To extend this, if multiple samples are available from the same individual it is possible
to gain more insight from serological data than simply estimating previous exposure.
When only one serum sample is available, a threshold titre is often used to define par-
ticipants as seropositive or seronegative. These threshold values can be used to infer
past exposure or protection or both (Hay et al., 2020). With multiple samples from
the same individuals, longitudinal serology can be used to estimate infection times or
attack rates, as has been done for influenza (Wu et al., 2014). These approaches have
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been used successfully with arboviruses. Salje et al. (2018), used longitudinal data in a
cohort from Thailand to detect sub-clinical infection of DENV. Longitudinal serology,
when paired with knowledge of circulating viruses over the same period, can also help us
better understand the complex cross-reactions of antibodies following flavivirus infec-
tions (Montoya et al., 2018). Generalised tools have been developed to enable analysis
of longitudinal serological data to better understand the immunology and epidemiology
of immune responses following infection (Hay et al., 2020).
3.1.4 2017 serological study outline
The primary outcome of the 2017 study was to characterise ZIKV transmission by esti-
mating seroprevalence and analysing changes in neutralising antibodies, but secondary
outcomes were prevalence and titres against other arboviruses. Before we collected
samples in 2017 we knew that there were 16 confirmed cases of locally acquired ZIKV
in Central Division, Fiji, between 2015 and 2016. We also had estimated that 21.9%
of the population were seropositive by multiplex immunoassay for ZIKV in samples
collected in November 2015 (Kama et al., 2019). The serological data indicated that
ZIKV was circulating before cases were detected by surveillance systems. Additionally,
at the time it appeared that major ZIKV epidemics on islands – such as in French
Polynesia in 2013-14 (Cao-Lormeau et al., 2014b) and Micronesia 2007 (Duffy et al.,
2009) – infected the majority of the population and hence there was sufficient herd im-
munity to prevent outbreaks in the near future (Kucharski et al., 2016). The situation
in Fiji however was less clear. Data from 2015 suggested that there had not been a large
ZIKV outbreak in Fiji yet. However, these results could have been consistent with a
large epidemic that was beginning when data were collected in 2015, or low level ZIKV
circulation over multiple years. We wanted to test more serum samples to characterise
ZIKV transmission over this period.
Representative pre- and post-epidemic paired data are extremely rare for ZIKV, so our
study presents a unique opportunity to investigate this pathogen – and its interaction
with related arboviruses – at multiple time points during an outbreak. Our study
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aimed to answer three main public health questions about ZIKV and other circulating
arboviruses. Firstly, what was the extent of ZIKV infection in Fiji and association
with other arboviruses? Paired serology would show what proportion of the population
are likely to have been infected between 2015-17 and how infection was distributed
spatially. Additionally, we could estimate risk factors for ZIKV infection and potential
association with serological evidence of other arbovirus infections, such as DENV.
Secondly, what proportion of ZIKV infections were reported and were they related
to other health complications? Sample collection would be accompanied by a health
questionnaire. This would make it possible to estimate the proportion of cases that
were asymptomatic, as well as health-seeking behaviour such as visiting their doctor or
healthcare centre.
Finally, what is the level of immunity in the population and what is the potential for
ZIKV to transition to an endemic state? Serological analysis would show how many
people remain susceptible to ZIKV infection and whether a threshold of herd immunity
has been reached. If the level of immunity in the population is too low to provide herd
immunity then it is possible that the effective reproduction number for ZIKV in Fiji
equals one and transmission could have become endemic.
3.2 Materials & Methods
Data collected in 2013 (Lau et al., 2016; Watson et al., 2017) and 2015 (Kama et al.,
2019) were combined with a third seroepidemiological survey in 2017 (Henderson et al.,
2020). The data collection in 2017 has been described in detail in Chapter 2. Briefly,
participants from previous serological surveys in Central Division were recruited for a
third round of data collection between May and July 2017.
Serum samples were tested at Institut Louis Malardé (ILM) in French Polynesia. Test-
ing has previously been described in several publications (Aubry et al., 2015a, 2017;
Beck et al., 2015; Cao-Lormeau et al., 2016; Henderson et al., 2020; Kama et al., 2019;
Kucharski et al., 2018; Watson et al., 2017) and is described in Section 2.2. Briefly, all
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320 serum samples collected in 2017 were tested for detection of immunoglobin class G
(IgG) antibodies against CHIKV, DENV, RRV, and ZIKV using a recombinant-antigen
based microsphere immunoassay (MIA).
3.2.1 Data analysis and serological modelling
I combined all data available from the three serological surveys in 2013, 2015 and 2017.
In total, over the three studies we collected 12,850 measurements of antibodies against
ZIKV, the four DENV serotypes, CHIKV and RRV. Seroprevalence was calculated using
prop.test in R. Tests for association for categorical variables were initially performed
with a χ2 test.
Explanatory variables with evidence of an association with the response variable from
the χ2 test were identified as potential risk factors. I wanted to analyse risk factors for
arbovirus seroprevalence in 2017. A multivariable model was developed from univari-
able risk factors with p values of less than 0.25, after-regrouping sparse cells for numer-
ical stability, using a backward step-wise approach, removing variables with p > 0.1
from a likelihood-ratio test (package lmtest (Hothorn et al., 2019)), with deletion of
observations with missing data.
To analyse non-linear relationships between seroprevalence (as measured by MIA) and
age (as measured by year of birth) I fit a Generalised Additive Model (GAM) (Hastie
and Tibshirani, 1986; Wood, 2017). I defined an explanatory variable X as the year of
birth and I defined serostatus as measured by MIA as the dependent variable Y in the
model, as follows:
g (E (Y )) = α + s1 (X) (3.1)
Where E(Y ) denotes the expected value, and g(Y ) denotes the link function, in this
case the logit function because of the binary outcome. The term s1(X) defines a
non-parametric function to model the non-linear relationship between X and Y and α
is the intercept value when X = 0. I used the mgcv package in R so smooth functions
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were represented using penalised regression splines (Wood, 2019).
3.3 Results
3.3.1 Study population
We collected 320 blood samples in 2017 from individuals in Central Division, Fiji, that
had been previously sampled in 2013. Our sample size decreased between 2013 and
2017, from 455 samples collected and tested in 2013, to 333 in 2015 and 320 in 2017
(Table 3.1). This presented us with a large data set to analyse arbovirus dynamics in
Fiji. To ensure comparability across the three data sets we wanted to validate that
our samples were similarly representative of the general population as they had been
in 2013.
We were particularly interested in the age distribution of the samples between surveys.
Age is strongly related to exposure to arboviruses and we expect seroprevalence to in-
crease with age. We therefore wanted each sample to be representative of the national
population. The sampling methods used in 2013 ensured that the collected sample
closely reflected the age distribution from census data (Figure 3.1). The samples col-
lected in 2015 and 2017 both included a higher proportion of children between 5 and 20
than are in the general population, suggesting that this age group was easier to recon-
tact and sample in follow up surveys. The sample collected in 2017 had a similar age
distribution to the 2013 study and 2007 census data for adults older than 20 (Figure
3.1).
As well as age, we wanted to collect a sample that was comparable across other de-
mographic variables. Table 3.1 shows a breakdown of the study population in each
sampling year by key demographic variables and Figure 3.2 shows these data graphi-
cally for four key variables: sex, rurality, ethnicity and occupation. Broadly, the three
samples collected in 2013, 2015 and 2017 have similar distributions for age, sex, house-
hold size, ethnicity. In 2017 43.8% of the sample were aged under 20, 57% were female
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Figure 3.1: Age distribution of Fijian population from 2007 census data compared to the age
distribution of serological surveys conducted in Central Division in 2013, 2015 and 2017
and 43% male, 42% of households had 4 or fewer occupants and 83.4% of the sample
were iTaukei ethnicity.
The main occupation of participants in the 2017 sample was similar to the previous
surveys in Fiji, although the proportion of our 2017 sample that were in out-of-home
work environments (neither at school or full time home keepers) did decrease (Figure
3.2D). 50% of study participants buried their garbage while 44% had it collected and
approximately one third (31%) of participants travelled regularly, 4-6 days per week
(Table 3.1).
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Table 3.1: Characteristics of the serological surveys conducted in Central Division, Fiji, in
2013, 2015 and 2017
Variable Level 2013 2015 2017
Total 455 [100%] 333 [100%] 320 [100%]
Age (in 2017) (5,10] 56 [12.3%] 32 [9.61%] 37 [11.6%]
(10,15] 42 [9.23%] 41 [12.3%] 42 [13.1%]
(15,20] 47 [10.3%] 38 [11.4%] 34 [10.6%]
(20,40] 145 [31.9%] 99 [29.7%] 105 [32.8%]
(40,60] 108 [23.7%] 81 [24.3%] 63 [19.7%]
(60+) 57 [12.5%] 42 [12.6%] 39 [12.2%]
Sex Male 207 [45.5%] 143 [42.9%] 139 [43.4%]
Female 248 [54.5%] 190 [57.1%] 181 [56.6%]
Rurality Peri-Urban 94 [20.7%] 77 [23.1%] 62 [19.4%]
Rural 157 [34.5%] 113 [33.9%] 135 [42.2%]
Urban 204 [44.8%] 143 [42.9%] 123 [38.4%]
Household (0,4] 227 [49.9%] 154 [46.2%] 135 [42.2%]
(4,8] 205 [45.1%] 159 [47.7%] 157 [49.1%]
(8,12] 22 [4.84%] 18 [5.41%] 21 [6.56%]
(12,16] 1 [0.22%] . .
Missing . 2 [0.601%] 7 [2.19%]
Ethnicity Indo-Fijian 67 [14.7%] 56 [16.8%] 49 [15.3%]
iTaukei 378 [83.1%] 269 [80.8%] 267 [83.4%]
Other 10 [2.2%] 8 [2.4%] 4 [1.25%]
Job Farming 34 [7.47%] 21 [6.31%] 28 [8.75%]
Housewife / husband 126 [27.7%] 95 [28.5%] 94 [29.4%]
Cont.
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Table 3.1: Characteristics of the serological surveys conducted in Central Division, Fiji, in
2013, 2015 and 2017
Variable Level 2013 2015 2017
Other 20 [4.4%] 14 [4.2%] 14 [4.38%]
Pre-School Child 50 [11%] 27 [8.11%] 32 [10%]
Office Worker 17 [3.74%] 12 [3.6%] 9 [2.81%]
Student 121 [26.6%] 102 [30.6%] 95 [29.7%]
Retired 28 [6.15%] 18 [5.41%] 13 [4.06%]
Skilled Manual Worker 35 [7.69%] 24 [7.21%] 21 [6.56%]
Unemployed 22 [4.84%] 19 [5.71%] 13 [4.06%]
Missing 2 [0.44%] 1 [0.3%] 1 [0.312%]
Home material Concrete / Brick 209 [45.9%] 143 [42.9%] 105 [32.8%]
Corrugated Iron 134 [29.5%] 105 [31.5%] 121 [37.8%]
Other 5 [1.1%] 5 [1.5%] 6 [1.88%]
Wood 105 [23.1%] 80 [24%] 88 [27.5%]
Missing 2 [0.44%] . .
Garbage Buried 197 [43.3%] 141 [42.3%] 161 [50.3%]
Collected 236 [51.9%] 169 [50.8%] 142 [44.4%]
Other 22 [4.84%] 23 [6.91%] 17 [5.31%]
Travel Every Day 5 [1.1%] 5 [1.5%] 7 [2.19%]
4 To 6 Days Per Week 147 [32.3%] 110 [33%] 100 [31.2%]
1 To 3 Days Per Week 78 [17.1%] 56 [16.8%] 54 [16.9%]
Once A Month Or More 141 [31%] 96 [28.8%] 96 [30%]
Less Than Once A Month 72 [15.8%] 55 [16.5%] 52 [16.2%]
Never 9 [1.98%] 9 [2.7%] 8 [2.5%]
Missing 3 [0.659%] 2 [0.601%] 3 [0.938%]
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Figure 3.2: Characteristics of serological survey samples in Central Division, Fiji. A, sex
distribution in samples between 2013 and 2017. B, rurality. C, ethnicity. D, occupation
The most notable deviation from previous sampling proportions in our 2017 sample
was with respect to rurality. The proportion of the 2017 sample from rural locations
increased to 42% in 2017 from previous levels in 2015 (34%) and 2013 (35%). Follow
up success rates were higher in rural areas compared to urban areas in 2017. 157 of the
original participants from 2013 lived in rural areas and in 2017 we resampled 86% (135)
of these participants. In peri-urban and urban areas, that percentage decreased to 66%
and 60.3% respectively. Figure 3.3 shows the follow-up success in rural areas compared
to the capital Suva. We typically resampled a higher proportion of participants in
clusters away from the capital and in more remote areas.
We also wanted to monitor the reason for loss to follow up in our study. We attempted
to contact all participants from the 2013 survey in each subsequent survey and did
not replace participants in our follow-up survey if they were lost to follow up. We
collected data on the reason a participant from 2013 was not sampled in follow-up
studies in 2015 and 2017. In 2015, 144 people were not resampled and the main reason
for failing to sample an individual was that they had moved home or could not be found.
By 2017, it was increasingly hard to find participants and 215 participants were not
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Figure 3.3: Follow up success rate in 2017 across Central Division. Dots are located at the
centroid of a cluster of 25 participants originally sampled in 2013. The opaqueness of the
dots indicated the percentage of that cluster successfully resampled in 2017. Darker indicates
a higher percentage were successfully resampled. All clusters in Suva (red diamond) have been
grouped for simplicity. We typically resampled a higher percentage (darker blue) of participants
in rural clusters away from the capital
resampled. It was also more difficult to ascertain whether the participant had moved
home (Figure 3.4). Loss to follow-up in our cohort due to death was small. However,
a larger proportion of potential participants refused to participate in the 2017 study
than had done in 2015.
3.3.2 Flavivirus seroprevalence in Fiji in 2017
We estimated that the most prevalent virus in Fiji was DENV-1 with an estimated 74%
(95% CI: 68.9-78.8%) of the population seropositive. While there have been no reported
outbreaks of DENV-1 in Fiji between 2013 and 2017, this high seroprevalence could
be a result of the large DENV-1 epidemic between 2001 and 2004 (Singh et al., 2005).
Seroprevalence against other DENV serotypes was below 50% for each. Only 25% (95%
CI: 21-30.8%) were seropositive against DENV-2, despite widespread transmission in
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Figure 3.4: Reasons for loss to follow up in serological surveys in 2015 and 2017
early 2017. Seroprevalence against DENV-3 and DENV-4 was estimated to be 45%
(DENV-3 95% CI: 39.8-50.9%) (DENV-4 95% CI: 39.5-50.6%), however there were no
reports of DENV-4 outbreaks in Fiji between 2013 and 2017 but there was a large
DENV-3 outbreak in 2013-14 (Cao-Lormeau et al., 2014a). Seroprevalence against
CHIKV (12.5%; 95% CI: 9.4-17%) and ZIKV (12.5%; 95% CI: 9.1-16.6%) was low
in 2017 and seroprevalence against Ross River virus was 39% (95% CI: 33.7-44.6%),
consistent with endemic circulation of RRV in Fiji (Aubry et al., 2019a) (Table 3.2).
I investigated the relationship between demographic data collected from questionnaires
in 2013 and arbovirus seroprevalence in 2017. I simplified analysis by focusing on
seropositivity to at least one DENV serotype instead of trying to analyse trends in
seroprevalence across all arboviruses that were tested. Overall, 289 of the 320 partici-
pants (90.3%; 95% CI: 86.5-93.3%) were seropositive to at least one DENV serotype in
2017. I used a χ2 test for uniform relationship between categorical variables (age, sex,
rurality etc.) and seroprevalence to at least one DENV serotype in 2017. I found strong
evidence that seroprevalence to at least one DENV serotype was different across groups
of age, rurality, occupation and garbage removal method (Table 3.2). The relative con-
tribution of these factors to risk of arbovirus infection is not known from these data
and there is likely to be strong confounding between groups. For example, younger
participants were more likely to be at school, and garbage removal method depends
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on the urbanisation of the area. Seroprevalence to at least one DENV serotype in-
creased with age from 51.4% (95% CI: 34.4-68.1%) in those between 5 and 10 years
old, to 97.4% (95% CI: 86.5-100%) in those over 60. Participants in rural areas had
lower seroprevalence for at least one DENV serotype compared to those living in ur-
ban or peri-urban settings. There was weak evidence that seroprevalence to at least
one DENV serotype varied by ethnicity with Indo-Fijian seroprevalence to at least one
DENV serotype higher than for iTaukei Fijians (p = 0.1). Seroprevalence to at least
one DENV serotype varied by job, but this is likely confounded by age since it was
highest for retired participants (100%; 95% CI: 75.3-100%) and lowest for students
(69.5%; 95% CI: 59.2-78.5%) and pre-school children (50%; 95% CI: 31.9-68.1%). Fi-
nally, seroprevalence varied by garbage collection method and was highest for those
that had garbage collected (90.1%; 95% CI: 84-94.5%) versus buried (70.2%; 95% CI:
62.5-77.1%). Garbage collection points are typically open areas at the end of residen-
tial streets and could plausibly lead to increased mosquito breeding grounds making
arbovirus infection more likely. There was no evidence of a difference in seroprevalence























Table 3.2: Arbovirus seroprevalence in Fiji in 2017. Number seropositive defined by MIA [percentage of sample]. CHIKV, chikungunya virus.
DENV-1,-2,-3,-4, dengue virus serotypes 1,2,3,4. ZIKV, Zika virus. RRV, Ross River Virus. ≥ 1 DENV, seropositive to at least one DENV
serotype). p, χ2 test comparing seroprevalence to at least one DENV serotype across all levels of that variable (the null hypothesis is that
seroprevalence is the same across all levels in that variable. Smaller p values therefore present stronger evidence against this null hypothesis
and evidence that there is an association between that variable and seroprevalence to at least one DENV serotype)
Variable Level N CHIKV DENV1 DENV2 DENV3 DENV4 RRV ZIKV ≥ 1 DENV p
Total Total 320 41 [12.8] 237 [74.1] 82 [25.6] 145 [45.3] 144 [45] 125 [39.1] 40 [12.5] 289 [90.3] -
Age (5,10] 37 1 [2.7] 14 [37.8] 9 [24.3] 15 [40.5] 9 [24.3] 10 [27] 5 [13.5] 19 [51.4]
***
(10,15] 42 10 [23.8] 22 [52.4] 10 [23.8] 14 [33.3] 17 [40.5] 10 [23.8] 10 [23.8] 27 [64.3]
(15,20] 34 6 [17.6] 24 [70.6] 5 [14.7] 15 [44.1] 17 [50] 10 [29.4] 9 [26.5] 26 [76.5]
(20,40] 105 17 [16.2] 83 [79] 24 [22.9] 48 [45.7] 53 [50.5] 38 [36.2] 4 [3.81] 87 [82.9]
(40,60] 63 4 [6.35] 56 [88.9] 20 [31.7] 32 [50.8] 29 [46] 36 [57.1] 5 [7.94] 59 [93.7]
(60+) 39 3 [7.69] 38 [97.4] 14 [35.9] 21 [53.8] 19 [48.7] 21 [53.8] 7 [17.9] 38 [97.4]
Sex Male 139 21 [15.1] 101 [72.7] 35 [25.2] 65 [46.8] 60 [43.2] 54 [38.8] 18 [12.9] 107 [77]
0.3











































Table 3.2: Arbovirus seroprevalence in Fiji in 2017. Number seropositive defined by MIA [percentage of sample]. CHIKV, chikungunya virus.
DENV-1,-2,-3,-4, dengue virus serotypes 1,2,3,4. ZIKV, Zika virus. RRV, Ross River Virus. ≥ 1 DENV, seropositive to at least one DENV
serotype). p, χ2 test comparing seroprevalence to at least one DENV serotype across all levels of that variable (the null hypothesis is that
seroprevalence is the same across all levels in that variable. Smaller p values therefore present stronger evidence against this null hypothesis
and evidence that there is an association between that variable and seroprevalence to at least one DENV serotype)
Variable Level N CHIKV DENV1 DENV2 DENV3 DENV4 RRV ZIKV ≥ 1 DENV p
Rurality Peri-Urban 62 12 [19.4] 52 [83.9] 20 [32.3] 38 [61.3] 39 [62.9] 28 [45.2] 11 [17.7] 53 [85.5]
***Rural 135 1 [0.741] 81 [60] 23 [17] 38 [28.1] 39 [28.9] 65 [48.1] 12 [8.89] 89 [65.9]
Urban 123 28 [22.8] 104 [84.6] 39 [31.7] 69 [56.1] 66 [53.7] 32 [26] 17 [13.8] 114 [92.7]
Household (0,4] 135 14 [10.4] 106 [78.5] 36 [26.7] 63 [46.7] 61 [45.2] 57 [42.2] 23 [17] 112 [83]
0.46
(4,8] 157 25 [15.9] 111 [70.7] 39 [24.8] 70 [44.6] 71 [45.2] 57 [36.3] 16 [10.2] 120 [76.4]
(8,12] 21 2 [9.52] 15 [71.4] 6 [28.6] 8 [38.1] 9 [42.9] 8 [38.1] 0 [0] 18 [85.7]
Missing 7 0 [0] 5 [71.4] 1 [14.3] 4 [57.1] 3 [42.9] 3 [42.9] 1 [14.3] 6 [85.7]
Ethnicity Indo-Fijian 49 15 [30.6] 42 [85.7] 15 [30.6] 27 [55.1] 27 [55.1] 10 [20.4] 7 [14.3] 44 [89.8]
0.1iTaukei 267 26 [9.74] 191 [71.5] 66 [24.7] 115 [43.1] 114 [42.7] 114 [42.7] 32 [12] 208 [77.9]























Table 3.2: Arbovirus seroprevalence in Fiji in 2017. Number seropositive defined by MIA [percentage of sample]. CHIKV, chikungunya virus.
DENV-1,-2,-3,-4, dengue virus serotypes 1,2,3,4. ZIKV, Zika virus. RRV, Ross River Virus. ≥ 1 DENV, seropositive to at least one DENV
serotype). p, χ2 test comparing seroprevalence to at least one DENV serotype across all levels of that variable (the null hypothesis is that
seroprevalence is the same across all levels in that variable. Smaller p values therefore present stronger evidence against this null hypothesis
and evidence that there is an association between that variable and seroprevalence to at least one DENV serotype)
Variable Level N CHIKV DENV1 DENV2 DENV3 DENV4 RRV ZIKV ≥ 1 DENV p




94 9 [9.57] 81 [86.2] 29 [30.9] 44 [46.8] 50 [53.2] 49 [52.1] 6 [6.38] 84 [89.4]
Other 14 4 [28.6] 13 [92.9] 3 [21.4] 7 [50] 6 [42.9] 3 [21.4] 3 [21.4] 13 [92.9]
Pre-School
Child
32 1 [3.12] 12 [37.5] 8 [25] 12 [37.5] 8 [25] 7 [21.9] 5 [15.6] 16 [50]
Office Worker 9 0 [0] 6 [66.7] 2 [22.2] 5 [55.6] 5 [55.6] 2 [22.2] 0 [0] 8 [88.9]
Student 95 18 [18.9] 56 [58.9] 16 [16.8] 37 [38.9] 38 [40] 24 [25.3] 19 [20] 66 [69.5]
Retired 13 0 [0] 13 [100] 6 [46.2] 8 [61.5] 7 [53.8] 6 [46.2] 4 [30.8] 13 [100]
Skilled Manual
Worker
21 3 [14.3] 17 [81] 8 [38.1] 13 [61.9] 10 [47.6] 9 [42.9] 1 [4.76] 17 [81]
Unemployed 13 4 [30.8] 12 [92.3] 4 [30.8] 7 [53.8] 7 [53.8] 5 [38.5] 0 [0] 12 [92.3]











































Table 3.2: Arbovirus seroprevalence in Fiji in 2017. Number seropositive defined by MIA [percentage of sample]. CHIKV, chikungunya virus.
DENV-1,-2,-3,-4, dengue virus serotypes 1,2,3,4. ZIKV, Zika virus. RRV, Ross River Virus. ≥ 1 DENV, seropositive to at least one DENV
serotype). p, χ2 test comparing seroprevalence to at least one DENV serotype across all levels of that variable (the null hypothesis is that
seroprevalence is the same across all levels in that variable. Smaller p values therefore present stronger evidence against this null hypothesis
and evidence that there is an association between that variable and seroprevalence to at least one DENV serotype)
Variable Level N CHIKV DENV1 DENV2 DENV3 DENV4 RRV ZIKV ≥ 1 DENV p
Home Concrete /
Brick




121 14 [11.6] 88 [72.7] 26 [21.5] 44 [36.4] 43 [35.5] 52 [43] 12 [9.92] 93 [76.9]
Other 6 0 [0] 3 [50] 2 [33.3] 1 [16.7] 1 [16.7] 2 [33.3] 1 [16.7] 4 [66.7]
Wood 88 11 [12.5] 64 [72.7] 22 [25] 43 [48.9] 43 [48.9] 32 [36.4] 16 [18.2] 70 [79.5]
Garbage Buried 161 4 [2.48] 105 [65.2] 34 [21.1] 54 [33.5] 56 [34.8] 82 [50.9] 18 [11.2] 113 [70.2]
***Collected 142 36 [25.4] 118 [83.1] 44 [31] 82 [57.7] 80 [56.3] 38 [26.8] 21 [14.8] 128 [90.1]
Other 17 1 [5.88] 14 [82.4] 4 [23.5] 9 [52.9] 8 [47.1] 5 [29.4] 1 [5.88] 15 [88.2]
p = χ2 test
*** p < 0.001


































































































































































































































































Figure 3.5: Arbovirus seroprevalence in 2017 in Central Division, Fiji, by demographic and environmental factors. Points, estimated sero-
prevalence. Lines, 95% confidence intervals.
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We conducted a short questionnaire when sampling participants in 2017 and asked
about health seeking behaviour and recent ZIKV-like symptoms. Participants were
asked if they experienced a fever or a rash in the previous two years and whether they
visited a doctor because of the symptom. One aim of our study was to test whether
ZIKV-like symptoms and health seeking behaviour were related with ZIKV infection.
We had 202 samples in 2017 that were paired with a 2015 sample. 40 of these 202
sampled participants reported no fever in the previous two years but only 2 reported
a rash in the past two years. There were too few seroconversions between 2015 and
2017 – only 7 out of the 202 paired samples seroconverted from negative to positive
– to investigate the association between health-seeking behaviour and risk of ZIKV
infection.
I wanted to assess whether certain demographic variables increased the probability of
and individual being seropositive. I focused on the most prevalent virus in our study,
DENV-1. I fit univariable logistic regressions and rejected variables with p > 0.5 from
an F -test. I built the final model in a backwards step-wise approach and removed
variables with p < 0.1 from a likelihood ratio test with that variable removed. The
initial full variable set included age group, the number of DENV positive serotypes in
2013, rurality, garbage collection method, home material, ethnicity, primary occupation,
household size and sex. The final model is shown in Table 3.3 and shows strong evidence
in the adjusted model that seroprevalence increases in smaller households, more urban
areas and with age, fully adjusted for each other. Compared to participants younger
than 20, those aged between 20 and 40 had 3.9 times higher odds of seropositivity (95%
CI: 2-8) and those aged 40 and above had 12 times higher odds of seropositivity (95%
CI: 5.2-35). Age had the largest effect on the odds of DENV-1 seropositivity in 2017,
but even after adjusting for age there was strong evidence that those in rural areas
had lower odds of seropositivity. Compared to residents of urban and peri-urban areas,
those in rural areas had 78% lower odds of DENV-1 seropositivity (95% CI: 61-88%),
adjusted for age and households size. There was weak evidence that larger households
(4 or more household members) had 0.63 (95% CI: 0.34-1.1) times the odds of DENV-
1 seropositivity compared to smaller households, adjusted for age and rurality (Table
3.3).
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Table 3.3: Risk factors for DENV-1 seroprevalence in 2017. Odds ratios from a simple
logistic regression and fully adjusted model are shown
Variable Level OR (95% CI) Adjusted OR (95% CI) p
Age (0,20] Ref Ref NA
(20,40] 3.4 (1.9-6.5) 3.9 (2-8) ***
(40+) 6.6 (2.9-18) 12 (5.2-35) ***
Rurality Urban/peri-urban Ref Ref NA
Rural 0.28 (0.16-0.47) 0.22 (0.12-0.39) ***
Household (0-4] Ref Ref NA
(4+) 0.66 (0.39-1.1) 0.63 (0.34-1.1) 0.13
*** p < 0.0001
3.3.3 Sensitivity of cutoff values for arbovirus seroprevalence
in Fiji in 2017
The seroprevalence results presented so far are estimated by converting continuous
measurements of relative fluorescence units (RFU) into positive or negative values ac-
cording to a cutoff value. This value was calculated by laboratory colleagues using
an ROC analysis. To assess the sensitivity of our findings in relation to the choice of
cutoff I analysed the distribution of MIA values in the 2017 serosurvey and recalculated
seroprevalence according to various cutoff values.
Figure 3.6 shows the distribution of RFU values for each virus included in the MIA in
2017 separated by serostatus. Values above the vertical dashed line were classified as
positive and evidence of a previous infection. These data are also presented as ‘S’ shaped
curves by ranking the participants by their MIA value for each virus. A robust assay
would clearly define values as either positive or negative. Ideally, the histograms would
show a bimodal distribution and there would be few values close to the cutoff value. Our
assay was robust when classifying values as positive or negative for CHIKV as there is
very little data near the cutoff value. This is less true for DENV-2 and DENV-4 where
the cutoff value cuts the data in an area of high density on the histogram. This means
100




































































































































































Figure 3.6: Arbovirus MIA RFU values in 2017. Left-hand column shows histograms of
the MIA RFU values for each virus with the cutoff value for seropositivity. Red values were
classified as positive. The right-hand column shows the same data ranked by value. Cutoff
value is shown as a dotted vertical line and red values were classified as seropositive
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that changing the cutoff value slightly would reclassify a lot of observations as positive
or negative and change our estimated seroprevalence.
DENV3 DENV4 ZIKV
CHIKV DENV1 DENV2
1344 1613 1792 1971 2240 1286 1543 1714 1885 2142 416 499 554 609 692
















































Figure 3.7: Arbovirus seroprevalence (2017) by variable cutoff values. The centre dot and
solid line shows the estimate for 2017 seroprevalence and 95% CI. Crosses and dot-dash
vertical lines show seroprevalence estimates if the cutoff was ± 10%. Triangles and dash
lines show seroprevalence estimates if the cutoff was ± 25%.
To test the sensitivity of our estimates of seroprevalence to the choice of cutoff value
I recalculated seroprevalence if the cutoff in 2017 was ± 10% or ± 25%. As seen in
Figure 3.6 the assay is robust to movements in the cutoff for CHIKV as the estimated
seroprevalence ranges between 12.8% and 13.1% across a ± 25% change in cutoff value
(Figure 3.7). For CHIKV, if the cutoff value was 10% higher, the estimated seropreva-
lence would have been 13.1% and if it was 10% lower it would have been 12.8%, a
relative difference of 2.4%. This relative difference in seroprevalence estimates with a
± 10% change in cutoff value was also low for DENV-1 at 3.3% but was higher for
DENV-3, -4, and ZIKV at 11.5%, 12.8% and 9.5% respectively. However, the virus
which was most sensitive to the choice of cutoff was DENV-2 where a ± 10% change in
the cutoff value changed estimated seroprevalence from 22% to 29%, a relative differ-
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ence of 17.6%. This analysis shows that some viruses are more sensitive to the choice
of cutoff value than others.
3.3.4 Trends in seroprevalence for outbreaks in Fiji
I used the cross-sectional serological data from 2017 to investigate the relationship
between seroprevalence and the arbovirus outbreaks an individual might have been ex-
posed to in Fiji. I wanted to assess whether our serological data sensibly recaptures
past outbreaks. To model this non-linear relationship I fit a generalised additive model
(GAM) to seroprevalence data for CHIKV, DENV-1, -2, -3, -4 and ZIKV in 2017 with
an explanatory variable of year of birth with five smooth terms. Figure 3.8 shows
the serostatus of individuals in the 2017 study by year of birth and the probability of
seropositivity for each of the viruses from the GAM. The age-specific pattern of seropos-
itivity broadly reflects the pattern of observed DENV outbreaks and hence potential
exposure to the virus. The probability of DENV-1 seropositivity is lower for those born
after 2003, the last known outbreak of this virus in Fiji. Seropositivity for DENV-3
in 2013-14 and DENV-2 in 2017 – the two DENV viruses that caused the most recent
epidemics – are consistently high across all age groups.





























































































































Figure 3.8: Arbovirus seroprevalence (as measured by MIA) by year of birth and known
outbreaks in Fiji, samples from 2017. Coloured dots, show serostatus by year of birth. Coloured
line and region, predicted serostatus from a GAM fitted to individual serostatus for each virus.
Vertical lines indicate timing of known outbreaks of that virus
This chapter has so far presented analysis of the 2017 data set as a cross-sectional
survey. However, a major strength of this study is that we collected longitudinal sera
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from the same individuals so can investigate changes in seroprevalence and antibody
response against arboviruses over time.
These longitudinal serological data are particularly valuable when combined with knowl-
edge from surveillance data of when certain viruses had confirmed transmission or out-
breaks between 2013 and 2017. There were four notable arbovirus outbreaks over the
study period. There was a large DENV-3 epidemic that began in late 2013 and ended
by July 2014 (Cao-Lormeau et al., 2014a; Kucharski et al., 2018). A DENV-2 out-
break began in January 2017 and spread until September 2017 (Ministry of Health
data). There was low level confirmed local transmission of ZIKV between 2015 and
2017 (Kama et al., 2019). Finally, there was an outbreak of CHIKV in 2016 (Aubry
et al., 2019b; Kama et al., 2019).
Figure 3.9 shows the confirmed and suspected cases from surveillance data for all DENV
viruses, CHIKV and ZIKV, as well as the seroprevalence at each serological survey in
2013, 2015 and 2017. The seroprevalence estimates connected by dotted lines uses all
available data at each survey. The seroprevalence estimates connected by solid lines are
from the subset of our study with observations at each time point (n = 189). DENV-2
and CHIKV show expected dynamics in the seroprevalence data with low pre-outbreak
seroprevalence that increases rapidly between 2015 and 2017. This is true also for
DENV-3 between 2013 and 2015 but estimated seroprevalence declined from 55% (95%
CI: 49.4-60.4%) to 45.3% (95% CI: 39.8-50.9%) after the outbreak. The ZIKV outbreak
shows the most unusual dynamics. Estimated ZIKV seroprevalence increased rapidly
from 7.7% (95% CI: 6-9.9%) to 22% (95% CI: 17.7-26.8%) between 2013 and 2015.
However, there were only 2 cases confirmed in surveillance data during this period.
ZIKV seroprevalence then declined sharply between 2015 and 2017. There were very
few reported cases of DENV-1 or DENV-4, however the seroprevalence estimates did
fluctuate over this period. DENV-1 increased from 68.4% (95% CI: 65-71.6%) in 2013
to 74.1% (95% CI: 68.8-78.7%) in 2017. DENV-4 increased significantly between 2015
and 2017 from 38.7% (95% CI: 33.5-44.2%) to 45% (95% CI: 39.5-50.6%).
In Section 3.3.3 I analysed the effect of changing the cutoff value on seroprevalence
estimates in 2017. This showed that seroprevalence estimates for some viruses were
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Figure 3.9: Seroprevalence for circulating arboviruses in Fiji between 2013 and 2017. Dots
and lines, estimated seroprevalence and 95% confidence interval. Dotted lines connect sero-
prevalence estimates using all available data at each time point. Solid lines connect seropreva-
lence from the same subset of the study with observations at every time point. Vertical lines in
the background show weekly cases of the corresponding virus (Confirmed and suspected cases
for DENV-3 and DENV-2. PCR confirmed cases for DENV-1, DENV-4, ZIKV and CHIKV)
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more sensitive to the cutoff value than others. Here I present those same estimates
alongside estimates from 2013 and 2015 to assess whether the choice of cutoff values
affects our interpretation of the trend in seroprevalence between 2013 and 2017. Figure
3.10 shows the variable 2017 estimates (± 10 or ± 25% change in cutoff value) alongside
the 2013 and 2015 estimates. While the 2017 estimates can range considerably if the
cutoff had been ± 25%, the effect on our conclusions about the trend in seroprevalence
would have been minimal. For example, ZIKV seroprevalence estimates ranged between
10-15% if the cutoff was shifted ± 25%. However, even this highest estimate still shows
a significant decrease from the 2015 estimate. One notable exception to this is DENV-3
where a 25% lower cutoff value would have shown very little change in seroprevalence
between 2015 and 2017.
DENV3 DENV4 ZIKV
CHIKV DENV1 DENV2
2013 2015 2017 2013 2015 2017 2013 2015 2017









































Figure 3.10: Sensitivity analysis of estimated seroprevalence in 2017. Dots, estimated sero-
prevalence. Vertical lines, 95% confidence interval. Triangles and dashed vertical lines, esti-
mated 2017 seroprevalence if cutoff was ± 25%. Crosses and dot-dash vertical lines, estimated
2017 seroprevalence if cutoff was ± 10%
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3.3.5 Change in raw MIA values between 2013 and 2017
The diverse range in seroprevalence dynamics is observable in the raw MIA values as
well as the summary seroprevalence estimates. As explained above, dividing the data
into positive and negative binary values according to a specific cutoff is sensitive to
cutoff value used. I analysed the changes in the raw continuous data between the three
serological surveys and found consistent trends in serological dynamics as in the binary
seroprevalence data.
Figure 3.11 shows the raw MIA relative fluorescence units (RFU) values for DENV-1,
-2, -3, -4, CHIKV and ZIKV in 2013, 2015 and 2017. To analyse whether changes
between surveys were significant I performed two separate paired t-tests to compare
the change in RFU between 2013 and 2015 (n = 312), then 2015 to 2017 (n = 189)
(Table 3.4).
The pattern in changes in raw MIA RFU is similar to that seen in the changes in
summary seroprevalence estimates between surveys. The mean RFU is highest for
DENV-1 in 2013 and very low for ZIKV, CHIKV, and DENV-2. There was very strong
evidence (p < 0.001) of an increase in mean RFU between 2013 and 2015 for DENV-1,
-3, -4 and ZIKV. There was very strong evidence (p < 0.001) of a continued increase
between 2015 and 2017 for DENV-1, -4 and an increase of CHIKV RFU. Meanwhile,
there was evidence (p < 0.01) of a decrease of ZIKV RFU between 2015 and 2017.
Another notable observation from this analysis is that, while the headline seroprevalence
estimate for DENV-3 appeared to decline between 2015 and 2017 from 55% 55% (95%
CI: 49.4-60.4%) to 45.3% (95% CI: 39.8-50.9%) (Figure 3.9), there was no evidence of
a change in mean DENV-3 RFU when analysing the raw MIA values over the same
time period (Table 3.4). This is consistent with an analysis of neutralising DENV-3
antibodies presented in Chapter 4.
Figure 3.12 shows the results from these paired t-tests alongside the summary seropreva-
lence estimates from all three surveys using the original cutoff values. This demonstrates
that the observed trend in estimated seroprevalence between all three surveys is broadly
consistent with the changes in raw MIA RFU values. With the exception of DENV-1,
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Figure 3.11: Arbovirus MIA RFU values between 2013 and 2017. Histograms of the MIA
RFU values for each virus with the cutoff value for seropositivity. Red values were classified
as positive. The right-hand column shows the same data ranked by value
which has the largest raw MIA RFU values (Figure 3.11), the changes in seropreva-
lence are matched by similar dynamics in the raw MIA RFU values. DENV-1 raw values
however, are so large that even a moderate increase in raw MIA RFU did not change
seroprevalence in 2017, and therefore infections in the raw values may have been missed.
Elsewhere, the decrease in ZIKV seroprevalence between 2015 and 2017 is consistent
with a negative change in raw MIA RFU. Large relative increases in seroprevalence
between 2015 and 2017 for CHIKV, DENV-2 and DENV-4 are also observed in the raw
MIA RFU changes.
3.4 Discussion
We successfully resampled 320 participants from a seroepidemiological survey conducted
in 2013 in Fiji and tested samples for evidence of previous infection with a range of
108
Mathematical Modelling of Arbovirus Outbreak Dynamics in Fiji and the Wider Pacific
Table 3.4: Arbovirus seroprevalence in Fiji between 2013 and 2017 as measured by RFU and
changes in RFU between surveys. The mean RFU value and standard deviation in 2013 is
shown alongside estimated change in RFU value between surveys (2013-2015 and 2015-2017).








DENV1 8839 [9840] 2268 (1382 – 3154)** 2580 (690 – 4471)**
DENV2 658 [1543] 126 (-1 – 252) 447 (46 – 848)*
DENV3 2574 [4348] 1227 (797 – 1657)** 93 (-748 – 933)
DENV4 2809 [4371] 650 (222 – 1078)** 2163 (833 – 3494)**
ZIKV -25 [973] 390 (189 – 592)** -287 (-537 – -37)*
CHIKV 170 [1285] -94 (-196 – 9) 2041 (1004 – 3078)**
* p < 0.01, ** p < 0.001






































































































































































































Figure 3.12: Comparison of estimated seroprevalence and raw values from the MIA. For
each virus the left-hand y-axis shows the estimated seroprevalence in each survey (vertical
lines show 95% CI). The right-hand y-axis shows the estimated change in MIA RFU value
(as in Table 3.4). The shaded region connects the 95% CI of the estimated change in MIA
RFU value from a baseline of 0 in 2013 or 2015. Grey horizontal line indicates no change in
the MIA RFU value between surveys
arboviruses. This original study used population representative sampling and, by fol-
lowing a systematic recontacting approach in 2017, our sample still represented the
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population in terms of age distribution and had a similar breakdown to the sample in
2013 in terms of ethnicity, sex and household size, but not by rurality. This serological
survey in 2017 found evidence that approximately 90% (95% CI: 86.5-93.3%) of the
sample were seropositive (as measured by MIA) to at least one DENV serotype (Table
3.2). Seroprevalence was highest for DENV-1 (74.1%; 95% CI: 68.9-78.8%) and lowest
for CHIKV (12.5%; 95% CI: 9.4-17%) and ZIKV (12.5%; 95% CI: 9.1-16.6%) despite
reported recent outbreaks of these viruses (Kama et al., 2019). We found evidence that
arbovirus seroprevalence differed across age groups, by rurality where rural populations
had a lower seroprevalence for all viruses, by occupation, method of garbage collection
and home material. We modelled age-specific seroprevalence – as measured by MIA in
2017 – and found that our data reflected the sequence of observed outbreaks of ZIKV
and DENV in Fiji (Figure 3.8).
We combined data collected in 2017 with previous arbovirus seroprevalence estimates
from the same participants in 2013 (Lau et al., 2016; Watson et al., 2017) and 2015
(Kama et al., 2019; Kucharski et al., 2018). We compared serological dynamics before
and after known outbreaks of DENV-3 between 2013-14 (Cao-Lormeau et al., 2014a;
Kucharski et al., 2018), ZIKV between 2015-17 (Kama et al., 2019), CHIKV between
2015-17 (Aubry et al., 2019b; Kama et al., 2019) and DENV-2 in 2017 (Fijivillage,
2017). Seroprevalence, as measured by MIA, increased following confirmed outbreaks
of each of these viruses (Figure 3.9). However, serological dynamics were different
for these outbreaks and this is reflected in the seroprevalence estimates at each time
point. The largest outbreak was DENV-3 in 2013-14 when seroprevalence increased
from 38% (95% CI: 34.4-41.3%) to 55% (95% CI: 49.4-60.4%) between 2013 and 2015.
In contrast, CHIKV seroprevalence increased from 0.6% (95% CI: 0.2-1.5%) in 2015 to
12.5% (95% CI: 9.4-17%) in 2017. The longer-term serological dynamics following an
outbreak differed as well. Seroprevalence for DENV-3 remained high in 2017 at 45%
(95% CI: 40-50.9%), whereas ZIKV declined rapidly from 22% (95% CI: 17.7-26.8%)
in 2015 to 12.5% (95% CI: 9.1-16.6%) in 2017. This trend will be explored in greater
detail in Chapter 4.
This study was susceptible to selection bias because of our sampling design. Partic-
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ipants in the original 2013 study were never recruited to a longitudinal study and
subsequent sampling was performed opportunistically. As a result, we relied on last
known addresses and contact details to recruit participants to this study in 2017. Some
participants are more likely to be contacted under this framework. Recontacting and
sampling took place during typical business hours and some evening and weekend work
was required, which meant that those who worked at home were more likely to be found
and sampled. This method also meant that we sampled very few young children. The
youngest participant in the study in 2013 was 2 years old, so was 6 by the time samples
were collected in 2017. One limitation of this is that we could not look at serological
patterns in younger children, who can only have experienced certain outbreaks. School-
age children and teenagers are also more likely to be at home during our visits which
helps explain their over-representation in our sample (Figure 3.1). If these groups are
systemically more or less likely to have been exposed to arboviruses then this could
introduce non-random bias to our results. We aimed to mitigate this bias by collecting
a sample as similar to the 2013 baseline as possible. Across a range of demographic
and lifestyle factors we were able to achieve this (Figure 3.2). One notable exception
was rurality, the type of urban area that participants lived. Participants in rural loca-
tions constituted 35% of the 2013 sample, 34% of the 2015 sample but this increased
to 42% of the 2017 sample. We also found evidence that rurality was associated with
lower odds of ZIKV seroprevalence in 2017 (Table 3.3). To estimate the importance
of this change we can compare the unadjusted ZIKV seroprevalence in 2017 of 12.5%
(95% CI: 9.1-16.6%) with the adjusted seroprevalence, using the rurality distribution
from the 2013 sample as weights, which was 12.3% (95% CI: 8.8-16.8%). While this
change in rurality distribution is not ideal it does not appear to have greatly affected
results from 2017. As further evidence for this, we also found similar seroprevalence
dynamics for known outbreaks of arboviruses using a restricted data set – participants
with repeated measurements from 2013, 2015 and 2017 – as in the unrestricted samples
(Figure 3.9). It is therefore reasonable to assume that our sample is representative of
the population, as the 2013 sample was. With respect to sample size we did collect
fewer than our target of 350 participants in 2017. However, with our sample size of 320
and allowing for the observed 3.5% seroconversion we were able to detect a reduction
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in ZIKV seroprevalence from 21.7% to 12.5% with 85.9% power and 95% sensitivity.
This was the third study of the same participants and the challenge to recontact and
resample participants became more difficult with each follow-up survey. As a result,
methods that recruited the maximum number of people in an efficient manner were
preferred to ensure that the sample size was sufficient to make valid inferences. Rurality
is one such example. Rural communities required a more cautious recontacting method
to respect local customs. Contact was made with a village representative, gifts were
offered to thank the village for welcoming us and their previous contributions to our
research. If permission for resampling in the village was granted then the study team
would revisit the next day and a large proportion of that cluster from the 2013 study
would be gathered in a central location in the village to contribute to our 2017 study.
This meant that resampling of rural clusters was more successful than in urban and
peri-urban areas (Figure 3.3). This change in rurality distribution in 2017 is a potential
weakness in the study since we were analysing transmission of viruses mostly spread
by urban-based mosquito species such as Aedes aegypti. As discussed above however,
our findings were valid across the unrestricted and restricted data sets so this logistical
benefit for our study is unlikely to have introduced bias to our results. Repeating
analysis in the restricted population sampled at three time points can help validate
results, as we did here. More broadly, this study design of opportunistic follow-up
appears to have a limit on how many repeat visits are possible without introducing
non-random bias to results and design of future studies should be mindful of this.
We designed our study to be as non-invasive as possible which reduced the extensiveness
of our 2017 data set, but was necessary in light of ethical consideration. Participants
had consented to be contacted for future health research but were not recruited to a
longitudinal study with pre-specified repeat visits. We therefore designed our ques-
tionnaire to be as short as possible so our visit with participants could be as brief as
possible. As a result of this abbreviated questionnaire we did not recollect demographic
or lifestyle information that was collected in 2013. We therefore assumed throughout
this study that values collected in 2013 were still true and valid in 2017. Certain de-
mographic variables such as sex are unlikely to change frequently. Details about a
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participant’s home material or garbage would change if they moved home but this in
turn would mean they were less likely to be part of our 2017 study because they would
have been harder to locate and resample. Another data quality issue is missing data
on household details when participants were resampled in centralised locations in rural
villages. In these settings it was more difficult to ascertain whether the household had
air conditioning or mosquito breeding sites. We had aimed to analyse these data as
potential risk factors for arbovirus seroconversion but due to these data quality issues
we removed this analysis.
We used data from an MIA and defined a cutoff for seropositivity using positive and
negative control sera analysed by ROC curve. The sensitivity and specificity of the MIA
assay were respectively 100% and 100% for DENV-1, 89.5% and 97.1% for DENV-2,
100% and 100% for DENV-3, 96.9% and 100% for DENV-4, and 79.6% and 94.9% for
ZIKV (Henderson et al., 2020). The lower sensitivity for ZIKV in particular suggests
that some ZIKV seropositive participants could have been falsely defined as negative in
our MIA results. These sensitivity and specificity values were calculated using control
sera that were collected shortly after symptomatic arbovirus infections (Cao-Lormeau
et al., 2016; Henderson et al., 2020). These control sera are therefore more likely to have
a strong antibody response to infection than in the general population where arbovirus
infections may be asymptomatic (Haby et al., 2018; Moro et al., 2010). The sensitivity
and specificity of the assay using general population sera may therefore be lower than
the values quoted here. Observed increases in DENV-1 and DENV-4 seroprevalence
over the study period when these viruses were not widely detected could be evidence
of cross-reaction in the assay. The increase in DENV-4 seroprevalence between 2015
and 2017 in particular could be a result of cross-reaction since samples were collected
at the end of an outbreak of closely related DENV-2 (Katzelnick et al., 2015).
Separating the values from our MIA into positive and negative serostatus enabled us
to succinctly summarise the findings from this seroepidemiological survey. However,
separating serological data into dichotomous data has limitations, especially around the
value used to cut data into positive or negative values. In this chapter I have presented
sensitivity analyses of the distribution of the raw MIA values, the effect of changing the
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cutoff value, and an analysis of the change in raw MIA values between surveys. This
work demonstrated that the MIA performed more robustly and was less sensitive to the
choice of cutoff for CHIKV than for DENV and ZIKV. However, although seroprevalence
estimates varied when the cutoff was shifted by ± 25% for DENV and ZIKV, it did not
materially change the conclusions of the trend in seroprevalence between 2013 and 2017
(Figure 3.10). In addition, the trend in seroprevalence estimates matched the changes
in raw MIA RFU values between 2013 and 2017. The large increases in estimated
seroprevalence for ZIKV and DENV-3 between 2013 and 2015, and the decrease of
ZIKV seroprevalence 2015-17, were also found with a paired t-test comparing raw MIA
values. In summary, although dichotomising serological data has limitations, in this
study the dichotomous and continuous versions of the MIA data were complimentary,
and findings were broadly robust to the choice of cutoff value.
Longitudinal serological studies such as this study can help us better understand im-
munity dynamics over time but there are limitations to generalising these results to
protective immunity. We do not know the direct relationship between a specific titre
value or serostatus and susceptibility to further infection. In the case of DENV, it has
been shown that higher values of neutralising antibodies correlate with protection from
symptomatic infection (Katzelnick et al., 2016). Studies have also shown that infection
with one DENV serotype can lead to a cross-reactive immune response against other
serotypes (Calisher et al., 1989; Guzmán and Kouŕı, 2002; Mansfield et al., 2011; Scott
et al., 1983; Wahala and de Silva, 2011). It has also been shown that prior DENV
infection could provide a cross-protective effect against symptomatic ZIKV infection
(Barba-Spaeth et al., 2016; Gordon et al., 2019; Rodriguez-Barraquer et al., 2019). We
found evidence that 12.5% (95% CI: 9.1-16.6%) of our study population had a previous
ZIKV infection but there were only 16 reported cases of ZIKV, which suggests that
most infections in Fiji were asymptomatic, possibly because of the high seroprevalence
for other DENV serotypes. This also shows evidence against the idea that ZIKV im-
munopathogenesis is enhanced in the setting of high seroprevalence of DENV antibodies
(Andrade and Harris, 2018; Dejnirattisai et al., 2016; Paul et al., 2016).
We collected 320 samples in 2017 to complete a population representative, longitudinal
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survey with serological data from two complimentary assays. Population representative
sampling is preferable to convenience sampling from populations such as blood donors
(Netto et al., 2017) as it enables us to generalise conclusions from our sample to the
wider population. Our study now benefits from longitudinal sera at three time points
for 189 study participants. Data from joined sera observations before and after a variety
of arbovirus outbreaks are rare and facilitated a comparison of serological response to
different outbreaks. Our study demonstrates the value of maintaining a sustainable
biobank following cross-sectional seroepidemiological surveys. It was not foreseen in
2013 that those data would be valuable for studying the population immune response
to a ZIKV epidemic but because of the banking of samples and testing for multiple
viruses we were able to maximise the value of samples collected in 2013.
We were able to investigate ZIKV dynamics from a case study in the Pacific where
transmission occurred before a global ZIKV pandemic was declared in 2016 (World
Health Organisation, 2016). This study aimed to answer three public health questions
focused on ZIKV transmission. Firstly, what was the extent of ZIKV infection in Fiji
and association with other arboviruses? We identified a lack of ZIKV spreading, espe-
cially in comparison to other related arboviruses such as DENV-1 and DENV-3 (Table
3.2), and in comparison to international studies of ZIKV seroprevalence (Flamand et al.,
2019; Netto et al., 2017; Zambrana et al., 2018).
Secondly, what proportion of ZIKV infections were reported and were they related to
other health complications? We expected more seroconversions between 2015 and 2017
on the assumption that ZIKV and DENV share similar immune responses following an
outbreak, an assumption with precedent given the antigenic similarity of these viruses
(Priyamvada et al., 2016). However, we found very few seroconversions so we dropped
this analysis because of a lack of power. Other studies have also shown that ZIKV case
detection may have been poorly defined (Burger-Calderon et al., 2020) and case counts
underestimated the burden of the ZIKV pandemic (Moore et al., 2019).
Finally, what is the current level of immunity and what is the potential for ZIKV to tran-
sition to an endemic state? We estimated that a low proportion of Fiji is seropositive
for ZIKV and potentially susceptible to infection. These dynamics and the implications
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for ZIKV herd immunity are explored in more detail in Chapters 4 and 5.
The data introduced in this chapter are used throughout the thesis to facilitate analysis
of arbovirus outbreaks in Fiji. In Chapter 4 I use these serological data to characterise
the long-term antibody response to ZIKV following outbreaks in Fiji and French Poly-
nesia. In Chapter 5 I combined these serological data with surveillance and molecular
data to estimate unobserved transmission dynamics of ZIKV. Finally, in Chapter 6, I
use pre-outbreak serology to improve a real-time forecasting model of a DENV outbreak
and estimate the effect of vector control on transmission.
In this study we collected a large sample of sera in 2017 and combined with previously
collected data, have a longitudinal serological data set to investigate trends in arbovirus
transmission. In this chapter I have presented a summary of what we have found and
how we were able to benefit from our study design. There are limitations that have
stopped us from exploring trends further but this remains a valuable data set for the
study of arbovirus transmission. We were able to explore the burden of arbovirus
transmission in Fiji by extending beyond seroprevalence and investigating antibody
dynamics. However, as the rest of this thesis will demonstrate, the value of these
data are maximised when combined with other data sources from Fiji and the wider
Pacific. Combined with mathematical modelling, these data can be used to investigate
long-term immune responses to ZIKV, unobserved transmission of ZIKV and improve
real-time forecasting of DENV outbreaks.
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4.1 Bridging section
This study, published in January 2020, presents an analysis of data from eight serological
surveys conducted at different time points during Zika virus (ZIKV) outbreaks in French
Polynesia and Fiji.
Serological data are crucial in the study of flaviviruses in humans and in animals.
Infection with dengue virus (DENV) or ZIKV in humans can be asymptomatic and, as
a result, confirmation of flavivirus infections is mostly based on rapid serological tests
such as enzyme-linked immunosorbent assays (ELISAs) (Beck et al., 2015). Multiplex
immunoassays (MIAs) (Aubry et al., 2017; Beck et al., 2015) and plaque reduction
neutralisation assays (PRNTs) (Collins et al., 2017) can be used to test for antibodies
against specific flaviviruses to show evidence of previous infection and estimate the level
of immunity in a population. Serological data has a well-established role in improving
understanding of transmission dynamics of other diseases, such as influenza (Wu et al.,
2011), malaria (Helb et al., 2015), chikungunya virus (Salje et al., 2016) and DENV
(Katzelnick et al., 2017; Salje et al., 2018). The rapid emergence of ZIKV between
2013 and 2016 means that most early seroprevalence estimates were from convenience
sampling (Gake et al., 2017; Gallian et al., 2017; Lozier et al., 2018; Netto et al.,
2017). Convenience sampling is well documented to provide flawed estimates of the
burden of disease, in Human Immunodeficiency Virus for example (Boerma et al., 2003).
We compared seroprevalence estimates from population-representative cross-sectional
studies in French Polynesia and longitudinal seroepidemiological data in Fiji.
The collection of longitudinal serological data from the same individuals allows for more
detailed analysis of population level and within-individual immunological responses to
viruses. The previous chapter in this thesis outlined the study population in Fiji of a
longitudinal seroepidemiological study. Samples collected in this study are positioned
around known periods of ZIKV circulation in Fiji. Samples were initially collected in
November 2013 (Lau et al., 2016; Watson et al., 2017). Chapter 5 will show evidence
that ZIKV began circulating in late 2014 and the follow up serological sample was
collected in November 2015. Community transmission of ZIKV cases were confirmed in
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2015 and 2016 and our final serological sample was collected in June 2017. Analysing
these serological data enabled us to study long-term immunological responses to these
outbreaks which are poorly understood, especially in the case of ZIKV.
This chapter describes a study of serological data from Fiji and French Polynesia and
the level of ZIKV-specific immunity in the population. Samples collected were analysed
by collaborators at Institut Louis Malardé (ILM) in Tahiti, French Polynesia. This is
the only published paper in this thesis. I share first authorship with Dr. Maite Aubry
(ILM) who led the serological analysis. I led the statistical analysis, wrote the R code
to analyse data and wrote the initial draft manuscript that was submitted to journals
and published as a pre-print on BioRxiv in January 2019. The version presented in
here is the published version in eLife (Henderson et al., 2020). The first draft was
conditionally accepted by eLife in June 2019 while I was on a placement at Epicentre
in Paris. I was unable to work on the revisions so Dr. Adam Kucharski led on these.
In the appendix to this chapter I have described the statistical methods used in more
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Abstract
It has been commonly assumed that Zika virus (ZIKV) infection confers long-term pro-
tection against reinfection, preventing ZIKV from re-emerging in previously affected
areas for several years. However, the long-term immune response to ZIKV following
an outbreak remains poorly documented. We compared results from eight serological
surveys before and after known ZIKV outbreaks in French Polynesia and Fiji, including
cross-sectional and longitudinal studies. We found evidence of a decline in seropreva-
lence in both countries over a two-year period following first reported ZIKV transmis-
sion. This decline was concentrated in adults, while high seroprevalence persisted in
children. In the Fiji cohort, there was also a significant decline in neutralising antibody
titres against ZIKV, but not against dengue viruses that circulated during the same
period.
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4.2 Introduction
Zika virus (ZIKV), a flavivirus primarily transmitted to humans by Aedes mosquitoes,
was first reported in the Pacific region on Yap island (Federated States of Micronesia)
in 2007 (Duffy et al., 2009). Six years later, there was a large ZIKV outbreak in French
Polynesia (Cao-Lormeau et al., 2014b) where an estimated 11.5% of the population vis-
ited healthcare facilities with clinical symptoms suggestive of ZIKV infection (Kucharski
et al., 2016). Since then the virus has spread across the Pacific region (Musso et al.,
2014), including to Fiji where cases of ZIKV infection were first detected in July 2015
(World Health Organisation Western Pacific Region, 2017). The same year, cases of
ZIKV infection in Latin America were reported for the first time (Zammarchi et al.,
2015). From February 1 to November 18, 2016, due to its rapid spread and association
with birth defects, microcephaly in newborns and Guillain-Barré syndrome in adults
(Cao-Lormeau et al., 2016) the WHO declared ZIKV a Public Health Emergency of In-
ternational Concern (World Health Organisation, 2016). At the end of 2016, outbreaks
had declined in most of the countries recently affected (O’Reilly et al., 2018). However,
ZIKV was still circulating in 2018 in several countries, including Fiji and Tonga in the
Pacific region (World Health Organisation, 2018).
In countries with known ZIKV outbreaks, the few serological surveys that have been
published found a high level of ZIKV seroprevalence following the outbreak. In French
Polynesia, a population-representative cross-sectional serological survey at the end of
the outbreak in 2014 found a seroprevalence of 49% (Aubry et al., 2017). In Martinique,
a study of blood donors showed a post-outbreak seroprevalence of 42% in 2015 (Gallian
et al., 2017). In Salvador, Northeastern Brazil, a serosurvey in 2016 of prospectively
sampled individuals including microcephaly and non-microcephaly pregnancies, HIV-
infected patients, tuberculosis patients, and university staff, found a post-outbreak
seroprevalence of 63% (Netto et al., 2017). Another study in Salvador, conducted in a
long-term health cohort, also found a post-outbreak seroprevalence of 63% (Rodriguez-
Barraquer et al., 2019). Finally, in paediatric and household cohort studies in Managua,
Nicaragua, ZIKV seroprevalence was estimated to be 46% in households following the
outbreak in 2016 (Zambrana et al., 2018).
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It has been suggested that infection with ZIKV confers immunity that lasts several
years; if so, the high level of seroprevalence in affected countries may reflect sufficient
herd immunity for the current ZIKV epidemic to be over in many locations, with
the virus unable to re-emerge for decades to come (Ferguson et al., 2016; Kucharski
et al., 2016; Netto et al., 2017; O’Reilly et al., 2018). Recent evidence suggests that
neutralising antibodies can distinguish between ZIKV and dengue virus (DENV) – a
closely related flavivirus – and that the immune response following ZIKV infection
can persist over a year (Griffin et al., 2019; Montoya et al., 2018). It has also been
suggested that primary ZIKV infection may confer protective immunity (Osuna et al.,
2016). However, ZIKV serosurveys conducted at the end of the outbreak in French
Polynesia and 18 months later found a drop in seroprevalence in the Society Islands,
the archipelago where over 85% of the inhabitants of French Polynesia reside (Aubry
et al., 2017). Therefore, the long-term antibody response following a ZIKV outbreak
remains unclear.
Here, we explore short- and long-term seroprevalence against ZIKV as well as neutral-
ising responses against ZIKV following two ZIKV outbreaks in the Pacific region. We
compared results from five serological surveys in the Society Islands, French Polynesia,
over a seven-year period, and three serial serological surveys in the same cohort of in-
dividuals in Central Division, Fiji, over a four-year period. These surveys span the pre-
and post- outbreak period in each country, allowing us to examine temporal changes in
antibody responses following a ZIKV outbreak.
4.3 Materials & Methods
4.3.1 Study location and participants
French Polynesia
Four separate ZIKV serosurveys were previously conducted in the Society Islands (Table
4.2). As reported previously (Aubry et al., 2015a, 2017), a first serosurvey (n = 593)
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was conducted in adult blood donors recruited between July 2011 and October 2013,
before the ZIKV outbreak that occurred between October 2013 and April 2014 (Cao-
Lormeau et al., 2014b). Two population-representative serosurveys were conducted
among the general population, firstly between February and March 2014 (n = 196),
and then between September and November 2015 (n = 700). The two studies in the
general population both spanned a range of adult age groups (Table 4.1). An additional
serosurvey was conducted among schoolchildren between May and June 2014 (n = 476).
Finally, a fifth serosurvey was conducted among schoolchildren in the Society Islands
in June 2018 (n = 457) using the same protocol as in 2014 (Aubry et al., 2017).
Table 4.1: Age distribution of study population in French Polynesia. Overall population





Samples in 2014 study Samples in 2015 study
0–9 42,770 0 0
10–19 43,705 3 22
20–29 48,914 10 135
30–39 42,144 5 131
40–49 40,886 8 119
50–59 34,478 15 128
60–69 21,099 2 85
70–79 10,481 5 46
80–89 3,773 0 9
90+ 416 0 0
Fiji
Three serosurveys were conducted in Fiji (Table 4.2). Individuals were first recruited
into a population-representative community-based typhoid/leptospirosis seroprevalence
study between September and November 2013 (Watson et al., 2017) (n = 1, 787), be-
fore autochthonous transmission of ZIKV was first detected in July 2015 (World Health
Organisation Western Pacific Region, 2017). Briefly, nursing zones were randomly
selected, from which one individual from 25 households in a randomly selected com-
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munity was recruited. Participants who had consented to being contacted again for
health research were subsequently recruited in November 2015 in 23 communities in
Central Division through last known addresses, phone numbers and the assistance of
local nurses (n = 327) (Kama et al., 2019). A third follow-up serosurvey was conducted
in June 2017 using the same protocol as in 2015 (n = 321) (Kucharski et al., 2018a).
Follow-up surveys were only performed in Central Division, which was the focus of a
DENV-3 outbreak in 2013–14 (Kucharski et al., 2018a). Only blood samples serially
collected from the same participants (n = 189) in 2013, 2015 and 2017 were analysed
in the main results presented in this study.
4.3.2 Informed consent and ethics approvals
French Polynesia
The five serosurveys were approved by the Ethics Committee of French Polynesia (ref
61/CEPF 08/29/2013, 60/CEPF 06/27/2013, 74/CEPF 05/04/2018, and 75/CEPF
05/04/2018).
Fiji
The original 2013 study, and the 2015 and 2017 follow up studies were approved
by the Fiji National Research Ethics Review Committee (ref 2013–03, 2015.111.C.D,
2017.20.MC) and the London School of Hygiene and Tropical Medicine Observational
Research Ethics Committee (ref 6344, 10207, 12037).
4.3.3 Serological analysis
French Polynesia
Serum samples collected from blood donors between July 2011 and October 2013 and
samples collected from the general population and schoolchildren in 2014 were all tested
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for presence of IgG antibodies against ZIKV and each of the four DENV serotypes using
a recombinant antigen-based indirect ELISA as reported previously (Aubry et al., 2015a,
2017). Samples collected from the general population in 2015 and from schoolchildren
in 2018 were tested by microsphere immunoassay (MIA) using the same recombinant
antigens as for the ELISA (Aubry et al., 2017; Cao-Lormeau et al., 2016; Kama et al.,
2019). Recombinant antigens used in both assays comprised domain III of the enve-
lope glycoprotein of ZIKV, DENV-1, DENV-2, DENV-3, or DENV-4 strains (respective
GenBank accession no. KJ776791, AF226686.1, FM986654, FJ44740.1, FM986672.1)
and were produced using the Drosophila S2 expression system (Life Technologies, USA)
as previously detailed (Aubry et al., 2015b). Serostatus was defined by a cut-off deter-
mined using positive and negative control sera analysed by ROC curve. The sensitivity
and specificity of the MIA assay were respectively 100% and 100% for DENV-1, 89.5%
and 97.1% for DENV-2, 100% and 100% for DENV-3, 96.9% and 100% for DENV-4,
and 79.6% and 94.9% for ZIKV. The positive control sera for ZIKV was collected 13
months after RT-PCR confirmed infection. In the serosurvey conducted among the gen-
eral population of the 5 archipelagos in French Polynesia in 2014 (Aubry et al., 2017),
196 samples were tested using both ELISA and MIA: among the 97 serum samples
that tested positive for anti-ZIKV IgG by ELISA, 78 (80%) were also found positive
by MIA; and among the 99 serum samples that tested negative for anti-ZIKV IgG by
ELISA, 70 (71%) were also found negative by MIA. This produced a value of Cohen’s
κ = 0.51 (Aubry et al., 2017).
Fiji
All serum samples collected in Fiji were tested using MIA to detect IgG antibodies
against ZIKV and all four DENV serotypes as previously reported (Aubry et al., 2017;
Cao-Lormeau et al., 2016; Kucharski et al., 2018a). To follow the evolution of antibody
titres at the individual level, a subset of samples collected from the same individuals
in 2013, 2015 and 2017 were tested for the presence of neutralising antibodies against
ZIKV and each of the four DENV serotypes using a neutralisation assay as previously
described (Cao-Lormeau et al., 2016). ZIKV log titres followed a bimodal distribution,
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Figure 4.1: Distribution of ZIKV neutralisation titres in the Fiji serosurveys. Results shown
for 45 participants who had samples available from 2013, 2015, and 2017. Dashed line shows
the threshold used to define seropositivity
Of the 9/45 participants who were seropositive to ZIKV by neutralisation assay in 2013,
all were seropositive to at least one DENV serotype (Figure 4.2). To assess the potential
for cross-reactive antibody responses, we examined the correlation between changes in
log titre to different viruses between 2013 and 2015. As well as the 45 participants who
had three samples from 2013, 2015, and 2017, we also had an additional 24 participants
from the same cohort for whom we had sufficient serum from 2013 and 2015 to test by
neutralisation assay (i.e. 69 paired samples in total). Among the 20/69 participants
that tested seronegative against all five viruses in 2013 and were re-tested in 2015, there
was no evidence of an association between changes in ZIKV titre and changes in titre
against any of the DENV serotypes, suggesting that the changes in ZIKV titre were
unlikely to be strongly influenced by DENV cross-reaction (Figure 4.3). However, the
49/69 participants who had a pre-2013 DENV exposure and a large rise against ZIKV
between 2013–15 tended to exhibit a smaller rise against DENV viruses (Figure 4.4).
A previous study, which tested serological samples from Fiji across three divisions
(Kama et al., 2019), found that of the samples reactive by MIA, 66/83 (79.5%) exhibited
neutralising activity for ZIKV (κ = 0.71) and 109/112 (97.3%) for DENV (κ = 0.80).
In this study, we tested what proportion of samples for the 45 participants in the full
data set (i.e. 135 samples in total) that were seropositive or seronegative by MIA had
the same result by the neutralisation assay. We found that 54/68 (79.4%) samples that
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were positive to ZIKV by MIA were also positive in the neutralisation assay, and 42/67
(62.7%) who were seronegative were also negative by neutralisation assay (κ = 0.42).
We also calculated the proportion positive by neutralisation assay that had the same
result by MIA. We found that 54/79 (68.4%) samples that were positive to ZIKV in the
neutralisation assay were also positive by MIA, and 42/56 (75%) who were seronegative
were also negative by MIA.
4.3.4 Statistical analysis
For data from Fiji, where serial samples were collected from the same individual, changes
in seroprevalence between studies were tested using McNemar’s test. In French Polyne-
sia, chi-squared tests were performed to test for evidence of a change in seroprevalence
between two cross-sectional surveys. Changes in mean log titre between groups were
analysed using a t-test. To analyse the potentially non-linear relationship between
DENV neutralisation titres and seroprevalence by MIA and neutralisation test (Fig-
ure 4.13), we used a generalized additive model via the mcgv package in R (Wood,
2019). The model was of the form g(E(y)) = b + f(x), where y was the binary out-
come variable, x was the predictor (i.e. titre), g was the link function, b was the
intercept, and f was a smooth function represented by a penalized regression spline.
Mean DENV titre was calculated as the mean of log titres against the four DENV
serotypes for each participant. All data and code used in the analysis are available at:
https://github.com/a-henderson91/zika-sero-pacific/.
4.4 Results
In French Polynesia, seroprevalence of IgG antibodies against domain III of the ZIKV
envelope glycoprotein in blood donors recruited before October 2013 was <1% (0.3%-
2%), which confirmed that the virus had not previously circulated in the population
(Table 4.2). Analysis of samples collected in the general population of the Society
Islands of French Polynesia after the emergence of ZIKV showed a decrease in ZIKV
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Figure 4.2: Individual-level neutralisation log titres against the four DENV serotypes and
ZIKV in Fiji. Points show assay results in the 2013, 2015 and 2017 sample collections for
each participant, coloured by virus (n=45)
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Figure 4.3: Correlation between rise in DENV and ZIKV neutralisation log titres between
2013-2015 for participants who were initially seronegative (i.e. log titre < 2) to all five viruses
in 2013 (n=20). There is significant correlation between DENV-1 and DENV-3 viruses (top
row, p=0.0012), suggesting likely cross-reactive responses. However, changes in ZIKV titres
were not associated with responses to any of DENV viruses (far right column), which strongly
indicates that the ZIKV results were genuine infections
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Figure 4.4: Correlation between change in DENV and ZIKV log titres between 2013-2015
for participants who were initially seropositive (i.e. log titre ≥ 2) to at least one DENV virus
in 2013 (n=49). There is significant correlation between ZIKV and other DENV viruses,
suggesting likely cross-reactive responses. However, there was limited circulation of viruses
such as DENV-1 and DENV-2 during 2013–15 (Figures 4.6, 4.7), suggesting that it was
infection with ZIKV that generated a cross-reactive response against these viruses, rather
than the other way around
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seroprevalence from 37% (26%-47%) to 22% (16%-28%) between February-March 2014
and September-November 2015 (chi-squared test, p = 0.03). In Fiji, analysis of the
serum samples serially collected from a cohort of participants in the Central Division
showed an increase in ZIKV seroprevalence from 6.3% (3.3%-11%) in October-November
2013 to 24% (18%-31%) in November 2015 (chi-squared test, p < 0.0001), and then
a decrease to 12% (7.9%-18%) by June 2017 (chi-squared test, p = 0.005). In this
cohort, based on IgG results tested by microsphere immunoassay (MIA), 6 of the 189
participants seroconverted (from negative to positive) and 28 seroreverted (from positive
to negative) to ZIKV between 2015 and 2017 (McNemar’s test, p = 0.0003).
Table 4.2: Seroprevalence of ZIKV among participants in five serological surveys in French


















18-75 (36) 5/593 0.8 [0.3-2.0]










General, MIA 4-88 (43) 154/700 22 [16-28]*

















Central Division, Fiji General, MIA 2-78 (27) 12/189 6.3 [3.3-11]
Jul 2015 First confirmed local transmission of ZIKV in Fiji
Nov 2015 Central Division, Fiji General, MIA 4-80 (26) 45/189 24 [18-31]
Jun-2017 Central Division, Fiji General, MIA 6-82 (28) 23/189 12 [7.9-18]
* CIs were calculated taking into account the cluster sampling design (Aubry et al., 2017) and using Fisher exact test
MIA - microsphere immunnoassay
To investigate possible factors influencing the decline in seroprevalence, we compared
the seroprevalence profiles in children (defined as ≤16 years) and adults (>16 years)
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in both settings (Table 4.2 and Figure 4.5). In French Polynesia, although ZIKV sero-
prevalence declined in the general population from the Society Islands over 18 months,
there was no evidence of a significant decline in seroprevalence in two serosurveys con-
ducted four years apart in schoolchildren aged 6 to 16 years, with 66% (60%-71%)
positive in 2014 and 64% (58%-69%) in 2018 (chi-squared test, p = 0.6) (Table 4.2).
When stratifying the general population from the Society Islands by age (≤16 years and
>16 years), there was a decline in adults in the two consecutive cross-sectional studies
conducted in 2014 and 2015, from 35.4% (22.2%-50.5%) to 21.3% (18.2%-24.5%) (Fig-
ure 4.5). A decline in adults was still observed, albeit with larger uncertainty, when
the two data sets were standardised according to the age distribution of the popula-
tion, with age-adjusted seroprevalence decreasing from 32.0% (16.7%–62.1%) to 26.0%
(20.1%–33.9%) (Table 4.3).
Table 4.3: Age-adjusted seroprevalence by MIA in participants aged over 16 in the general
population of the Society Islands in French Polynesia, based on serosurveys conducted in 2014












DENV1 85 (72-94) 83 (55-100) 80 (77-83) 80 (71-91)
DENV2 48 (33-62) 50 (28-87) 19 (16-22) 21 (15-21)
DENV3 75 (60-86) 72 (47-100) 56 (52-60) 55 (48-64)
DENV4 63 (47-76) 65 (40-100) 42 (38-46) 45 (38-54)
ZIKV 35 (22-50) 32 (16-62) 21 (18-25) 26 (20-34)
* chi-squared test comparing 2014 bootstrap estimates with 2015 results
In Fiji, in the subset of individuals who were aged over 16 years (n = 122), there was a
decrease in seroprevalence by MIA from 24% (17%-33%) in 2015 to 7.3% (3.4%-13%)
2017 (Figure 4.5). There were two seroconversions in the collected samples over this
period but 23 seroreversions (McNemar’s test, p < 0.0001) (Table 4.4). In contrast sero-
prevalence in participants aged 16 and under (n = 67) remained relatively stable over
this period (Figure 4.5), with four seroconversions and five seroreversions (McNemar’s
test, p = 1) (Table 4.4).
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Figure 4.5: Dynamics of ZIKV seroprevalence following outbreaks in Fiji and French Poly-
nesia. A) Seroprevalence by MIA in Fiji. Red, seroprevalence and 95% confidence intervals
for children (aged ≤16 years). Orange, seroprevalence and 95% confidence intervals for adults
(aged >16 years). Solid lines, trends in data collected from the same individuals. Dotted line
indicates the first confirmed ZIKV case. (Continued on the following page)
141
Chapter 4. Zika seroprevalence in Fiji and French Polynesia
Figure 4.5: caption (continued): B) Epidemiological dynamics in Fiji between 2013 and
2018. Coloured bars show number of PCR-confirmed samples of different DENV serotypes
and ZIKV in Fiji; black lines show reported prolonged fever in Fiji from the Pacific Syn-
dromic Surveillance System (World Health Organisation, 2018). There was a major outbreak
of DENV-3 outbreak in 2013–14 (Kucharski et al., 2018a) with a smaller DENV-2 outbreak
in early 2017 (Aubry et al., 2019). C) Seroprevalence by MIA in French Polynesia. Dashed
lines, trends in seroprevalence between population representative cross-sectional surveys. Note
that the pre-outbreak samples were collected between July 2011 and October 2013; for brevity,
the latest possible collection date is used in the plot. D) Epidemiological dynamics in French
Polynesia between 2013 and 2018. Solid black line shows reported symptomatic dengue cases;
dashed lines showed reported symptomatic Zika cases. In French Polynesia, between the sam-
pling periods, there were no reported DENV outbreaks for serotypes 2,3,4, and there was
hyper-endemic DENV-1 circulation. In April 2019, a DENV-2 outbreak was declared, the
first since 1997 (Aubry et al., 2019)
In order to assess whether the decline in ZIKV seroprevalence was also observed for other
circulating flaviviruses, the MIA seroprevalence pattern against each of the four DENV
serotypes was analysed in both countries, by age group (Figures 4.6, 4.7, 4.8, 4.9).
In Fiji, seroprevalence for DENV-1, DENV-2 and DENV-4 increased in participants
in both age groups between 2013 and 2017. DENV-3 seroprevalence also increased in
both age groups between 2013 and 2015 following an outbreak in 2013–14 (Kucharski
et al., 2018a) and then declined in 2017 from 44% (32%-57%) to 40% (28%-52%) in
children (McNemar’s test, p = 0.6) and from 59% (50%-68%) to 49% (40%-58%) in
adults (McNemar’s test, p = 0.01) (Figure 4.8). In French Polynesia between 2014 and
2018, seroprevalence in children aged under 16 years showed no evidence of a change for
DENV-1 and DENV-2 (chi-squared test, p = 0.1917 and p = 1, respectively) (Figures
4.6, 4.7) and decreased for DENV-3 and DENV-4 (chi-squared test, p < 0.0001 and
p = 0.0085, respectively) (Figures 4.8, 4.9). In adult participants from the general
population, seroprevalence for all four DENV serotypes declined between 2014 and
2015.
The age-adjusted values for seroprevalence by MIA for the four DENV serotypes were
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Figure 4.6: Seroprevalence against DENV-1 in Fiji and French Polynesia, by age group.
Figure colour scheme and data characteristics are same as in Figure 4.5
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Figure 4.7: Seroprevalence against DENV-2 in Fiji and French Polynesia, by age group.
Figure colour scheme and data characteristics are same as in Figure 4.5
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Figure 4.8: Seroprevalence against DENV-3 in Fiji and French Polynesia, by age group.
Figure colour scheme and data characteristics are same as in Figure 4.5
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Figure 4.9: Seroprevalence against DENV-4 in Fiji and French Polynesia, by age group.
Figure colour scheme and data characteristics are same as in Figure 4.5
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Table 4.4: Detection of IgG by MIA against ZIKV in the paired samples from participants
aged under and over 16 years recruited during October-November 2015 and June 2017 in the
Central division in Fiji (n = 189). Age groups are defined using age of participants when
recruited to the study in 2013
2017
≥ 16 years >16 years Total participants
2015 ZIKV+ ZIKV- ZIKV+ ZIKV- ZIKV+ ZIKV-
≥16 years
ZIKV+ 10 5 – – – –
ZIKV- 4 48 – – – –
> 16 years
ZIKV+ – – 7 23 – –
ZIKV- – – 2 90 – –
Total
Participants
ZIKV+ – – – – 17 28
ZIKV- – – – – 6 138
similar to the raw values, suggesting that the decline in French Polynesia could not
be explained by differences in sampling by age. However, a higher proportion of the
samples in 2014 tested positive by MIA for all four DENV serotypes (Table 4.5), sug-
gesting that the sampling included a group at higher risk for arbovirus infection than
those sampled in 2015. To check that the estimated decline in ZIKV seroprevalence
was not an artefact of this sampling bias, we re-estimated seroprevalence for the four
DENV serotypes and ZIKV using a bootstrap sample of the 2014 responses, with re-
placement, weighted by the DENV exposure profile (excluding the virus of interest) in
the 2015 survey so that the bootstrap sample of the 2014 responses had a similar DENV
exposure profile as in the 2015 responses. For example, when generating bootstrap es-
timates for DENV-1 in 2014, we resampled participants based on the distribution of
number of exposures to DENV-2, DENV-3, and DENV-4 in the 2015 data (Table 4.6).
After adjusting for prior exposure, there was no significant decline in seroprevalence for
DENV-1, DENV-3, or DENV-4, which had all circulated in the five years preceding the
2014 data collection, whereas the decline in ZIKV was still present (chi-squared test,
p = 0.0047).
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Table 4.5: Age distribution and profile of DENV exposure history in two cross-sectional
surveys conducted in the general population from the Society Islands, French Polynesia, in
2014 and 2015. While the age distribution is similar in both studies, the sample in 2014 has
a higher proportion of individuals who have tested positive for infection from all four DENV
serotypes by MIA
Variable 2014 (n = 49) 2015 (n = 700)
Age distribution (median [IQR]) 47 [29-56] 43 [29-57]
Number of DENV serotypes positive at time of sample collection (n [%])
0 3 [0.061] 118 [0.17]
1 6 [0.12] 163 [0.23]
2 11 [0.22] 159 [0.23]
3 11 [0.22] 154 [0.22]
4 18 [0.37] 106 [0.15]
To explore dynamics of antibody waning at the individual level, we performed neutrali-
sation assays (NT) on a subset of 45 participants from Fiji for whom sufficient sera were
available to test against ZIKV from all three collection periods. We found that in the 31
individuals who were ZIKV seronegative (i.e. log titre < 2) in 2013 and had a rise in log
titre ≥ 2 against ZIKV between 2013 and 2015, anti-ZIKV antibody responses waned
significantly in 2017, with an average decline in log titre of -1.94 (t-test, p < 0.0001)
(Figure 4.10A and Table 4.7). In total, four participants seroreverted between 2015 and
2017; all had a log titre of 4 against ZIKV in 2015. We observed a similar effect when
we analysed all participants who had a rise in log titre of at least 2 between 2013–15,
regardless of serostatus in 2013 (Figure 4.11).
To test whether the dynamics of anti-ZIKV antibody waning were different from the
responses to DENV infection, we compared results for ZIKV to the neutralisation re-
sponse following a DENV-3 infection in the same cohort from Fiji. There was a large
DENV-3 epidemic during 2013–14 in Fiji (Osuna et al., 2016), which meant most sero-
conversions to DENV-3 occurred between the collection of samples in 2013 and 2015.
In those individuals that seroconverted to DENV-3 (n = 19) or ZIKV (n = 31) be-
tween 2013 and 2015, the initial rise in NT log titres against ZIKV was larger than for
DENV-3, with a mean change of 5.0 and 3.37 respectively (4.10B and Table 4.7). All
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Table 4.6: Bootstrap estimated seroprevalence for each of the four DENV serotypes and
ZIKV adjusted for sampling bias in two cross-sectional surveys conducted in the general pop-
ulation from the Society Islands, French Polynesia, in 2014 and 2015. Results from the
cross-sectional surveys in the Society Islands, French Polynesia, in 2014 and 2015 show a de-
cline in seroprevalence by MIA against all 4 DENV serotypes and ZIKV. However, the 2014
sample included more individuals that tested positive for >1 DENV serotype and are assumed
to be a higher risk group. We used a bootstrap method with 10,000 iterations which estimated
seroprevalence from a sample of the 2014 data set, taken with replacement, weighted by the ex-
posure distribution to other DENV viruses in the 2015 survey. After adjusting for the sample
bias, there was no evidence of a decline in seroprevalence for DENV-1, DENV-3, or DENV-4,
which had circulated in the years preceding the 2014 sample collection (World Health Organi-










(95% CI) (n = 700)
p-value*
DENV1 86 (73-94) 74 (61-86) 80 (77-83) 0.36
DENV2 47 (33-62) 38 (24-53) 18 (15-21) 0.0008
DENV3 76 (61-87) 64 (51-78) 55 (51-59) 0.21
DENV4 63 (48-77) 50 (37-65) 42 (38-46) 0.42
ZIKV 37 (23-52) 42 (29-55) 22 (19-25) 0.0047
* chi-squared test comparing 2014 bootstrap estimates with 2015 results
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individuals who had seroconverted to DENV-3 remained seropositive to the virus in
2017, while four individuals who had seroconverted to ZIKV were seronegative in 2017.
Although the NT log titres increased by a mean of 0.89 for DENV-3 between 2015 and
2017 (two-sided t-test, p = 0.04), log titres against ZIKV declined by a mean of 1.94
over the same period (two-sided t-test, p < 0.001) (Figure 4.10A and Table 4.7).


































Figure 4.10: Waning of neutralising antibody responses against ZIKV and DENV-3 in Fiji
for participants who were seronegative in 2013 and seroconverted in 2015. A) Histogram of
change in neutralisation assay log titre against DENV-3 (n =19) and ZIKV (n=31) between
2013–2015 for individuals who seroconverted to these respective viruses between 2013–2015
(i.e. log titre < 2 in 2013 and log titre ≥ 2 in 2015). B) Histogram of change in log titre
against DENV-3 and ZIKV between 2015-2017 for these individuals
In Fiji, there was a delay of around 18 months between the end of the 2013–14 DENV-
3 epidemic and collection of samples in 2015. As DENV titres can wane following
infection, particularly in individuals with a prior DENV exposure (Clapham et al.,
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Figure 4.11: Waning of neutralising antibody responses against ZIKV and DENV-3 in Fiji
for participants who had a four-fold rise between 2013 and 2015. Histogram of change in
neutralisation assay log titre against DENV-3 (n =25) and ZIKV (n =35) between 2013–2015
for individuals who had a rise in log titre of at least 2 to these respective viruses between
2013–2015. B) Histogram of change in log titre between 2015–2017 against DENV-3 and
ZIKV for individuals who had a rise of at least 2 during this period
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Figure 4.12: Waning of neutralising antibody responses against DENV-1 and DENV-2 in
Fiji for participants who were seronegative in 2013 and seroconverted in 2015. Histogram of
change in neutralisation assay log titre against DENV-1 (n=26) and ZIKV (n=18) between
2013–2015 for individuals who seroconverted between 2013–2015 (i.e. log titre < 2 in 2013
and log titre ≥ 2 in 2015). B) Histogram of change in log titre against DENV-1 and DENV-2
between 2015-2017 for these individuals
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Table 4.7: Change in neutralisation titre between 2013-2017 in a cohort of 45 study partic-
ipants in Fiji. ZIKV and DENV-3 both circulated between the collection of samples in 2013
and 2015 with ZIKV first reported in July 2015 and DENV-3 circulating between October 2013
and January 2015. neutralisation titre levels rose significantly over this period. Between 2015
and 2017, DENV-3 titre levels still increased with a mean change in tire of 0.89. By contrast,














3.4 [2.9, 3.9] 0.89 [0.046, 1.7]
* t-test comparing change in neutralisation titre for ZIKV and DENV-3 between 2013-2015, and 2015-2017
2016), titres against DENV-3 in Fiji may therefore have had more time to wane and
reach a stable persistent level than titres against ZIKV, which may have circulated
later than DENV-3. We therefore analysed changes in titre for participants who were
initially seronegative to DENV-1 and DENV-2, which were circulating at low levels
in Fiji between the two serological surveys in 2013 and 2015 (Figure 4.5). As with
DENV-3, we found no evidence of a subsequent overall decline during 2015–17 for
those participants who seroconverted to DENV-1 or DENV-2 during 2013–15 (Figure
4.12).
Of the 45 participants tested by neutralisation assay, 9 were initially seropositive to
ZIKV by NT in 2013. Fitting a generalised additive model to these data, we found that
higher baseline mean NT log titres against DENV were associated with an increased
probability of seropositivity to ZIKV (Figure 4.13A). In contrast, higher baseline mean
DENV titres were not associated with increased seropositivity by MIA in 2013. There
was little difference between the assay results in the 2015 samples (Figure 4.13B), but
we did find evidence of a difference in the 2017 results, with 15/45 participants positive
by MIA and 31/45 positive by NT. This difference was associated with participants’
2013 DENV titres: those with intermediate DENV titres in 2013 had a significantly
lower probability of being seropositive in the MIA in 2017 compared to NT (Figure
4.13C).
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Figure 4.13: Relationship between mean DENV log neutralisation titre across the four
serotypes in 2013 and ZIKV seroprevalence using different assays. (A) Seroprevalence by
MIA, shown in grey, and neutralisation test (NT), shown in orange, for sera collected in
2013. Line shows prediction from GAM fitted to each data set, with shaded region show-
ing 95% CI, and points show raw data. (B) Seroprevalence for sera collected from the same
participants in 2015. (C) Seroprevalence for sera collected from the same participants in 2017
4.5 Discussion
Analysing data from serological surveys conducted in French Polynesia and Fiji at
different time points after the first reported autochthonous ZIKV transmission, we
found evidence of a decline in ZIKV seroprevalence. The high number of participants
from the Fijian cohort that seroreverted between 2015 and 2017 suggested that anti-
ZIKV antibody levels waned in these individuals to the point that they were no longer
detectable by MIA. Using a neutralisation assay to test longitudinal sera collected in
Fiji, we found that the mean change in neutralising antibody titres against ZIKV also
decreased significantly between 2015 and 2017, showing that individual-level antibody
titres against ZIKV as well as overall seroprevalence decreased over time. In contrast,
over the same period, neutralising antibody titres against DENV-3, a closely related
flavivirus which caused a large epidemic in Fiji in 2013-2014 (Kucharski et al., 2018a),
remained stable.
In both countries we found seroprevalence against ZIKV in individuals aged over 16
declined over the two-year period following an outbreak, while the overall level of sero-
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prevalence persisted in children. This pattern was unique to ZIKV compared to DENV
in both countries. It is possible that this is related to the DENV immunological pro-
file of individuals, given that the older population is likely to have experienced more
DENV infections over their lifetime. If an individual has experienced prior DENV in-
fections, high numbers of weakly neutralising cross-reactive B cells may outcompete
näıve B cells for ZIKV antigen (Midgley et al., 2011), leading to a short-term boost
in antibody response against ZIKV following ZIKV infection (Robbiani et al., 2017)
but not a persistent specific response; a similar phenomenon has been observed for
other antigenically variable viruses like influenza (Kucharski et al., 2018b). In the 2017
samples, more participants remained seropositive in the neutralisation assay – which
measures the overall ability of sera to neutralize ZIKV – than in the MIA, which tests
for IgG antibodies against domain III of the envelope glycoprotein. This difference was
greatest for participants who had intermediate baseline titres to DENV in 2013 (Figure
4.13C), which would support the hypothesis that prior DENV exposure may result in
a detectable short-term specific response against ZIKV following ZIKV infection (as
measured by MIA), but not a persistent specific response.
To our knowledge, the only other study to date that has investigated the long-term
persistence of neutralising antibodies against ZIKV was conducted in 62 residents of
Miami (Florida, USA), who had a confirmed ZIKV infection in 2016 (Griffin et al.,
2019). This cross-sectional study found that all participants had neutralising antibodies
against ZIKV 12–19 months after infection. This study also found that at least 37% of
the participants had no evidence of past DENV infection, which is consistent with the
hypothesis that anti-ZIKV immune responses may persist longer in populations that
have had less exposure to DENV. More data are therefore needed to test hypotheses
about the potential impact of pre-existing anti-DENV immune response on anti-ZIKV
antibody waning.
Although we found evidence of a decline in seroprevalence for antibodies against domain
III of the envelope glycoprotein, as well as waning neutralising antibody responses fol-
lowing two ZIKV outbreaks, the implications for susceptibility to future ZIKV infection
remain unclear. Given the antigenic similarity of DENV and ZIKV (Priyamvada et al.,
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2016), it is commonly assumed that the immune response to ZIKV infection will be sim-
ilar to that following DENV infection. High levels of neutralising antibodies to DENV
have been shown to correlate with protection from symptomatic infection (Katzelnick
et al., 2016). Moreover, infection with a single DENV serotype can confer lifelong im-
munity to the infecting serotype as well as a transient period of cross-neutralisation
against heterologous serotypes (Wahala and de Silva, 2011). However, it is unclear in
the context of ZIKV what the relationship is between a specific titre value and suscep-
tibility to further infection. A key aim for future work will be establish how waning
antibody levels as measured by MIA and neutralisation assays may impact protective
immunity, and hence susceptibility to reinfection in populations that have already ex-
perienced transmission of ZIKV.
There are some additional limitations to our analysis. First, we did not have reverse
transcription polymerase chain reaction (RT-PCR) confirmation of ZIKV infection in
individuals sampled in this study. We have presented analysis of representative serolog-
ical surveys in two locations with known, RT-PCR-confirmed ZIKV outbreaks (Mallet
Anne-Laure Musso, Didier and de veille Sanitaire, 2016). However, RT-PCR confir-
mation for ZIKV at the individual level remains difficult to obtain, in particular from
blood samples, and there have been relatively few confirmations globally compared to
the number of suspected cases (Ferguson et al., 2016), let alone analysis of long-term
antibody dynamics in RT-PCR confirmed patients. In French Polynesia, there were ap-
proximately 32,000 reported clinical cases of ZIKV infection, but only 297 documented
RT-PCR-confirmed cases (Mallet Anne-Laure Musso, Didier and de veille Sanitaire,
2016). As a result, antibody responses in RT-PCR-confirmed cases may not necessarily
be representative of immune responses against ZIKV in the wider population, partic-
ularly following asymptomatic infection. Although MIA seropositivity in our study
was defined using control sera collected over a year after RT-PCR-confirmed infection,
our results suggest that this threshold may not detect long-term waning responses in
individuals who had unreported, and likely less severe, infections.
Our analysis was also limited by study design. In French Polynesia, surveys were cross-
sectional, so we were unable to examine temporal antibody dynamics at the individual
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level. However, both cross-sectional studies of the general population were conducted
using population representative cluster sampling (Aubry et al., 2017) in the same remote
island locations with stable population composition, which enabled robust comparisons
of overall seroprevalence. We did identify one potential source of sampling bias with
different DENV exposure profiles in the two surveys, but our conclusions of declining
seroprevalence for ZIKV persisted once we adjusted for this bias. We also used a
different serological testing method between the studies in French Polynesia in 2014 and
2015. However, both used the same recombinant antigens and it has been shown that
there was good agreement between ELISA and MIA in the 2014 samples (see Materials
& Methods). In Fiji, a strength of our study was the collection of longitudinal samples
from the same individuals at three time points. However, our sample size was limited
given the logistical challenge of recontacting participants twice over a four-year period.
These data provided strong evidence that ZIKV seroprevalence declined over the two-
year period following first reports of circulation, but our sample size was insufficient
to fully explore the potential effect of anti-DENV pre-existing immunity on anti-ZIKV
antibody waning once we stratified individuals by previous DENV exposure. Although
the outbreaks of DENV-3 in Fiji and ZIKV in French Polynesia were well-documented
and occurred over a relatively brief period of time (Figure 4.5), it was harder to identify
the likely time of infection for other viruses – such as ZIKV in Fiji or DENV in French
Polynesia – in our study populations. Several participants in Fiji were seropositive to
ZIKV by neutralisation assay (NT) in 2013, but this result may be influenced by cross-
reaction; participants who had high pre-existing titres to DENV in 2013 were more
likely to be seropositive by NT (Figure 4.13A). In our main analysis of titre dynamics,
we therefore focused on the subset of participants who were seronegative by NT in 2013
(Figure 4.10). However, we obtained the same conclusion when participants who were
initially seropositive were also considered (Figure 4.11).
The global ZIKV epidemic began in the Pacific islands in 2013 before spreading in Cen-
tral and South America from 2015. Seroprevalence studies following ZIKV epidemics in
Latin America have been reported but data have either been non-representative (Netto
et al., 2017) or not enough time had elapsed since the outbreak to observe long-term
dynamics (Rodriguez-Barraquer et al., 2019; Zambrana et al., 2018). To our knowl-
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edge, these are the first studies of community seroprevalence over a long-term period
following a ZIKV outbreak. Therefore, patterns observed in Pacific islands may be an
early indication of what might happen to seroprevalence in Latin America where ZIKV
outbreaks began two to three years after the French Polynesia epidemic (Bogoch et al.,
2016; Cao-Lormeau et al., 2014a).
In the short-term, our findings have implications for the design of follow up studies
of ZIKV. Our results provide evidence that levels of seroprevalence one to two years
following ZIKV circulation may be lower than previously expected and study designs
may need to be adapted to reflect this, particularly in settings that exhibit long-term
low level circulation of ZIKV as opposed to large sporadic outbreaks (Ruchusatsawat
et al., 2019). For example, estimates of microcephaly risk may be inflated if derived
from long-term seroprevalence data that underestimate the true extent of infection
within the population, and results of clinical trials could also be biased if post-outbreak
seroprevalence is used an indicator of infection within a population (Cohen, 2018). In
the longer-term, our results demonstrate the value of longitudinal serological studies
of flaviviruses, and analysis using multiple serological tests, including neutralisation
assays (Clapham et al., 2016). Such studies will be essential to understand different
aspects of the short and long-term immune antibody response against ZIKV, and how
prior exposures to DENV may influence these responses.
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4.6 Technical Appendix
4.6.1 Baseline neutralisation titres
In this chapter I have presented an analysis of changes in neutralisation titre between
2013 and 2017. For completeness, the baseline neutralisation titre is presented here for
DENV-3 and ZIKV in those that seroconverted to these viruses between 2013 and 2015
(as in Figure 4.10), and for DENV-1 and DENV-2 in those that seroconverted between
2013 and 2015 (as in Figure 4.12).
4.6.2 Comparison tests
I used a Chi-squared test for association for comparison of cross-sectional seroprevalence
estimates in French Polynesia, and McNemar’s test for seroprevalence estimates from
longitudinal sera from Fiji. Details of both tests are presented in this section.
In the French Polynesia data I wanted to compare the proportion seropositive in 2014
and 2015. I used the χ2 goodness of fit test with the null hypothesis that the proportion
positive in 2014 π2014 and in 2015 π2015 are independent.
Table 4.8 shows an example 2x2 contingency table for the French Polynesia data.
Table 4.8: 2x2 contingency table with observed counts for serostatus in French Polynesia
2014 2015 Total
Seronegative O00 O10 O0.
Seropositive O01 O11 O.1
Total O.0 O.1 O..
Provided the entries in the contingency table are reasonably large the null hypothesis
of no association can be tested with a χ2 test, with test statistic (with continuity
159




















































Figure 4.14: Neutralisation titres for ZIKV and DENV-3 between 2013 and 2017 in those
that were seronegative in 2013 and seroconverted in 2015 for DENV-3 (n=19) and ZIKV
(n=31)
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Figure 4.15: Neutralisation titres for DENV-1 and DENV-2 between 2013 and 2017 in those
that were seronegative in 2013 and seroconverted in 2015 for DENV-1 (n=26) and DENV-2
(n=18).
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Under H0 : χ
2 ∼ χ21 so p-values are calculated comparing the test statistic to a χ21
distribution using the chisq.test function in R.
The data for Fiji was matched by design so individuals could act as their own controls.
This affords us greater statistical power to detect differences between samples as some
unobserved variation is accounted for by samples being taken from the same individual.
Table 4.9 shows an example arrangement of data from a matched study for observed
serostatus in the Fijian data.




Seronegative q r q + r
Seropositive s t s+ t
q + s r + t n
In 2015, the proportion of seropositive individuals is p1 = q + s/n and in 2017 the pro-
portion seropositive is p1 = q + r/n. I want to test whether these two proportions differ.
Under H0 the two proportions are equal and the number of discordant pairs should
be balanced, i.e. the number of seroreversions and seroconversions should be equal, or
r = s in Table 4.9. Therefore, if H0 is true then:
r ∼ Binomial(r + s, 0.5) (4.2)
I can then test this using an exact binomial test with the function mcnemar.test in R.
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4.6.3 Age adjusted seroprevalence
We compared seroprevalence estimates in French Polynesia from two independent cross-
sectional surveys conducted in 2014 and 2015. To remove, as far as possible, the effect
of differences in age when comparing these two populations we calculated age-adjusted
seroprevalence Table 4.3.
We used weights for 10-year age bands calculated as the estimated proportion in each
age band in population data collected in 2017 (Table 4.1). We removed age bands with
no samples for that survey, and the proportion in each age-group made a set of weights
for each survey, which represented the age-specific standard population.
Using the ageadjust.direct function from the epitools package (Aragon, 2020) in
R, we calculated age-adjusted seroprevalence for each survey using the direct method.
The function calculates the age-specific seroprevalence rate pj in age-group j as the
number of events Xj divided by the population in that age-group Nj. The age-adjusted
seroprevalence is then the rate in age-group j multiplied by the weight for that age-
group ωj. Confidence intervals are calculated according to Fay and Feuer (1997) which
have been shown to be conservative even in cases where the two populations differ
non-proportionally.
4.6.4 Bootstrap adjustment
The two seroprevalence surveys conducted in French Polynesia in 2014 and 2015 had
different sample sizes. 49 samples were collected in 2014 and 672 in 2015. We wanted
to check for possible biases in the two samples that could have explained the decrease in
estimated ZIKV seroprevalence between the two surveys. One potential confounder was
age but the two age distributions were similar and age-adjusted seroprevalence (Table
4.3) also showed a decrease in ZIKV seroprevalence.
Further investigation showed that the samples in 2014 included a higher proportion of
individuals that had evidence of multiple past DENV infections (Table 4.5). To remove,
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as far as possible, the effect of differences in risk of arbovirus infection in the two samples
we adjusted the estimates of 2014 seroprevalence to match the DENV-exposure profile
of the 2015 survey.
I estimated DENV-exposure adjusted seroprevalence in 2014. For ZIKV, I obtained
the sampling frequency from the 2015 survey of individuals who were seropositive to
(0, 1, 2, 3, 4) DENV serotypes. For each of the DENV serotypes I excluded the serotype
being adjusted. A bootstrap sample was then selected from the 2014 survey with
probability equal to the sampling frequency weights, with replacement, and estimated
the seroprevalence using this bootstrap sample. This process was repeated for 1,000
bootstrap samples and the DENV-exposure adjusted seroprevalence for each virus was
calculated as the mean of these samples. These results are shown in Table 4.6.
I chose this method because I assumed that the 2015 sample was a better representation
of the underlying arbovirus exposure profile in French Polynesia. I therefore attempted
to match the 2014 results to the 2015 sample. This process could have been performed
in reverse, using the 2014 exposure distribution as the weights to take bootstrap samples
from the 2015 survey (Table 4.10). Using this alternative method produced consistent
findings as in the main analysis (Table 4.6) for DENV-1, DENV-3, and DENV-4 which
showed no evidence of a decline. All three of these viruses had circulated in the years
preceding 2014 sample collection (World Health Organisation, 2018). However, with
this alternative method there was a non-significant decline in ZIKV seroprevalence
from 37% (95% CI: 23-52%) to 28% (95% CI: 25-31%) (p=0.25) between 2014 and the
2015 bootstrap estimates.
This sensitivity analysis demonstrates that the evidence for declining ZIKV seropreva-
lence from the two cross-sectional surveys in French Polynesia is less robust than the
results from three longitudinal seroepidemiological surveys in Fiji. The high seropreva-
lence estimate for ZIKV in 2014 in French Polynesia could be a result of a higher
proportion of high infection risk individuals in the sample. The evidence from French
Polynesia alone would have been insufficient to conclude that ZIKV seroprevalence
wanes within two years of an outbreak. This is likely because of the small and non-
representative sampling in 2014. However, the findings from this study were consistent
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with seroprevalence estimates from Fiji over a similar time frame which also demon-
strated waning neutralising antibody dynamics.
Table 4.10: Sensitivity of selected distribution to generate bootstrap estimated seroprevalence
for each of the four DENV serotypes and ZIKV in two cross-sectional surveys. Result are as
in Table 4.6 except 2015 sample were bootstrap sampled, with replacement, weighted by the




(95% CI) (n = 49)
2015 seroprevalence (95%





DENV1 0.86 (0.73-0.94) 0.8 (0.77-0.83) 0.92 (0.89-0.94) 0.26
DENV2 0.47 (0.33-0.62) 0.18 (0.15-0.21) 0.25 (0.22-0.28) <0.01
DENV3 0.76 (0.61-0.87) 0.55 (0.51-0.59) 0.7 (0.67-0.74) 0.55
DENV4 0.63 (0.48-0.77) 0.42 (0.38-0.46) 0.61 (0.57-0.64) 0.89
ZIKV 0.37 (0.23-0.52) 0.22 (0.19-0.25) 0.28 (0.25-0.31) 0.25
* chi-squared test comparing 2014 results with 2015 bootstrap estimates
4.6.5 GAM modelling
Generalised additive models (GAMs) have previously been introduced in chapter 3.
In this chapter we used GAMs to analyse the relationship between seroprevalence as
defined by MIA or PRNT and mean DENV log titre (from the PRNT) in 2013. I
wanted to analyse whether the observed decline in ZIKV seroprevalence in older age
groups was because of the history of DENV-exposure in adults compared to children.
The original published version of this analysis includes one such model (Figure 4.13)
(Henderson et al., 2020). In this appendix I compare this GAM with other possible
models to capture ‘previous DENV exposure’ and analyse the relationship with ZIKV
and DENV-3 seroprevalence in 2017.
I defined our explanatory variable X as either mean log titre in 2013, age in 2013,
or number of seropositive DENV serotypes in 2013 as measured by MIA. I defined
serostatus in the 2017 serological survey for each assay α, Yα. The model was as
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follows:
g (E (Yα)) = β + s1 (X) (4.3)
Where E(Y ) denotes the expected value, and g(Y ) denotes the link function, in this
case the logit function because of the binary outcome. The term s1(X) defines a non-
parametric function to model the non-linear relationship between X and Yα, and β
is the intercept. I have used GAMs to flexibly capture the relationship between the
explanatory variable and the binary outcome, instead of determining the parametric
form of this association a priori as in a generalised linear model. I used the mgcv
package in R so smooth functions were represented using penalised regression splines
(Wood, 2019).
Using GAMs to explore ZIKV seroprevalence in 2017
In the original publication we included a GAM comparing ZIKV seroprevalence from
both assays by previous DENV exposure, as measured by mean DENV PRNT titre in
2013 (Figure 4.13) (Henderson et al., 2020). From this analysis it appeared that those
with higher levels of DENV neutralising antibodies (NAbs) in 2013 were less likely
to have ZIKV specific antibodies (i.e. test positive by MIA) in 2017. However, the
probability of seropositivity as measured by PRNT was similar regardless of the level
of DENV NAbs in 2013.
Here I investigate this association further with supplementary GAMs. The model pre-
sented in the original publication used a subset of our study participants, those with
PRNT titre values at all three time points: 2013, 2015, and 2017. This left only 45
participants to be used in the analysis. The panel for 2017 ZIKV seroprevalence has
been recreated here for comparison (Figure 4.16A). If we change the variable used to
quantify the level of prior DENV exposure, then we can include more data. For exam-
ple, we can use age as a proxy for previous DENV exposure and include all of the MIA
data, since age and previous DENV exposure are positively correlated. In a second
166
Mathematical Modelling of Arbovirus Outbreak Dynamics in Fiji and the Wider Pacific
model I used age (in 2013) as the explanatory X variable for ZIKV seroprevalence in
2017 using different assays (Figure 4.16B). Similar to the original model, seroprevalence
by PRNT shows a slight positive association with age but seroprevalence by MIA does
not increase with age in this larger data set (n=320).
Age, however, is not directly related to prior DENV exposure so I used another variable
that would reflect DENV infection history but keep all 320 participants in the model.
I defined previous DENV exposure (the X variable in Equation 4.3) as the number of
positive DENV serotypes by MIA in 2013. This set five levels of prior DENV exposure:
0, 1, 2, 3, or 4. This does not measure strength of DENV immunity as well as the original
model, which used mean DENV PRNT log titre in 2013, but it is available for all 320
participants. In theory, more DENV infections prior to 2013 suggests that a participant
is particularly prone to arbovirus infections and we would expect them to be more likely
to have anti-ZIKV antibodies following the ZIKV outbreak. However, in Figure 4.16C
we see the opposite is true for seroprevalence by MIA. As with the restricted data set
in the original model (Figure 4.16A) people with more DENV exposure previously are
slightly more likely to be seropositive by PRNT but are less likely to be seropositive by
MIA (Figure 4.16C). The advantage of using all 320 participants in this model is clear
when comparing panels A and C, where confidence intervals are more precise in the new
model. The disadvantage of this explanatory variable is that it does not directly capture
the level of anti-DENV antibodies in a serum sample since it relies on binary cut-offs
for seroprevalence. However, despite differences in these two models, the conclusions
drawn from their output are similar.
There is evidence in DENV research that during a secondary DENV infection, the
presence of antibodies from a previous DENV infection are capable of responding more
rapidly during the secondary infection. This altered immune response is referred to as
‘original antigenic sin’ (Halstead et al., 1983; Rothman, 2011). Given the antigenic sim-
ilarity between DENV and ZIKV (Priyamvada et al., 2016) it is possible that previous
DENV infection could also affect the immune response to a subsequent ZIKV infection.
A schematic of this process is shown in Figure 4.17 comparing two hypothetical indi-
viduals, one born several decades ago and has had multiple DENV infections before
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Figure 4.16: Relationship between different exposures to DENV before 2013 and ZIKV or
DENV-3 seroprevalence in 2017 using different assays. (A) The original model (Figure 4.13C)
showing 2017 seroprevalence in a subset (n=45) of participants with PRNT measurements
from all 3 surveys. Seroprevalence by MIA, shown in grey, and neutralisation test (PRNT),
shown in orange, for sera collected in 2017. Line shows prediction from GAM fitted to each
data set, with shaded region showing 95% CI, and points show raw data. (B) Seroprevalence
for sera collected from all participants in 2017 (n =320) by age (in 2013). (C) Seroprevalence
for sera collected from all participants in 2017 (n =320) by the number of positive DENV
serotypes by MIA (in 2013)
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infection with ZIKV (A). The other individual is only infected with ZIKV without any
DENV infections (B). In individual A there is a short-term boost to the specific in
antibody response to ZIKV following ZIKV infection but it is lower than the immune
response to earlier DENV infections. Whereas for individual B the antibody response

































Figure 4.17: Schematic of immune response against sequential arbovirus infections. A, an
older individual with two previous DENV infections before infection with ZIKV. B, a younger
individual who is näıve to DENV and ZIKV until a ZIKV infection at the same time as
individual A. In this simple illustration, individual A develops high levels of antigen-specific
long-term IgG antibodies to DENV-1, the first infection of their life. This infection generates a
cross-reactive response in related viruses. When infected with DENV-3 the virus population is
neutralised with DENV-3 specific antibodies and cross-neutralising antibodies from the previous
infection. The level of DENV-3 specific antibodies therefore does not reach the antigen-specific
response from the primary infection, which produces the ‘antigenic seniority’ effect. This effect
repeats when infected with ZIKV such that the ZIKV-specific response declines in individual
A. In individual B, the ZIKV-specific response is larger and persistent because it is their first
infection
Our results in Figure 4.16 show some evidence that previous DENV exposure alters the
immune response to ZIKV infection. I used three different variables as a proxy for pre-
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vious DENV exposure. In each model (Figure 4.16A-C) there was a trend that DENV
näıve individuals were more likely to be seropositive by MIA, i.e. have ZIKV specific
antibodies. This could have implications if people with previous DENV exposure do
not have a persistent specific response against ZIKV following infection. Cross-reactive
antibodies from previous infections can still be strong neutralisers, however they may
not have optimal avidity for the infecting virus (Midgley et al., 2011; Rothman, 2011).
The strength of these GAMs is the ability to flexibly model non-linear relationships
between explanatory and dependent variables without specifying the parametric form
of this association. From these models, we found some evidence that those with higher
levels of DENV exposure prior to the emergence of ZIKV in Fiji (pre-2013) were less
likely to be seropositive by MIA for ZIKV in 2017, but were equally or more likely to
be seropositive by PRNT. Our study results suggest that previous DENV exposure has
an effect on the long-term immune response to a subsequent ZIKV infection.
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Abstract
Since 2007, Zika virus (ZIKV) has caused several large, brief outbreaks in isolated pop-
ulations. However, recent evidence suggests ZIKV can also persist at low levels over
multiple years. The reasons for these diverse transmission dynamics remain poorly un-
derstood. In Fiji, which has experienced multiple large single-season dengue epidemics,
there was evidence of multi-year low level transmission of ZIKV between 2013 and 2017.
To identify factors that could explain these differences in dynamics between closely re-
lated mosquito-borne flaviviruses, we jointly fitted a transmission dynamic model to
surveillance, serological and molecular data collected during this period. We estimated
that the observed dynamics of ZIKV were the result of two key factors: strong seasonal
effects, which created an ecologically optimal time of year for outbreaks; and introduc-
tion of ZIKV after this optimal time, which allowed ZIKV transmission to persist over
multiple seasons before a combination of immunity and seasonal forcing ended trans-
mission in 2017. We found the basic reproduction number was slightly lower in Fiji
for ZIKV than for a concurrent dengue outbreak but that the main determinant of the
different outbreak dynamics was the timing and amplitude of the introduction of the
virus. With our model, we were also able to identify a period of high epidemic risk in
Fiji. The ability to jointly fitted to multiple data sources could help identify a similar
range of possible outbreak dynamics in other settings.
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5.1 Background
5.1.1 Flavivirus dynamics are poorly understood
Zika virus (ZIKV) and dengue virus (DENV) are two closely related flaviviruses that
share the same primary vector of transmission, the Aedes genus of mosquitoes (Musso
and Gubler, 2016). Due to these similarities, both viruses often create similar outbreak
dynamics in the same population with large, brief outbreaks, particularly in isolated
island populations (Craig et al., 2018; Duffy et al., 2009; Kucharski et al., 2016). How-
ever, alongside examples of clearly-defined outbreaks of ZIKV with a high attack rate
during 2014-16 (Cao-Lormeau et al., 2014; Rodŕıguez-Barraquer et al., 2016; Zambrana
et al., 2018), there is evidence of low-level, multi-year circulation (Ruchusatsawat et al.,
2019). ZIKV epidemics have occurred in humans since 2007 (Musso et al., 2019) and
understanding the factors that caused this plurality of outbreak dynamics during the
global ZIKV epidemic remains unclear.
Explanations of different outbreak dynamics are often attributed to local factors. The
climate, population, people movement and mosquito populations differ greatly between
locations and these all have an effect on arbovirus transmission. We do, however, expect
these two viruses to behave similarly in the same location. Funk et al. (2016), studied
DENV and ZIKV outbreaks in the islands of the Federated States of Micronesia and
found greater similarity between viruses on the same island than the same virus between
different islands. We might therefore expect similar outbreak dynamics from DENV
and ZIKV in the same location.
Studying flavivirus outbreaks is complicated by the difficulties in collecting data on in-
fections with these viruses. Primarily this is because of the large proportion of asymp-
tomatic infections. A systematic review of the prevalence of asymptomatic ZIKV infec-
tion estimated that these account for 61.8% (95% CI: 33-87.1%) of all ZIKV infections
(Haby et al., 2018). Collecting data during an emerging outbreak is challenging, even
for well-established surveillance systems and this is especially true in the case of a novel
virus like ZIKV which circulated in the Pacific before there was global attention once
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outbreaks began in the Americas (Musso et al., 2019). The challenges of collecting
data during an emerging outbreak mean that the reasons for these diverse flavivirus
dynamics are currently not well understood.
5.1.2 Recent DENV and ZIKV in Fiji
To investigate which factors shape the invasion dynamics of DENV and ZIKV outbreaks
we studied recent outbreaks in Fiji in the South Pacific. We combined surveillance,
serological and molecular data to analyse the emergence of ZIKV and re-emergence of
dengue virus serotype 3 (DENV-3) in the same population in Fiji, which resulted in
very different outbreak dynamics.
In 2013-14, a large number of DENV-3 cases were reported October 2013 and May 2014.
During this period, 12,413 suspected cases were reported in Central Division (Kucharski
et al., 2018). Of the 8,734 laboratory tested cases from Central Division that were noti-
fied to the Fiji National Centre for Communicable Disease Control, 3,633 (41.6%) were
reactive for DENV nonstructural protein 1 (NS1) and/or anti-DENV immunoglobulin
class M antibodies (IgM) (Kucharski et al., 2018). This was a large and short outbreak
that likely ended due to a combination of increased herd immunity, seasonal forcing
and an additional reduction in transmission possibly from interventions on the vector
population (Kucharski et al., 2018). This outbreak was similar in dynamics to typical
flavivirus outbreaks in Fiji (Kiedrzynski et al., 1996; Roth et al., 2014; Singh et al.,
2005).
In contrast, there is evidence that ZIKV was locally transmitted in Fiji but there were
only 16 PCR-confirmed cases between July 2015 and February 2017 in Central Division.
Kama et al. (2019), studied data from a longitudinal community serological survey and
found an increase from 7.8% seroprevalence to ZIKV in November 2013 to 21.9% in
November 2015, with evidence of low-level circulation over multiple seasons. This sug-
gests that ZIKV had been circulating during this period despite only 2 confirmed cases
being reported. This outbreak was very different to typical flavivirus outbreaks in Fiji.
Firstly, the serological data suggests that transmission mostly occurred unobserved, be-
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fore any ZIKV cases were detected. Secondly, there was confirmed transmission of ZIKV
over several years when typical DENV outbreaks occur over a single high temperature
season in Fiji (Kiedrzynski et al., 1996; Kucharski et al., 2018).
Further, the estimated time to most recent common ancestor (tMRCA) estimated in
phylogenetic analysis of available ZIKV gene sequences – including from 3 ZIKV cases
from Central Division, Fiji – suggested that ZIKV may have been introduced into
Fiji in late 2013 or 2014 (Kama et al., 2019) (Figure 5.1). This raises the possibility
that DENV-3 and ZIKV were circulating at the same time. This could be a potential
factor that determined unusual flavivirus dynamics since DENV outbreaks in Fiji have
typically been of a single serotype and co-circulation has not been common (Kiedrzynski
et al., 1996; Singh et al., 2005).
Studying the data on ZIKV transmission raises several questions about this outbreak.
What was the overall burden of infection? When did the virus emerge and start spread-
ing in Fiji? Where might it have arrived from? We wanted to analyse this ZIKV
outbreak to understand why it looked so different to the DENV-3 outbreak of 2013-14.
5.1.3 Available flavivirus data in Fiji
A unique aspect of this study is the combination of three different data sources with
a mathematical model of transmission. By working closely with partners and collab-
orators in Fiji and international researchers, we acquired surveillance, serological and
molecular data on flavivirus transmission between 2013 and 2017. A summary of avail-
able data is shown in Figure 5.1.
Surveillance data was provided by the Fijian Ministry of Health and includes informa-
tion on the timing and burden of confirmed cases of ZIKV and DENV-3. Cases of ZIKV
were confirmed using reverse transcription polymerase chain reaction (RT-PCR), cases
of DENV-3 were suspected DENV with a proportion reactive for DENV NS1 and/or
anti-DENV IgM in laboratory tests (Kucharski et al., 2018). There were 16 cases of
ZIKV confirmed in Central Division between 2015 and 2017 but only 2 of these were
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reported in 2015 and one in 2017. Between October 2013 and May 2014 there were
12,413 suspected cases of DENV-3 in Central Division (Kucharski et al., 2018).
Data are available from a longitudinal serological study in Fiji with data collected in
2013, 2015 and 2017. Colleagues at Institut Lois Malardé in French Polynesia tested
sera to test if they were reactive for immunoglobulin class G (IgG) antibodies for the four
DENV serotypes and for ZIKV (Henderson et al., 2020; Kama et al., 2019). DENV-3
seroprevalence increased from 33.1% (95% CI: 27.4-39.1%) in November 2013 to 53.2%
(95% CI: 47-59.4%) in November 2015, after the outbreak (Kucharski et al., 2018).
ZIKV seroprevalence in participants that were sampled three times in 2013, 2015 and
2017 was low in 2013 at 6.3% (95% CI: 3.3-11%) and increased to 24% (95% CI: 19-
31%) in November 2015 before decreasing to 12% (95% CI: 7.9-18%) in 2017 (Henderson
et al., 2020).
Finally, molecular data was collected by colleagues for a separate study on ZIKV trans-
mission in Fiji and they helpfully shared the raw data for this analysis. Envelope (E)
gene sequences were isolated from five ZIKV patients in Fiji and three of these were
from individuals in the Central Division. A previous phylogenetic analysis of these
sequences combined with other Pacific and global sequences estimated a tMRCA of
November 2013 (95% HPD: March 2013-July 2015) (Kama et al., 2019).
5.1.4 Modelling ZIKV transmission in Fiji
Both ZIKV and DENV can cause asymptomatic or subclinical infections (Haby et al.,
2018; Mitchell et al., 2019), which means many infections will not appear in routine
surveillance data. We therefore wanted to combine the information available in these
three separate data sources to estimate transmission dynamics of DENV-3 and ZIKV.
We chose a simple deterministic model structure for arbovirus transmission that was ap-
propriate for modelling DENV or ZIKV transmission. We used a Susceptible-Exposed-
Infectious-Recovered framework for the human population and a Susceptible-Exposed-
Infectious framework for the mosquito population. We jointly fitted our model to
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Figure 5.1: Available data on ZIKV transmission in Fiji. (A) Dated Bayesian phylogeny of
three sequences recovered from Central Division, Fiji, and other locations in the Pacific and
Americas. Nodes with a posterior probability of 1.00 are indicated. Branch lengths correspond
to time in calendar years. (inset B) Detailed phylogeny of the Central Division cluster. The
estimated time to most recent common ancestor (tMRCA) for the two closely related Central
Division sequences, selected based on previous analysis (Kama et al., 2019), is shown. (C)
Green region, density of estimated tMRCA from phylogenetic analysis. This distribution was
used as a prior for ZIKV introduction time in the main transmission model fitting. Pink line,
cases of DENV3. Blue bars, cases of ZIKV. Grey bars, serological samples collected in Central
Division.
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surveillance data, three longitudinal serological surveys and virus sequences to estimate
unobserved ZIKV infection dynamics in Fiji during 2013-18. We used this model to
identify factors that could explain why the dynamics of ZIKV and DENV-3 were so
different.
There are several possible explanations for differences in flavivirus dynamics in the same
population. We designed a mathematical model that would be flexible enough to com-
pare four possible explanations for the diverse outbreak dynamics. Firstly, that ZIKV
was less transmissible than DENV in Fiji: analysis of flavivirus outbreaks on other Pa-
cific islands found that ZIKV can have a slightly lower basic reproduction number, R0,
than DENV in the same location (Champagne et al., 2016; Funk et al., 2016). Another
factor is seasonality: because mosquito populations are influenced by environmental
factors like temperature and rainfall (Lourenço et al., 2017; Mordecai et al., 2017) there
is a strong temporal component to flavivirus transmission in Fiji (Kucharski et al.,
2018); the time of year the virus is introduced therefore could influence the dynamics
of the resulting outbreak. Additionally, flavivirus outbreak dynamics will depend on
prior immunity within the population, as well as immunity that accumulates during an
outbreak (Funk et al., 2016; Kucharski et al., 2018; Netto et al., 2017), or wanes follow-
ing infection (Henderson et al., 2020). Finally, the tMRCA of ZIKV in Fiji spans the
duration of a large DENV-3 outbreak (Figure 5.1C), so it is possible that infections dur-
ing the DENV-3 outbreak also conferred a degree of transient cross-protection against
other flaviviruses (Gordon et al., 2019; Montoya et al., 2018; Rodriguez-Barraquer et al.,
2019).
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5.2 Materials & Methods
5.2.1 Ethics statement
Each serosurvey had ethical approval from both the Fiji National Research Ethics Re-
view Committee (2013-03, 2015.111.C.D and 2017.20.MC) and the London School of
Hygiene & Tropical Medicine Observational Research Ethics Committee (6344, 10207
and 12037). All participants in follow-up studies in 2015 and 2017 had agreed to
be recontacted for further health research and an updated informed consent was ob-
tained. To respect local customs and ensure research activities were culturally accepted,
the head of the household or village was visited with local bilingual field teams. The
study was explained in English or iTaukei at the preference of the potential participant.
Parental/guardian consent was obtained for children under 18.
5.2.2 Data
Surveillance data
Between June 2015 and August 2017 there were 16 RT-PCR confirmed cases of ZIKV
through laboratory surveillance in Central Division, Fiji. The collection of surveillance
data in Fiji has been previously described (Chapter 1) (Kucharski et al., 2018). Over the
period 27th October 2013 to 31st August 2014, there were 12,413 DENV-3 suspected
cases reported in Central Division. This data set has been previously published by
Kucharski et al. (2018).
Serological data
I used serological data collected from a longitudinal seroepidemiological survey over
the period 2013-2017 with three visits to the same participants in Central Division,
Fiji. Samples were tested for detection of IgG antibodies against ZIKV using a re-
combinant antigen-based microsphere immunoassay (MIA). Full details of the data
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collection method and serological tests used has been previously described (Chapters 2,
4) (Aubry et al., 2017; Cao-Lormeau et al., 2016; Henderson et al., 2020; Kama et al.,
2019; Kucharski et al., 2018).
Molecular data
A previous study details the recovery of the envelope (E) gene of ZIKV strains from
Fiji and the original phylogenetic analysis that informed this study (Kama et al., 2019).
The sequences from Central Division were recovered from two saliva samples collected in
2015 and a serum sample collected in 2016. The retrieval of sequences from GenBank
has been detailed previously (Kama et al., 2019). In brief, sequences were retrieved
from GenBank and selected using nucleotide BLAST searches (Altschul et al., 1990). I
retained all sequences with a reported date of sampling and country of origin sharing
more than 99% genetic identity to the Fiji sequences. I removed duplicates as done in
the original study, but I retained all sequences including those from Europe and Africa.
In total, the ZIKV alignments contained 120 sequences including five from Fiji, three
of which were from Central Division.
Climate data
I collated daily maximum and minimum temperature from the Fiji Meteorological Ser-
vice which covered the study period up to June 2017. I calculated the daily average
temperature as the mean of the maximum and minimum temperature recorded on that
day. Data on diurnal variability were not available for this study. I was also limited
by a lack of rainfall data for the study period. However, previous work has found that
temperature, not rainfall, was the key determinant of seasonal fluctuations of ZIKV
transmission (Lourenço et al., 2017).
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5.2.3 Modelling
Data on ZIKV transmission in Fiji was sparse and apparently contradictory. Serologi-
cal data showed evidence that approximately 17% of the population developed ZIKV-
specific antibodies between November 2013 and November 2015, however only 2 cases
were confirmed in surveillance data over that period. To model the underlying transmis-
sion dynamics, I collected data from other sources that could inform ZIKV transmission
dynamics in Fiji between 2013 and 2017. A summary of available data and how it was
included in our final ZIKV transmission model is shown in Figure 5.2.
Each step in this analysis is outlined in detail later in this section but is briefly sum-
marised here. I initially estimated the dynamics of seasonal forcing on transmission
from temperature data in Fiji and used these values in a model of the 2013-14 DENV-3
epidemic. This DENV-3 model was fitted to DENV-3 surveillance and serology using
a model similar to a previous study in Fiji (Kucharski et al., 2018). Prior distributions
were specified for the full ZIKV transmission model for parameters determining the
seasonal forcing of transmission (βamp, βmid) and the effect of a mosquito clean-up cam-
paign in March 2014 on arbovirus transmission (βbase) by using a posteriori estimates
from this DENV-3 model.
At the same time, I performed a phylogenetic analysis of three ZIKV sequences from
Central Division, Fiji, aligned with 117 other global ZIKV (Asian lineage) sequences.
From this analysis I obtained an estimate of the distribution of the tMRCA for the
Central Division cluster and used this as a prior for the midpoint of the introduction
of ZIKV to Central Division (ψm).
Finally, these informative priors were used in the full ZIKV transmission model which
was fitted to both surveillance and serological data using a Markov Chain Monte Carlo
(MCMC) framework.
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Prior (βbase)
Figure 5.2: Schematic of modelling approach and available data. The final ZIKV transmis-
sion model (red rectangle) used direct data inputs on ZIKV surveillance and serology. Data
(orange circles) were used to fit models (blue rectangles) and estimate certain parameters.
Information from these model fitting processes was incorporated into this final transmission
model through specification of informative priors and fixed values (red arrows)
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Figure 5.3: A, daily temperature (°C) in Fiji. B, relationship between average daily tem-
perature and R0 in Suva, Central Division, Fiji. Black line, mean posterior estimate of the
relationship between temperature and relative R0 for arboviruses transmitted by Aedes aegypti
mosquitoes (Mordecai et al., 2017). Blue line and region, median and interquartile range of
average daily temperature in Fiji between November 2013 and June 2017
Modelling seasonal forcing using temperature data
I assumed a linear relationship between temperature in Fiji and the relative trans-
mission of ZIKV based on research from Mordecai et al. (2017). The authors of this
study integrated data from several laboratory experiments into a mathematical model of
temperature-dependent transmission. The study defined the relationship between tem-
perature and relative R0 of ZIKV transmitted by Aedes aegypti mosquitoes and found
maximal transmission occurring in a range from 26-29°C. Data from this study were
publicly available and are shown in Figure 5.3 along with the median and interquartile
range of the average daily temperature from Fiji over our study period. Although the
relationship between temperature and R0 is non-linear, it is mostly linear in the range
of temperatures observed in Fiji across our study period.
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Seasonal variation in temperature is known to affect the population and ability of the
primary vector of ZIKV, Aedes aegypti mosquitoes, to transmit viruses (Descloux et al.,
2012; Gubler, 1998; Mordecai et al., 2017). Annual temperature in Fiji follows a wave-
like pattern so to capture variation in transmission over time I defined a sine function
with parameters that determine the amplitude (βamp) and midpoint (βmid) of the sine
wave (Equation 5.1). I assumed that transmission of both DENV and ZIKV would
vary seasonally. Under the assumption of a linear relationship, the rate of transmission
from mosquitoes to humans (βZ) and humans to mosquitoes (βM) both vary with time
t. The transmission rate at time t is defined by the seasonality function:
seasonali(t) = 1 + βamp sin (2π (t+ βmid)) ; i = Z,M (5.1)
The sine function 5.1 was fitted to daily average temperature data (Fiji Meteorological
Service, 2017) using MCMC via a Metropolis-Hastings algorithm with weakly informa-
tive priors. I assumed that the temperature data at time t was normally distributed
with mean µ and standard deviation σ derived from the overall time series temperature
data. Let the parameter set Υ = (βamp, βmid), the corresponding estimated temperature
data from the sin function S = {st}Tt=1 and recorded temperature data Y = {yt}Tt=1.
The overall log-likelihood was then:




I used bootstrap samples of the a posteriori estimates of βamp and βmid to obtain
samples of the sine wave defined in Equation 5.1. I defined the amplitude of seasonal
forcing as the range between peak and low temperature from the sine function rather
than the maximum and minimum temperature in the raw data which could have been
influenced by outliers. However, this method does exclude the delay between changes
in temperature and changes in transmission intensity (Lourenço et al., 2017). I then
used the previously defined relationship between temperature and relative R0 (Mordecai
et al., 2017) to convert this temperature range into a range of relative transmission
of ZIKV or DENV. This value for βamp and the median estimate for βmid was then
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fixed when modelling DENV-3 and ZIKV transmission subsequently. This reduced the
number of parameters to estimate in the main ZIKV transmission model while capturing
the effect of temperature fluctuations on arbovirus transmission in Fiji.
Modelling the 2013-14 DENV-3 epidemic and the effect of vector control
interventions in March 2014
There is evidence that a vector control campaign reduced transmission during the 2013-
14 DENV-3 outbreak (Kucharski et al., 2018). Given the overlapping geographic region
of this DENV-3 epidemic and the ZIKV transmission of this study, I assumed that the
effect of the clean-up campaign in March 2014 would have the same effect on ZIKV
transmission if ZIKV was circulating at this time.
I adapted the control function used by Kucharski et al. (2018) which was a flexible
sigmoid function. An example of the relative effect of this function on transmission is
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Figure 5.4: Schematic of control function in ZIKV transmission model
This function is defined by four parameters. According to Equation 5.3, relative trans-
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mission at time t would reduce to level βbase with midpoint βcentre. In the original
analysis relative transmission remained at βbase permanently. In this analysis of ZIKV
the study period is much longer than that of the DENV-3 outbreak so I adapted the
function with a quadratic denominator and a scaling factor of 4. This function then
temporarily reduces transmission relative to a baseline level before returning to the
original baseline level (Figure 5.4).
controli(t) = 1− 4βbase
e (βcentre − t)/βwidth
(1 + e (βcentre − t)/βwidth)
2 (5.3)
I initially used this function when fitting the 2013-14 DENV-3 epidemic. For this
analysis I fixed βcentre so that the reduction centred around March 2014 when the vector
control campaign was implemented as demonstrated in Kucharski et al. (2018). From
fitting to DENV-3 surveillance and serological data I obtained a posteriori estimates
for βbase and βwidth.
I fitted our SEIR model to surveillance and serological data using MCMC and a negative
binomial likelihood over 25,000 iterations using the priors outlined in Table 5.1 below.
I then fixed the value of βwidth and used an informative prior for the parameter βbase to
reduce the number of parameters estimated in the final model.
Phylogenetic modelling of ZIKV sequences
I reproduced previous phylogenetic analysis by Bayesian MCMC inference (Kama et al.,
2019). I reconstructed phylogenies in nucleotide substitutions per sites and in unit of
time (‘dated’ phylogenies) by Bayesian MCMC inference, using the package BEAST
(v1.10.4) (Drummond et al., 2012). I had a data set of 120 aligned ZIKV sequences
and generated a taxon set for two of the Central Division sequences. There were three
sequences isolated in Central Division, however the phylogenetic analysis gave weak
branch support for a cluster of all three sequences (Kama et al., 2019). There was
very strong branch support for the relationship between two of the sequences – 18A,
recovered in 2015; and 1568, recovered in 2016 – so I formed a monophyletic taxon
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set and estimated the tMRCA for these two samples as the estimate for the tMRCA
for Central Division as a whole. The analysis was performed using the General Time
Reversible (GTR) model to allow flexibility in the nucleotide substitution rate matrix.
I used gamma-distributed rate heterogeneity with four gamma categories (Kama et al.,
2019; Lemey et al., 2009; Yang, 1995). I used a coalescent Bayesian skyline tree prior
with ten groups and a piecewise-constant skyline model (Drummond et al., 2005). The
analysis was run using a strict clock and an uncorrelated relaxed clock with a lognormal
distribution (Drummond et al., 2006). The joint distributions were compared and
showed improved performance from the uncorrelated relaxed clock model so this model
was used. A mean substitution rate prior of 4e−4 substitutions per site per year was
used. The MCMC chains were run with 20 million iterations. Convergence of the
estimates was considered satisfactory when the effective sample size (ESS) calculated
in Tracer v1.6.0 was >200.
Modelling ZIKV: Introduction function
The main ZIKV transmission model used a continuous flow of infectious individuals into
the infectious compartment to better represent real introduction dynamics rather than a
single introduction event at a single fixed point in time. This does not capture multiple
separate introduction waves across multiple years. The number of introductions varied
with three parameters, the peak (ψb), midpoint (ψm) and width (ψw) according to the
introduction function (for time t):
ψ(t) = 4ψb
(
e (ψm − t)/ψw




Where ψ(t) is the number of infectious introductions in time t. Equation 5.4 produces
a symmetric function centred around ψm as demonstrated in Figure 5.5. the integral
of Equation 5.4 between −∞ and ∞ gives the total number of ZIKV introductions
and is equal to 4ψbψw. ψm had an informative prior derived from the tMRCA from
a phylogenetic analysis. I took the posterior distribution of the tMRCA from the
BEAST analysis and used the fitdistr function from the R package MASS to estimate
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Figure 5.5: Schematic of introduction function in ZIKV transmission model
the empirical mean and standard deviation of this distribution. These parameters were
then used to define a Gaussian distributed informative prior for ψm.
Modelling ZIKV: Transmission model
I developed a model which had flexibility to consider four possible factors that could
identify the cause of diverse flavivirus dynamics: accumulation of herd immunity during
the outbreak, seasonal variation in climate and the impact of virus introduction time,
interaction between DENV and ZIKV resulting from cross-protection, and inherent
viral transmissibility.
I modelled ZIKV transmission using a deterministic compartmental model with transi-
tions following a susceptible-exposed-infectious-removed (SEIR) structure. The model
had ten compartments in total. Upon exposure to ZIKV, humans moved from ini-
tially susceptible (SZ) to a latent class (EZ), then an infectious class (IZ) and finally
a recovered class (RZ). During the 2013-14 DENV-3 outbreak, a proportion (χ) of
those infected with DENV-3 but susceptible to ZIKV were temporarily removed from
the SZ compartment while clearing the DENV-3 infection. For DENV-3, the human
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population similarly moved between susceptible (SD), latent (ED) and infectious com-
partments (ID) before returning to the susceptible-to-ZIKV compartment SZ over two
transitional compartments T1D and T2D. Two compartments were used so that the
duration to return to susceptible would follow an Erlang, not exponential, distribution
(Camacho et al., 2011; Wearing et al., 2005). Using an exponential distribution means
that there is nonzero density for the null duration in a compartment, so some people
can transition artificially rapidly. Using an Erlang distribution solves this problem and
is particularly valuable when the average duration of in a compartment is long as it is
between T2D and SZ .
The model included seasonal forcing on the transmission rate using a sinusoidal function
and a temporary reduction in transmission in March 2014 from a mosquito clean-up
campaign as previously characterised (Kucharski et al., 2018) and described in Equa-
tions 5.1 and 5.3. In this main transmission model, the parameters that determined the
force of infection for the simultaneous DENV-3 epidemic (SD, ED, ID, T1D, T2D) were
fixed such that R0 was 1.3 and a proportion (χ) of those infected with DENV-3 would
become temporally immune from ZIKV. The force of infection at time t for ZIKV
infection in humans λZ(t) was as follows:
λZ(t) = βZ (seasonalZ(t)× controlZ(t)) (5.5)
(5.6)
The full model was as follows. The compartment C is introduced to capture the cumu-
lative incidence of infections in the model.
dSZ/dt = η − SZ(λZ(t)IZ/N)− χ (SDβDID/N) + χ(2ωT2D)− µSZ (5.7)
dEZ/dt = SZ(λZ(t)IZ/N)− (µ+ αZ)EZ (5.8)
dIZ/dt = αZEZ − (µ+ γZ)IZ + ψ(t) (5.9)
dRZ/dt = γZIZ − (µ+ ρ)RZ (5.10)
dC/dt = αZEZ (5.11)
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(5.12)
dSD/dt = − (SDβDID/N) (5.13)
dED/dt = (SDβDID/N)− αDED (5.14)
dID/dt = αDED − γDID (5.15)
dT1D/dt = γDID − 2ωT1D (5.16)
dT2D/dt = 2ωT1D − 2ωT2D (5.17)
All parameters except the force of infection λi(t) and introduction of ZIKV infections
ψ(t) were fixed over time. I fixed values for the duration (in days) of the intrinsic
incubation period 1/αZ = 1/αD = 6.1 days (Fourie et al., 2018). Likewise, the duration
of the infectious period for ZIKV and DENV-3 in humans 1/γD = 1/γZ = 5 days (Duong
et al., 2015). I also fixed the duration of cross-protection from DENV-3 1/ω = 30 days
which was a conservative estimate as ZIKV neutralising antibodies in DENV infected
patients had been shown in vitro to not persist beyond 6 months previously (Collins
et al., 2017). In a sensitivity analysis I fitted the model assuming that cross-protection
persisted for 6 months. I also fixed the duration of detectable ZIKV antibodies ρ−1 =
400 days based on our serological studies in French Polynesia and Fiji which found
a decrease in ZIKV-specific antibodies 18 months after outbreaks in both locations
(Henderson et al., 2020). This study also showed no evidence that DENV-3 antibodies
did not wane over time so the parameter ρ was set to ∞ when running the model for
DENV-3.
I set the initial population size N to be 342,000 as per Fiji census data from 2007 (Fiji
Bureau of Statistics, 2018; Kucharski et al., 2018). I used a death rate (µ) of the inverse
of life expectancy in Fiji of 67 years (The World Bank, 2020a). Data from the World
Bank shows that the birth rate in Fiji is approximately 2.5 times higher than the death
rate (The World Bank, 2020b,c). I therefore set η = 2.5µ.
The DENV outbreak for this model was fixed and did not include seasonality for par-
simony. The parameters βD, αD and γD were set such that 20% of the population were
infected between October 2013 and April 2014, consistent with previous modelling
(Kucharski et al., 2018).
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As detailed above, the force of infection λZ(t) was time dependent according to seasonal
forcing and the effect of a clean-up campaign in March 2014. The force of infection was
relative to the baseline transmission rate βZ , which is used as a single term to incorpo-
rate number of female mosquitoes, biting rate, probability of contact and probability of
transmission. Without better entomological data from Fiji I used this simpler approach
with a single transmission rate.
The introductions of infected individuals ψ(t) was time dependent as defined above
in Equation 5.4. The introduction of DENV-3 to the model was fixed such that 160
individuals were introduced at the start of the outbreak in November 2013, consistent
with previous research (Kucharski et al., 2018).
The effective reproduction number, R, was defined as follows. The basic reproduction,
R0, was calculated by the same method, but assuming that both humans and vectors





Deterministic models can generate artificially cyclical epidemics. To better reflect re-
ality, I included two conditions explicitly in the model. Firstly, there had to be at
least one infectious individual for the virus to transmit to prohibit virus persistence at
implausibly low levels over the low-transmission season. Secondly, I set the number of
infectious introductions to zero if the effective reproduction number was below 1. This
prevents epidemic take-off at implausible points of the year.
Full transmission model fitting
This model was used to separately fit both the DENV-3 and ZIKV epidemics to serolog-
ical and surveillance data. I have described equations, compartments and parameters
as ZIKV or DENV because ZIKV is the primary focus of the study. However, the
same model was used to fit DENV-3 as the primary infection of interest, which was
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Figure 5.6: Model schematic of ZIKV transmission model. Dotted lines show demographic
transitions. People do not move from the Zika compartments to the Dengue compartments.
However, a proportion (χ) of those infected with dengue are temporarily removed from the
Zika compartments while they transition from SD to T2D and return to SZ at rate ω
done to obtain estimates for parameters controlling the seasonal forcing and reduced
transmission during the clean-up campaign. The parameter χ was set to zero for this
DENV-3 model run so that the SD, ..., T1D compartments did not affect the dynamics
in the primary infection compartments.
An informative prior was used for the introduction time for all ZIKV model runs. I
fitted an empirical distribution to the posterior distribution presented in our study
(Figure 5.1C) and used this as the prior for ψm. Since the posterior for tMRCA from
the phylogenetic analysis had an imprecise estimate, the prior information in the trans-
mission model fitting was weak. I fixed the value of ψw to 10 days because of mixing
problems from a larger parameter set. To keep the flow of infected individuals to the
model below a plausible value I used a uniform prior on the parameter ψb. This re-
stricted the total number of introductions for each simulation of the model to be >1
and <800 (Table 5.1).
The full ZIKV transmission model was jointly fitted to case and serological data using
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Table 5.1: Parameter set for arbovirus model fitting
Parameter DENV-3 model prior ZIKV model prior





Initial immune (R0) N(0.331, 0.2) Fixed to zero
Reporting proportion (r) U(0, 1) U(0, 1)
Test specificity (1− ε) Fixed N(0.07, 0.15)∗∗∗∗
Test sensitivity (ζ) Fixed N(0.8, 0.15)∗∗∗∗






N(0.57, 0.15)∗∗∗ N(µDENV 3, σDENV 3)
ZIKV introduction date
(ψm)




∗ Seasonal parameters are fixed from fitted values to temperature data
∗∗ Clean-up campaign in March 2014
∗∗∗ (Kucharski et al., 2018)
∗∗∗∗ (Henderson et al., 2020)
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adaptive MCMC with a Metropolis-Hastings algorithm. I assumed that cases were
distributed according to a negative binomial distribution with mean equal to the number
of incident infections reported in the model ct = r(Ct −Ct−1), where r is the reporting
proportion. The dispersion parameter φ adjusted for the inequality between mean and
variance in the case data and was fixed to improve the mixing and convergence of other
parameters.
I also fitted the model to the proportion seropositive at each time point of the corre-
sponding serosurvey in 2013, 2015 and 2017. I assumed the proportion seropositive at
each survey was binomially distributed with size equal to the population size at the
time of the corresponding survey and probability equal to:
Rjζ + (1−Rj)ε/Nj
Where Rj is the number of people in the recovered (R) compartment and Nj is the
population size at time j in our model. Therefore Rj/Nj is the total proportion of true
infections that could be detected by an assay. ζ is then the estimated sensitivity of the
assay, and ε is the estimated false positive rate of the assay. I assumed that sensitivity
and specificity were fixed over time which is unlikely to hold true in reality. However,
I did not attempt to estimate time varying assay sensitivity and specificity because of
the limited size of our data available.
Let the random variable Xj ∼ Bin(N, Rjζ + (1−Rj)ε/N). The overall log-likelihood for
the transmission model with surveillance data Y = {yt}Tt=1 and serological data Z =
{zj}j∈{2013,2015,2017} is:






logP (Xj = zj) (5.19)
The joint posterior distribution of the parameter set θ was obtained from 1,200,000
MCMC iterations with a burn in of 480,000. I used adaptive MCMC by adjusting the
covariance matrix to obtain a target acceptance rate of 0.234 (Roberts and Rosenthal,
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2009). All models were implemented in R version 4.0.2 (R Development Core Team,
2011; RStudio Team, 2012) using the mvtnorm (Genz et al., 2015) and deSolve packages
(Soetaert et al., 2010) and parallelised using the doMC library (Revolution Analytics,
2013). All data and code used in the analysis are available at: https://github.com/
a-henderson91/fiji-zikv-model.
Model comparison
This full transmission model was designed to be flexible enough to test multiple expla-
nations for the ZIKV outbreak dynamics. The model could capture reduced transmis-
sion from inherent differences in transmissibility, seasonal forcing, increased immunity
and temporary cross protection during the 2013-14 DENV-3 epidemic. As a sensitiv-
ity analysis of these assumptions I ran the model with certain parameters constrained
and jointly fit the transmission model using adaptive MCMC over 50,000 iterations to
compare the output.
The metric to compare model performance was the Deviance Information Criterion.
For a likelihood p (y|Θ), we define the deviance as:
D(Θ) = −2 log p (y|Θ) (5.20)
Where p (y|Θ) is the likelihood of the data given Θ. The DIC can be computed as:
DIC = D(Θ̄) + 2pD (5.21)
Where Θ̄ is the mean of Θ with respect to the posterior distribution, and pD is the
effective number of parameters, which is approximately equal to half of the variance of





A difference in DIC of >10 was considered as evidence that the model with the lower
DIC was better. A difference between 5 and 10 was considered borderline evidence and
any difference less than 5 was considered as no evidence that the models performed
differently (MRC Biostatistics Unit, 2020).
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5.3 Results
I fitted the full transmission model to serological and surveillance data and used prior
information from an analysis of molecular data. I constrained model parameters in sep-
arate runs to compare different explanations for the observed ZIKV outbreak dynamics
in Fiji and why there was not a single-year large epidemic. There were four explanations
that I wanted to explicitly test. Firstly, that the reproduction number was different
for ZIKV and DENV in Fiji. Secondly, that seasonal forcing impacted transmission
dynamics. Thirdly, that pre-existing immunity and the immune response were different
for DENV and ZIKV. Finally, that the viruses were introduced at a similar time and
DENV infection conferred cross-protection against ZIKV in early 2014.
5.3.1 ZIKV arrived later than DENV and persisted for mul-
tiple years
I found the best fitting explanation for the observed ZIKV outbreak dynamics was
through the following combination of factors: ZIKV was introduced into Central Divi-
sion, Fiji, after the ecologically optimal time of year and transmitted at a low level over
3 years until a combination of seasonal forcing and accumulation of ZIKV immunity
resulted in the end of transmission in 2017 (Figure 5.7A).
Although the first case of ZIKV was reported in July 2015, we found evidence that
transmission of ZIKV likely began in early 2015 in Central Division, Fiji. Infectious
individuals were introduced to our model using a continuous logistic function defined
by parameters for the peak, width and midpoint of the wave of introductions. The 95%
credible interval for the most likely midpoint ranges from October 2014 to February
2015 with a median of January 2015 (Figure 5.7B). By using a posterior estimate from
a previous phylogenetic analysis as a prior in our model, our joint inference produced a
more precise estimate than the original phylogenetic analysis alone,(Kama et al., 2019)
which had an inferred introduction date of May 2014 (95% HPD: Feb 2013 – Jul 2015).
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Figure 5.7: Estimated transmission of ZIKV in Fiji using a mathematical model and multiple
data sources. (A) Pink line, weekly cases of DENV-3. Blue bars, monthly cases of ZIKV.
Blue dashed line and region, model estimated cases of ZIKV and 95% CrI. (B) Seroprevalence
and introduction of ZIKV. Green line and region, estimated introduction of ZIKV infected
individuals and 95% CrI. Grey line and region, estimated proportion of the population that
had recovered from ZIKV infection (median and 95% CrI). Orange dashed line and region,
estimated observed seroprevalence and 95% CrI. Seroprevalence includes an estimated 6.3%
(95% CrI: 4.4–8.5%) false positive rate and 79% (95% CrI: 52–98%) assay sensitivity. Orange
dots and vertical lines, observed ZIKV seroprevalence from 3 serological surveys. (C) ZIKV
infection dynamics in Central Division. Yellow line and region, median and 95% CrI of the
number of people susceptible to ZIKV. Blue line and region, median and 95% CrI of the number
infected on the natural log scale. (D) Pink line and region, estimated basic reproduction number
for ZIKV. Green line and region, effective reproduction number. This included an estimated
decline in transmission coinciding with a 2014 vector clean-up campaign (Kucharski et al.,
2018). Grey line, monthly temperature data from Suva, Central Division
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Figure 5.8: Density of estimated introduction time of ZIKV to Central Division, Fiji. Esti-
mate from a phylogenetic analysis of sequence data (pink) (Kama et al., 2019) used as a prior
in this analysis. The estimated midpoint (ψm) from this transmission model (blue)
5.3.2 Seasonal variation in transmission defines a period of
substantially higher risk for ZIKV introduction
To estimate the role of seasonal variation in temperature on transmission, the model
included sinusoidal forcing in transmission with timing and amplitude estimated from
available daily temperature data (Fiji Meteorological Service, 2017). We then converted
this into a relative transmission rate using the published data on the mechanistic rela-
tionship between temperature and basic reproduction number for transmission driven
by Aedes aegypti mosquitoes (Mordecai et al., 2017).
In Fiji, we found a strong seasonal variation in transmission which peaked in February
(Figure 5.7C). The seasonality of transmission resulted in a period with an effective
reproduction number (R) below 1 (Figure 5.7D). However, we estimated that this was
insufficient for the epidemic to fade-out over the colder months between 2015–2016 and
2016–2017 as the prevalent number of infections was consistently above 100 (Figure
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5.7C).
The seasonal pattern of transmission also created a period of heightened epidemic risk
if a flavivirus was introduced during this period. Towards the end of the calendar year
as temperatures, and therefore the transmission rate, increased the required number of
initial cases to seed an outbreak was lower than during the colder months. We excluded
the possibility of an outbreak emerging from an implausibly small introduction during
the period when R was below 1.
To examine how introduction dynamics could shape subsequent ZIKV outbreaks, we
simulated model trajectories using the maximum a posteriori estimates, then varied
the midpoint of the introduction function. We found that the timing of introductions
had a large effect on ensuing outbreak dynamics (Figure 5.9A-D). For example, using
our model with an introduction event centred around January 2015 – slightly after
peak transmission – there were three waves of infections at a low level, as in our main
findings (Figure 5.9C). We found that shifting the introduction event 2 months earlier
to November 2014 – slightly before transmissibility had peaked – caused a larger single
season outbreak comparable to the 2013-14 DENV-3 epidemic (Figure 5.9B). An intro-
duction centred around February 2015, generated a smaller first wave in a shorter high
transmission season given the later introduction. However, this delayed the epidemic
and there was a larger second wave in 2016 (Figure 5.9C). In our model, varying the
timing of the introductions alone could create diverse outbreak dynamics from single
large outbreaks to seasonal annual persistence for multiple years.
5.3.3 Estimated R0 and reporting proportion for ZIKV was
lower than the DENV-3 outbreak
In the model, the basic reproduction number (R0) varied according to seasonal forcing;
over the course of a year, we estimated a median ZIKV R0 of 1.18 (95% CrI: 0.82–
1.54) (Figure 5.7C). Before fitting to ZIKV data we initially fitted the same model to
DENV-3 surveillance serological data from the 2013-14 epidemic (Figure 5.10). From
this analysis we estimated a higher but comparable median and 95% credible interval
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Figure 5.9: Transmission dynamics by varying introduction time. Simulated ZIKV outbreaks
using the maximum a posteriori parameter set and adjusting the midpoint of the introduction of
ZIKV infectious individuals. Changing the introduction time alone can vary resulting outbreak
dynamics between low level circulation over multiple years to large single-season epidemics.
The modelled DENV-3 infections during the 2013-14 epidemic is reproduced here for compar-
ison. Introduction time centred around October 2014 (A), November 2014 (B), January 2015
(C), February 2015 (D). Blue line, model simulation for the prevalence of ZIKV infections
(not cases). Green line, modelled DENV-3 2013-14 infections. Pink line, introduction of
infectious individuals. The date of the midpoint of the introduction function is displayed in
pink. The attack rate is equal to the sum of all ZIKV infections divided by the population size
at the start of the outbreak, 342,000 people.
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for R0 for the 2013-14 DENV-3 epidemic (1.84; 95% CrI: 1.3–2.4).
Other studies have found evidence that inherent DENV transmissibility is similar or
slightly higher than ZIKV in the same location (Bowman et al., 2016; Funk et al.,
2016; Ho et al., 2017; Nishiura et al., 2016). A more complex modelling analysis of
this 2013-14 DENV-3 epidemic estimated an R0 of 1.12 (95% CrI: 1.02–1.25), similar
to our estimate of ZIKV for the same region (Kucharski et al., 2018). Our results are
consistent with these findings, that ZIKV is similarly but slightly less transmissible in
the same population as DENV. This likely contributed, but was insufficient, to explain
the diverse outbreak dynamics between DENV-3 and ZIKV in Central Division.
I also estimated a very small reporting proportion for ZIKV from our model of 0.01%
(95% CrI: 0.006–0.02%). This implies that nearly all infections were not reported as
cases and were either asymptomatic, not severe enough to seek medical attention, not
referred for ZIKV tests by clinicians in Fiji or undetected ZIKV in tests. This low
reporting proportion is uncommon for arbovirus outbreaks in Fiji. We estimated a re-
porting proportion of 16% (95% CrI: 12–23%) for DENV-3 during the 2013-14 epidemic.
This discrepancy is the main cause of the diverse observed outbreaks in surveillance case
data. However, it is insufficient to explain why ZIKV infections transmitted at a low
level for multiple years.
I initially fitted our transmission model to DENV-3 surveillance and serological data
for the 2013-14 epidemic to estimate the parameter set Θ as in Table 5.1. Figure 5.10
shows the estimated transmission dynamics of DENV-3 using a mathematical model
fitted to multiple data sources. Parameter estimates from this model are shown in Table
5.2.
5.3.4 Posterior parameter estimates
The estimate for the relative effect of “cross-protection” on ZIKV infection during the
DENV-3 epidemic shows no evidence of an effect as the 95% credible interval extends
from 0.013 (no effect) to 0.98 (total protection). This is unsurprising since most model
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Figure 5.10: Estimated transmission of DENV-3 in Fiji using a mathematical model and
multiple data sources. (A) Blue line, weekly cases of DENV-3. Blue dashed line and re-
gion, model estimated cases of DENV-3 and 95% CrI. (B) Seroprevalence and introduction
of DENV-3. Green line, fixed introduction of DENV-3 infected individuals. Grey line and
region, estimated proportion of the population that had recovered from ZIKV infection (me-
dian and 95% CrI). Orange dashed line and region, estimated observed seroprevalence and
95% CrI. Seroprevalence includes an estimated 2.3% (0.35–8.2%) false positive rate and 73%
(95% CrI: 23–99%) assay sensitivity. Orange dots and vertical lines, estimated ZIKV sero-
prevalence from 3 serological surveys. (C) DENV-3 infection dynamics in Central Division.
Yellow line and region, median and 95% CrI of the number of people susceptible to DENV-3.
Blue line and region, median and 95% CrI of the number infected on the natural log scale.
(D) Pink line and region, estimated basic reproduction number for DENV-3. Green line and
region, effective reproduction number. This included an estimated decline in transmission co-
inciding with a 2014 vector clean-up campaign (Kucharski et al., 2018). Grey line, monthly
temperature data from Suva, Central Division
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Table 5.2: Parameter estimates from arbovirus transmission model fitted to the DENV-3









Median R0 1.84 (1.27-2.39) 1.18 (0.82-1.54) -
Median R 1.08 (0.403-1.61) 0.942 (0.518-1.56) -
βZ 0.35 (0.33-0.38) 0.24 (0.23-0.25) 6880
Reporting proportion (%) 16 (12-23) 0.011 (0.0061-0.019) 725
Cross protection NA 0.51 (0.013-0.98) 158
(1 minus) Test specificity (%) 2.3 (0.35-8.2) 6.3 (4.4-8.5) 1900
Test sensitivity (%) 73 (23-99) 79 (52-98) 1920
ZIKV introduction date (mid) Oct 2014
Jan 2015 (Oct 2014-Feb
2015)
217
ZIKV introductions (n) 400 394.6 (56.51-963.7) 115
Relative reduction during
clean-up campaign (Mar 2014)
0.74 (0.71-0.77) 0.68 (0.64-0.73) 22600
Initial proportion immune 0.29 (0.23-0.35) 0 –
DIC 621.6 76.3 –
simulations had ZIKV outbreaks that started after the DENV-3 outbreak had ended,
so there would be no signal about cross-protection in these simulations. The effective
sample size – the number of effectively independent draws from the posterior distribu-
tion – for the estimated eight parameters are above 100 and six have an ESS greater
than 200. The full set of parameter estimates are shown in Table 5.2 and density plots
of the eight estimated parameters are shown in Figure 5.12. Density plots of the six
estimated parameters in the DENV-3 model fit are shown in Figure 5.12
5.3.5 Hypothetical ZIKV reported cases if ZIKV was reported
the same as DENV-3
Figure 5.13 shows the expected observed number of ZIKV cases from our modelled
outbreak if ZIKV cases were reported at the same rate as DENV-3 cases during the
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Figure 5.11: Density plot of estimated parameters in ZIKV transmission model. Grey bars,
posterior density. Red lines, prior density
2013-14 epidemic. This demonstrates that the underlying outbreak dynamics were
similar in magnitude but that the main difference in the size of outbreaks in surveillance
data was the discrepancy in reporting proportions.
5.3.6 MCMC diagnostics and convergence
The trace plots for the eight estimated parameters in the main ZIKV transmission
model are shown in Figure 5.14. Estimation of four of the eight parameters achieve
an appropriate level of mixing in all three chains used in the MCMC fitting process.
There is poor mixing for the parameter measuring cross-protection because if ZIKV
transmits after the DENV-3 outbreak then there is no additional information provided
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Figure 5.12: Density plot of estimated parameters in DENV-3 transmission model. Grey
bars, posterior density. Red lines, prior density
by this parameter. The two parameters for the introduction function mix less efficiently,
possibly because of their strong correlation (Figure 5.15).
The trace plots for the DENV-3 model fit are shown in Figure 5.16.
5.3.7 Sensitivity analysis of waning seroprevalence, cross-protection
duration and early ZIKV introduction
I designed a transmission model that was flexible enough to test multiple explanations
for the observed ZIKV transmission dynamics. There were four explanations that I
wanted to explicitly test and I found evidence that three of them affected transmission
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Figure 5.13: Hypothetical ZIKV case dynamics if the reporting mechanism was equivalent to
that of the DENV-3 epidemic. Pink line and region, estimated DENV-3 cases and 95% CrI.
These estimates include an estimated 16% (95% CrI: 12–23%) reporting proportion. Blue line
and region, hypothetical reported ZIKV cases if the reporting mechanism for ZIKV was the
same as DENV-3. These estimates use the modelled infections from the ZIKV model but the
reporting proportion from the DENV-3 model fit. The time scale for this plot is monthly not
weekly, so the observed DENV-3 cases from surveillance data are reproduced on a monthly
time scale as vertical lines.
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Figure 5.14: Trace plot of MCMC convergence for full ZIKV transmission model after burn-
in of 40%. The three colours represent three separate MCMC chains used in the fitting of the
model to surveillance and serological data.
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Figure 5.15: Correlation between estimated ZIKV model parameters. The histograms show
estimates of the parameter value. The scatter plot shows the relationship between estimated
values of these parameters.
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Figure 5.16: Trace plot of MCMC convergence for full DENV-3 transmission model after a
burn-in of 40%. The three colours represent three separate MCMC chains used in the fitting
of the model to surveillance and serological data.
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dynamics: the reproduction number was similar but slightly lower for ZIKV than DENV
in Fiji, seasonal forcing impacted transmission dynamics, and pre-existing immunity
and the immune response were different for DENV and ZIKV.
The fourth explanation I considered was that ZIKV and DENV-3 were introduced to
Fiji at a similar time and DENV infection conferred cross-protection against ZIKV in
early 2014. It seemed plausible that ZIKV could have arrived in Fiji in 2013 given
the circulation of ZIKV in the Pacific at that time (Cao-Lormeau et al., 2014; Musso
and Gubler, 2016; Roth et al., 2014) and this is consistent with a previous phylogenetic
analysis (Kama et al., 2019). I compared the model results with an alternative model
which constrained the introduction of ZIKV to Fiji to 2013. This forced DENV-3 and
ZIKV to transmit at the same time in my model and therefore tested the hypothesis
that DENV-3 infection provided cross-protection against ZIKV infection in early 2014.
I also tested some of the key assumptions I made when modelling ZIKV transmission.
Firstly, I relaxed the assumption that seropositivity wanes in the population. Secondly,
I extended the duration of the cross-protection for ZIKV following DENV infection.
Finally, I forced ZIKV to start spreading in Fiji before the DENV-3 epidemic. A
summary of the three models and the main ZIKV model used for this comparison are
presented in Table 5.3. All four models were fitted to the same data using MCMC over
20,000 iterations.
Table 5.3: Sensitivity analysis of key assumptions in the modelling of ZIKV transmission
dynamics in Fiji. Estimated deviance information criterion (DIC) and basic reproduction
number (R0) for each model are shown
Model DIC R0 (95% CrI)
A Main model 76.8 1.15 (0.8–1.5)
B No reduction in seropositivity 103.1 1.06 (0.7–1.4)
C Longer cross-protection duration 75.9 1.14 (0.8–1.5)
D ZIKV introduction in 2013 129.8 1.24 (0.9–1.6)
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Model A - full model
These are the results from the “best fitting model” but from a shorter fitting process
over 20,000 iterations. To reiterate, the key assumptions that have been made are that
detectable ZIKV-specific antibodies wane over time and that the model could accurately
identify the reporting proportion. The estimated DIC from this main model was 76.8.
Model B - no reduction in seropositivity
I wanted to test the assumption that ZIKV-specific antibodies wane over time below
a detectable threshold. There is good evidence for this assumption in serological data
from Fiji (Henderson et al., 2020). However this is a novel concept so I wanted to
compare it to a model where antibodies do not wane over time. The results from
this alternative model show that, if ZIKV seropositivity does not wane, the estimated
seroprevalence from the model fitting does not recapture the observed seroprevalence
data (Figure 5.17B). As a result the model fit is worse with a DIC of 103.1 compared
to 76.8 from the main model.
Model C - longer period of cross-protection following DENV infection
I chose a conservative estimate for the duration of cross-protection between DENV-3
and ZIKV of 30 days. This proved uninformative in our main model findings since I
estimated that ZIKV was introduced in late 2014, long after the DENV-3 epidemic. As
a sensitivity analysis I set the duration of cross-protection to 6 months (Collins et al.,
2017) to test whether this an early introduction and long suppression of ZIKV during
the DENV-3 epidemic could capture the observed ZIKV data. However the model still
converged on a late 2014 introduction date (December 2014; 95% CrI: Oct 2014–Feb
2015) similar to the main model results.
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Figure 5.17: Model B: estimated ZIKV transmission, as in Model A but seropositivity cannot
decrease. (Estimated DIC: 103.1). (A) Pink line, weekly cases of DENV-3. Blue bars, monthly
cases of ZIKV. Blue dashed line and region, model estimated cases of ZIKV and 95% CrI.
(B) Seroprevalence and introduction of ZIKV. Green line and region, estimated introduction
of ZIKV infected individuals and 95% CrI. Grey line and region, estimated proportion of the
population that had recovered from ZIKV infection (median and 95% CrI). Orange dashed
line and region, estimated observed seroprevalence and 95% CrI. Seroprevalence includes an
estimated false positive rate and assay sensitivity. Orange dots and vertical lines, estimated
ZIKV seroprevalence from 3 serological surveys. (C) ZIKV infection dynamics in Central
Division. Yellow line and region, median and 95% CrI of the number of people susceptible to
ZIKV. Blue line and region, median and 95% CrI of the number infected on the natural log
scale. (D) Pink line and region, estimated basic reproduction number for ZIKV. Green line
and region, effective reproduction number. This included an estimated decline in transmission
coinciding with a 2014 vector clean-up campaign (Kucharski et al., 2018). Grey line, monthly
temperature data from Suva, Central Division.
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Model D - Early ZIKV introduction and interaction with DENV was not
well supported by the data
It has been proposed that infection with DENV may result in transient cross-immunity
against ZIKV (Gordon et al., 2019; Montoya et al., 2018; Priyamvada et al., 2016;
Rodriguez-Barraquer et al., 2019; Zhao et al., 2016). I therefore examined whether
the large DENV-3 epidemic in 2013/14 could have induced temporary cross-immunity
against ZIKV that delayed the emergence of ZIKV until 2015. The model allowed a
proportion of those infected with DENV-3 during the 2013-14 to potentially be tem-
porarily protected from ZIKV infection. With introduction of ZIKV constrained to
2013, I found that a combination of DENV-3 cross-immunity and reduced transmission
from a vector control campaign in March 2014 could have suppressed ZIKV transmis-
sion in 2014 (Figure 5.18). However, the Deviance Information Criterion (DIC) from
this model was much higher than the best fitting model (Table 5.3), suggesting very
little support for this alternative explanation. The reason for poor model performance
is the short outbreak duration that resulted from this interaction: DENV did not just
influence ZIKV in 2014 in this model: by suppressing ZIKV transmission to a large
extent, subsequent multi-year outbreaks of ZIKV during 2015-2017 were not possible
in the model, in contrast with the observed reported cases during this period.
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Figure 5.18: Model D: Estimated transmission of ZIKV in Fiji in a model with ZIKV
introduction constrained to 2013 (Estimated DIC: 129.8). (A) Pink line, weekly cases of
DENV-3. Blue bars, monthly cases of ZIKV. Blue dashed line and region, model estimated
cases of ZIKV and 95% CrI. (B) Seroprevalence and introduction of ZIKV. Green line and
region, estimated introduction of ZIKV infected individuals and 95% CrI. Grey line and region,
estimated proportion of the population that had recovered from ZIKV infection (median and
95% CrI). Orange dashed line and region, estimated observed seroprevalence and 95% CrI.
Seroprevalence includes an estimated false positive rate and assay sensitivity. Orange dots and
vertical lines, estimated ZIKV seroprevalence from 3 serological surveys. (C) ZIKV infection
dynamics in Central Division. Yellow line and region, median and 95% CrI of the number of
people susceptible to ZIKV. Blue line and region, median and 95% CrI of the number infected
on the natural log scale. (D) Pink line and region, estimated basic reproduction number for
ZIKV. Green line and region, effective reproduction number. This included an estimated
decline in transmission coinciding with a 2014 vector clean-up campaign (Kucharski et al.,
2018). Grey line, monthly temperature data from Suva, Central Division
5.4 Discussion
We combined multiple data sources with a dynamic transmission model to reconstruct
unobserved transmission dynamics of ZIKV in Fiji between 2013 and 2017. We found
that transmission persisted over multiple years with three consecutive small annual
outbreaks between 2015 and 2017, with strong seasonal forcing in transmission resulting
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in a high risk period of the year for ZIKV introduction. This means there is potential
for large, brief flavivirus outbreaks, as well as a period of lower risk where low-level
transmission is more likely. We estimated a mean basic reproduction number of 1.18
(95% CrI: 0.82–1.54) for ZIKV, which combined with seasonality in transmission meant
there was insufficient infection – and hence acquired immunity – in 2015 or 2016 to
prevent re-emergence of the virus in the following year.
We found that ZIKV was slightly less transmissible than DENV in the same popula-
tion and that nearly all ZIKV infections were undetected, unlike the estimated reporting
proportion during the DENV-3 epidemic. We show that if the ZIKV reporting propor-
tion was equivalent to DENV-3 then the two epidemics would appear similar in overall
magnitude. However, this is insufficient to explain why ZIKV transmitted at a low level
over multiple years, unlike DENV-3 which caused a large single-season epidemic. We
have demonstrated that small changes to the introduction time can produce a diverse
range of outbreak dynamics because of the strong seasonal forcing in ZIKV transmission
in Fiji (Figure 5.9).
The estimated multi-season transmission dynamics of this ZIKV outbreak in Fiji are
different to flavivirus outbreaks observed elsewhere in the Pacific, and even within Fiji,
where large outbreaks typically last a single season (Kiedrzynski et al., 1996; Singh
et al., 2005). Our ability to infer unobserved dynamics benefited from being able
to simultaneously fit a transmission dynamic model to serological, surveillance and
viral sequence data. Each data source provided insights into different aspects of the
dynamics. The surveillance data provided information on the temporal distribution
of symptomatic infections, the serological surveys provided estimates of community-
level exposure at different points in time and the analysis of sequence data provided
informative prior information on the potential time of ZIKV introduction to Fiji. To
synthesise these complementary information sources, we used mathematical model that
could generate observations representing the serological and surveillance data, then we
jointly fitted the model to these data sets in a Bayesian framework, while the sequence
data formed an informative prior on the time of introduction. The data available for
Fiji presented a unique opportunity to compare and contrast the dynamics of ZIKV
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and DENV infection; without the combination of these three data sets it would have
been far more challenging to reliably infer the unobserved ZIKV outbreak dynamics.
In our study we allowed flexibility in the timing and size of the initial virus intro-
duction, but in all scenarios we assumed that there was a single introduction wave
with continuous transmission afterwards, rather than multiple separate introductions
in consecutive years. We also assumed in our model and all sensitivity analyses that
the virus persisted over colder months and could therefore be modelled in a determin-
istic framework. ZIKV outbreaks in other locations have however shown evidence of
multiple introductions (Griffin et al., 2019; Grubaugh et al., 2019), including in island
settings (Black et al., 2017). Although we cannot rule out multiple early introduc-
tions that did not result in widespread transmission, a previous phylogenetic analysis
of ZIKV sequences from the region identified two distinct clusters of Fiji sequences,
one of which included sequences recovered from Western Division and the other from
Central Division (Kama et al., 2019). The small sample size and weak branch support
for the Central Division cluster in both analyses means we cannot distinguish between
one or more introduction events. The fact that we estimated a cluster that included
all three Central Division sequences, with a close relationship between sequences from
2015 and 2016, suggests persistence rather than separate introductions. Although this
clustering could also be generated by separate introductions from a similar location, we
assumed a single introduction wave. Single ZIKV introduction events have also been
estimated for other Pacific Islands (Delatorre et al., 2018), and an introduction during
2014-15 in Fiji is further supported by context of ZIKV transmission across the Pacific.
The majority of large outbreaks in the Pacific occurred in 2014 and early 2015, rather
than 2016 onwards: the first large outbreak occurred in French Polynesia in late 2013;
during 2014 there were ZIKV outbreaks confirmed in New Caledonia, Easter Island
and the Cook Islands and in 2015 in Vanuatu and Solomon Islands (Delatorre et al.,
2018; Musso and Gubler, 2016). Moreover, the level of seroprevalence found in Fiji in
2015 suggests there was widespread transmission between 2013 and 2015, rather than
a series of isolated cases (Kama et al., 2019).
In our model we assumed that detectable anti-ZIKV antibodies could wane over time
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and therefore seroprevalence in the population could decline over time, as has been ob-
served in serological studies (Henderson et al., 2020; Moreira-Soto et al., 2020). How-
ever, as the precise relationship between a specific titre value and susceptibility to ZIKV
infection is unclear, we assumed that seroreversions did not lead to loss of protection.
This is consistent with other ZIKV modelling studies (Ferguson et al., 2016; O’Reilly
et al., 2018) and the fact that many participants in the Fiji survey who were seronega-
tive for ZIKV (as measured by MIA) still had evidence of neutralising titres (Henderson
et al., 2020).
In the Fiji serological survey, ZIKV seroprevalence was already 7.8% in November 2013.
Given the antigenic similarity of DENV and ZIKV, we assumed that this level of ZIKV
seroprevalence may be the result of cross-reactive antibody responses from prior fla-
vivirus infections. To reflect this, we included a parameter that measured the false
positive proportion (1 minus the specificity) of the assay, which was estimated as 6.3%
(95% CrI: 4.4–8.5%) in the model fitting. This may explain why there was some ev-
idence of seroprevalence before our model estimated ZIKV had arrived in Fiji. Simi-
larly, we estimated a sensitivity of 79% (95% CrI: 52–98%). Both are consistent with
the previously reported assay sensitivity and specificity for ZIKV of 79.6% and 94.9%
(Henderson et al., 2020). With these adjustments we found that the observed sero-
prevalence was broadly consistent with our expected seroprevalence from the model.
However, in 2015 the observed value was at the limit of our expected seroprevalence
(Figure 5.7B). It is possible the assay was more sensitive or less specific during this
serological analysis. It is unlikely that there were more true infections than our model
produced since this would require a higher transmission rate and therefore increase the
likelihood of a single season large epidemic, which is inconsistent with the surveillance
data.
The surveillance data collected during the 2013-14 DENV-3 epidemic was primarily
from syndromic surveillance and did not have laboratory confirmation (Kucharski et al.,
2018). However, all confirmed cases attributed to ZIKV in this study had reverse
transcription PCR confirmation in Fiji (Kama et al., 2019). There is significant overlap
in the definitions of dengue-like illness, Zika-like illness, influenza-like illness, and acute
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fever and rash, so it is a challenge for doctors and nurses to classify patients into these
categories and there are inherent uncertainties in the reported numbers. It is therefore
possible that some of the cases defined as DENV-3 in 2013-14 were actually caused by
ZIKV infection and ZIKV was introduced earlier to Fiji than we suggest here. However
the probability of ZIKV arriving in Fiji in 2013 unobserved and still circulating in
2017 was not well supported by our model (Table 5.3). To estimate the proportion
of reported DENV-3 cases that were actually ZIKV was not identifiable without more
information on the test positive rate during the DENV-3 epidemic, and complicated by
a change in reporting during the 2013-14 DENV-3 epidemic from laboratory testing to
suspected cases (Kucharski et al., 2018).
Despite these limitations, our results show that ZIKV does not necessarily cause large,
brief outbreaks in settings where other flaviviruses have done so, and can persist over
multiple seasons, mostly undetected, even in isolated locations. We found that these
dynamics most likely resulted from the timing and the magnitude of the introductions
of infections prior to the first reported cases. Given the strong seasonal forcing on
transmission of vector-borne infections in Fiji, the timing of the introduction had a
large impact on the resulting dynamics. This indicates a period of high epidemic risk
in Fiji – specifically as temperatures begin to increase – during which surveillance
should be particularly vigilant. It also suggests that a wide range of outbreak dynamics
are possible if infections are introduced outside this period, including repeated, low-
level outbreaks over varying numbers of years. By estimating this range of possible
transmission dynamics with such models, it should be possible to improve forecasts
about likely outbreak dynamics when new cases are identified. More broadly, with a
similar joint analysis of wider data sources for virus outbreaks, there is potential to
characterise the range of possible dynamics for other settings as well.
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Abstract
Dengue virus (DENV) outbreaks occur with increasing regularity in the Pacific islands
but designing rapid responses to emerging outbreaks is limited because outbreaks are
challenging to predict and there is limited evidence on the effectiveness of current in-
tervention strategies. We combined transmission models with surveillance, serological,
environmental and intervention data during an outbreak of DENV-2 in 2017 to fore-
cast the outbreak in real-time and determine what role control measures played in the
decline in transmission. We found that, by fitting models to emerging outbreak data
and a historic outbreak we were able to accurately forecast the outbreak in real-time
and capture the transmission dynamics before the peak of the epidemic had occurred.
Additionally, using complete data after the outbreak we found that herd immunity
and seasonal forcing of transmission were insufficient to recapture the transmission dy-
namics. We show that an additional reduction in transmission when vector control
interventions were implemented helps to explain the observed outbreak dynamics. This
study demonstrates the potential benefit of real-time modelling of emerging outbreaks
and adds to the limited evidence base on the effectiveness of DENV control interventions
in Fiji.
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6.1 Background
6.1.1 History of dengue virus in Fiji
Dengue virus (DENV) outbreaks in Fiji are typically large with tens of thousands of
cases reported in a country with a population of 884,887 (Fiji Bureau of Statistics,
2018b; Kucharski et al., 2018). DENV can transmit efficiently in Fiji because there
are between four and six species of Aedes that can transmit DENV, the most effective
of which is Aedes aegypti (Prakash et al., 2001). Since 1971 a pattern has emerged
where one DENV serotype is introduced to a mostly immunologically näıve popula-
tion resulting in a large outbreak. Since infection with one DENV serotype provides
lifelong immunity for that serotype and temporary heterogeneous immunity against all
serotypes (Sabin, 1952) there follows a gap of several years before a new serotype can
emerge in Fiji, and over ten years before the same serotype causes another outbreak.
This arbovirus outbreak pattern is common in island populations and as a result of this
they make for excellent study sites for outbreak dynamics. These locations are isolated
and therefore less likely to sustain endemic transmission and have a pattern of self-
contained epidemics with reintroduction after an interval period of several years (Black,
1966; Keeling and Grenfell, 1997; Teissier et al., 2020). It is possible to study an out-
break in these settings for observations about the dynamics of transmission (Kucharski
et al., 2018), to compare different disease dynamics (Funk et al., 2016), and analyse
risk factors for severe disease (Cao-Lormeau et al., 2016). If we are able to accurately
model a previous outbreak then we may also be able to accurately model an emerging
outbreak in real-time to predict outbreak dynamics.
This chapter will focus on a recent outbreak of DENV-2 in Fiji in 2017. Cases were first
recorded in January 2017. Between January and September 2017 there were 755 cases
recorded in Suva, Nasinu, and Nausori in Central Division, Fiji, and at the peak in May
2017 there were 61 cases recorded in one week. I studied this outbreak to analyse the
contribution of control efforts to stopping the outbreak, and to assess the performance
of a real-time forecast of the outbreak.
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6.1.2 Summary of public health interventions for DENV in
Fiji
Interventions are available in Fiji to attempt to reduce the burden of DENV cases,
mostly targeted at reducing the mosquito population. The primary method used in
Fiji for reducing the DENV vector population is to remove breeding sites. This is a
year-round routine activity that can be intensified if an outbreak is declared but is
also intended to reduce the likelihood of DENV epidemics emerging. An entomological
study from 1980 found Aedes mosquitoes in miscellaneous containers such as tin cans
and plastic food containers, as well as coconut shells, flower vases and old motor parts
(Goettel et al., 1980). Tyres and drums were found to be less common breeding sites
for Aedes larvae, however they were very productive breeding sites so are responsible
for the majority of adult Aedes produced (Prakash et al., 2001). As a result, tyres and
large receptacles are targeted in source reduction clean-up campaigns (Goettel et al.,
1980), including during the 2017 DENV-2 epidemic (Ministry of Health report).
In the case of an epidemic a more targeted response is used, which is chemical spraying
to kill adult mosquitoes in areas with a high burden of reported cases. The active
ingredient in the chemical spraying used is pyrethrins which is a widely used insecticide
(Ministry of Health report). Previously, Malathion ULV spraying has been used (Goettel
et al., 1980; Prakash et al., 2001). Spraying is performed with both truck ULV and hand-
held portable devices (Figure 6.1). The location of chemical spraying is determined by
the number of reported DENV case notification and preventative spraying in heavily
populated areas. Chemical spraying takes place in the early morning and evening when
Aedes mosquitoes are most active (Nelson et al., 1978). Residents in the area are
advised to open doors and windows prior to the spraying.
Intervening to reduce the DENV vector population is expensive and there is very little
evidence about the effectiveness of these interventions. A study from 1980 showed
evidence that environmental sanitation and, to a lesser degree, insecticide spraying
were effective in reducing the adult mosquito population over the study period (Goettel
et al., 1980). There is no evidence about the relationship between Ministry of Health
230
Mathematical Modelling of Arbovirus Outbreak Dynamics in Fiji and the Wider Pacific
(a)
(b)
Figure 6.1: (A) Insecticide spraying using handheld devices at Suva grammar school (Min-
istry of Health report). (B) Insecticide spraying from van mounted devices at Bureta Street,
Suva (Ministry of Health report)
interventions and the burden of DENV disease in Fiji. Globally, a recent review of
current vector control methods and their effectiveness on reducing DENV concluded
that “almost nothing is known about how well they prevent disease” (Achee et al.,
2015).
My objective with this analysis was to improve understanding of how vector control
interventions can reduce the burden of DENV during an outbreak in Fiji by developing
a mathematical model and estimating any additional reduction in transmission during
vector control campaigns.
6.1.3 Modelling of the 2013-14 DENV-3 outbreak
I developed a Ross-Macdonald model of vector-borne transmission for this DENV-2 epi-
demic. This class of models has previously been used in a study of the 2013-14 DENV-3
outbreak in Fiji (Kucharski et al., 2018). Between November 2013 and August 2014
a large DENV-3 epidemic emerged with over 25,000 suspected cases across all of Fiji,
and 12,413 suspected DENV cases in Central Division, where longitudinal serological
data were available. Pre- and post-outbreak sera were collected in Central Division
and tested for evidence of previous DENV infection using a multiplex microsphere im-
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munoassay (MIA) and found an increase in DENV-3 seroprevalence from 33.1% (95%
CI: 27.4–39.1%) in November 2013 to 53.2% (95% CI: 47–59.4%) in November 2015.
One major strength of this study was that the model combined surveillance data and
serological data in the likelihood when model fitting, which was an approach we carried
into this DENV-2 analysis.
The 2013-14 DENV-3 outbreak could have ceased for a variety of reasons, but three
likely explanations were built into the model. Firstly, the outbreak was self-limiting
driven by a decline in the susceptible population. The change in climate conditions
over the outbreak could have introduced seasonal forcing on transmission of DENV-3.
There was also a large clean-up campaign in March 2014, at the peak of the outbreak, to
remove mosquito breeding sites and this could have had a direct effect on transmission.
The inclusion of serological data allowed for the estimation of the relative effect of
these three factors, which was not possible using surveillance data alone. The outbreak
ceased because of a combination of increased immunity, seasonal forcing and control
measures.
This analysis of the 2013-14 epidemic found evidence that vector control had an ef-
fect on DENV transmission. However, the signal was too weak to analyse further and,
working with the Ministry of Health, it was clear that they wanted more detail on how
effective these interventions were and how to improve their effectiveness. Control mea-
sures are not implemented uniformly across the Division which presents an opportunity
to compare different levels of interventions in different areas. I wanted to analyse the
relationship between intervention and transmission reduction at a finer spatial scale.
This was the prior objective of this study, however, while I was working on data collec-
tion in Fiji the DENV-2 epidemic was ongoing so I was able to use this model to forecast
the outbreak in real-time. In this chapter I will firstly present work on forecasting the
DENV-2 epidemic, then examine control measures retrospectively.
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6.1.4 Real-time forecasting the 2017 DENV-2 outbreak
The use of mathematical modelling of infectious diseases to conduct real-time analy-
ses of outbreaks and consequently forecast the likely path of an emerging epidemic is
growing rapidly (Camacho et al., 2015; Finger et al., 2019; Kucharski et al., 2020). The
main advantage of this practice is that forecasting the burden of an outbreak can im-
prove preparedness and allow public health bodies to mobilise resources appropriately.
Additionally, a successful forecast can assess underlying factors that are affecting the
transmission dynamics. In the case of arboviruses such as DENV this may be changing
climate conditions or the role of direct interventions on the vector population. A case
study of a diphtheria outbreak in a crisis setting demonstrates the value of effective
real-time forecasting. Finger et al. (2019), fitted a compartmental transmission model
to incidence data in real-time. The model was able to produce reliable forecasts three
weeks before the outbreak ended which supported the operational response, such as
bed need, and advocacy for control measures. Similarly, during the 2014 West Africa
Ebola virus disease epidemic Camacho et al. (2015), used a stochastic mathematical
model to forecast the course of the Ebola virus epidemic in the worst affected country,
Sierra Leone. Their results suggested that the epidemic had already peaked in Sierra
Leone. A subsequent assessment of the model performance during this outbreak found
that the model was well calibrated – the ability of the model to correctly identify its
own uncertainty in making predictions – up to 2-3 weeks ahead (Funk et al., 2019).
Real-time forecasting has been proven to provide valuable information during an out-
break, however they have serious limitations. Most importantly is the quality of data
that is available during an outbreak. Fiji has an established and successful health
surveillance system (Sheel et al., 2019) which produces reports for the Pacific Public
Health Surveillance Network (PPHSN). However, during the DENV-2 epidemic, the
burden on the laboratory analysis meant that only a small proportion of test results
were available in real-time. In addition a mixture of diagnostic methods were used.
Reverse transcription polymerase chain reaction (RT-PCR) was used to identify the
circulating serotype (Aubry et al., 2012), the majority of laboratory diagnosis was ei-
ther through detection of the nonstructural protein 1 (NS1) or an assay testing for
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evidence of anti-DENV immunoglobulin class M (IgM) antibodies. Another issue is
the rapid evolution of outbreaks and the impact of changes in behaviour and direct
interventions may have on transmission dynamics during the outbreak (Bausch and
Edmunds, 2018). Finally, improving real-time modelling performance is a challenge
without an agreed characterisation of what constitutes a ‘good’ forecast. This is being
addressed in the literature (Funk et al., 2019) but will also depend on the priorities
during the outbreak. In the case of DENV-2 in Fiji in 2017 the priority was to learn
of the possible overall magnitude of the outbreak, and therefore potential benefits for
intervening and reducing the vector population. Real-time modelling remains just one
tool in a public health response during an outbreak, but in the case of DENV-2 we
were able to demonstrate its utility when working directly with the Ministry of Health
in Fiji.
In May 2017 I was in Fiji setting up the third in a longitudinal seroepidemiological
study (chapters 3 and 4). A DENV-2 outbreak had emerged with the first confirmed
case in January 2017 and by the time I arrived in Fiji there had been 223 suspected and
confirmed cases reported. We extended the model developed for analysis of the DENV-
3 2013-14 outbreak (Kucharski et al., 2018) to forecast the epidemic. Importantly, the
Ministry of Health was most concerned that this could become another large epidemic
with thousands of cases unless the mosquito density was reduced. After the outbreak, I
obtained the full surveillance data with final results from all laboratory tests performed
during the outbreak. I used these data to assess the performance of the forecast and
wanted to identify how early in the outbreak we would have been able to reliably predict
the epidemic dynamics.
6.1.5 Assessing the role of interventions in the end of the 2017
DENV-2 outbreak
I also performed a retrospective analysis of control measures that were introduced dur-
ing the outbreak. Previous work in Fiji found evidence that DENV-3 transmission
dynamics could be captured in a model with an additional reduction in transmission
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intensity at the same time as a government intervention removing mosquito breeding
sites (Kucharski et al., 2018). Evidence on the effectiveness of mosquito control pro-
grammes to reduce DENV transmission is weak (Bouzid et al., 2016; Bowman et al.,
2016; Heintze et al., 2007; Reiter, 2016). As a result, I wanted to use this island epidemic
of DENV-2 to analyse the impact of vector control interventions during the outbreak.
I was based at Mataika House in Suva, Fiji, between May and July 2017 and I worked
with the Ministry of Health and the entomological control department to obtain more
information on control measures and interventions used during the outbreak. Having
contributed to update and decision-making meetings during the outbreak it was clear
that the vector control response was heterogeneous across Suva, some areas were more
intensely targeted than others. I aimed to expand on published DENV analysis in
Fiji (Kucharski et al., 2018) and jointly fitted a model in different regions of Suva,
the capital city of Fiji. These regions within Suva had varying case incidence, pre-
outbreak population immunity and interventions during the DENV-2 outbreak. Using
this model, I aimed to estimate the effectiveness of different intervention strategies in
different areas.
Interventions used during the outbreak were mostly chemical spraying to reduce the
adult mosquito population. Information were available from detailed reports on when
and where these spraying activities were performed and the area they covered. In ad-
dition to this the entomological control department kept details on clean-up campaigns
to reduce mosquito breeding sites, including location, date and the amount of waste
disposed of. For serological data, because population representative sampling across
Fiji was used (Lau et al., 2016; Watson et al., 2017), the sample included a large num-
ber of participants from Suva. There were thirteen clusters in our DENV-2 study area
in Suva, each with twenty-five participants sampled either once in 2013 or followed up
in 2015 and/or 2017 as well. These sera were tested using a microsphere immunoassay
(MIA) so we had estimates of pre-outbreak DENV-2 seroprevalence which was collected
in November 2015. The third sample collection was during the tail end of the DENV-2
outbreak, collected in June 2017. Combining these data sources with complete surveil-
lance data I was able to fit a model to DENV-2 transmission at a more detailed spatial
level.
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The aim of this section of the study was to analyse the DENV-2 2017 outbreak to
identify any effect of control measures on transmission intensity at a Division level.
Following this, I aimed to estimate variation in effectiveness of interventions in differ-
ent areas by fitting the model to seroprevalence estimates and reported cases in each
region. Given the variety in vector control intervention efforts in these regions dur-
ing the outbreak, I expected that it would be possible to identify differences in the
effectiveness of different intervention strategies.
6.2 Materials & Methods
6.2.1 Ethics
Ethics approval was obtained from the London School of Hygiene & Tropical Medicine
(reference 12037) and the local research ethics committee in Fiji. In 2018 we submitted
an ethics amendment application for our project titled “Serosurvey to study Zika and
related arboviruses in Central Division, Fiji” (reference 2017.20.MC). Approval for the
amendment was granted on 23rd October 2018. Our original ethics application was
focused on researching Zika virus (ZIKV) but included an objective to understand the
“potential association with serological evidence of other arbovirus infections, such as
dengue”. We submitted an ethics amendment request for additional data to study the
effect of vector control interventions during the 2017 outbreak by combining surveillance
and serological data.
6.2.2 Data
Real-time modelling projections were made between May and June 2017 and were fitted
to weekly reported case data as they became available. Cases were defined as positive
if they met one of the following criteria: DENV RNA detected by RT-PCR, positive for
NS1 antigen, anti-DENV IgM antibodies detected by Enzyme-linked immunosorbent
assays (ELISAs). A dengue outbreak is declared in Fiji once the incidence rate exceeds a
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predefined threshold of more than two standard deviations above the average incidence
rate for the last five non-outbreak years (Ministry of Health and Medical Services, 2016).
In an outbreak setting dengue surveillance can move from laboratory confirmation to
clinical-based reporting, i.e. dengue-like illness. In the case of the DENV-2 epidemic,
all reporting was laboratory confirmed because the incidence rate never exceeded the
threshold for declaring an outbreak. This switch of reporting method was cited as
a limitation when analysing the 2013-14 DENV-3 epidemic (Kucharski et al., 2018).
Real-time data were unreliable as a result of the logistical constraints of laboratory
testing during the epidemic. The proportion of samples tested was variable week-to-
week and most test results were from rapid NS1 detection tests instead of ELISAs. As
a result, when performing retrospective analyses of forecast performance and analysing
intervention strategies I used post-outbreak confirmed case data. This data should be
more accurate as it includes ELISA data where available and will include cases that
may have been confirmed later in the outbreak. After the outbreak all samples collected
during the outbreak had been tested and we had NS1 or ELISA confirmation for cases
in the Suva-Nausori study region between January and September 2017. I obtained
seroprevalence estimates from serological surveys previously described in Chapter 2.
Study regions in Suva
The study area was divided into five regions based around a health centre that could
collect and record cases during the outbreak (Figure 6.2). Colonial War Memorial
hospital (CWM) is the largest health facility in Suva. The area around the hospital is
the central business district and tourism hub of the capital and includes the working
docks and most of the coastal region of Suva. North of CWM are two suburban districts
of Suva, on the east coast is Raiwaqa and to the north is Samabula, both of which are
predominantly residential areas. Moving further north the regions increase in altitude
as well from 57m above sea level at CWM hospital to 124m at Nuffield Health Centre.
The Nuffield region is a peri-urban area and forms the ‘corridor’ that connects Suva city
to Nausori town. Finally, the Nasinu/Nausori area has several health facilities across
the region but the largest is Makoi Health Centre in the north of the region, where
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Figure 6.2: Map of study area. Suva and Nausori in the southeast of Viti Levu, Fiji. Each
region is represented by a different shade of blue. White crosses indicate the largest health
care centre in each of the five regions
Our serological sampling included several clusters in Suva, Nasinu or Nausori because
this is where most of the Central Division population resides (Fiji Bureau of Statistics,
2018a). Figure 6.3 shows the centroid for a cluster of up to twenty-five participants
recruited in the original 2013 study (Lau et al., 2016; Watson et al., 2017). Participants
in the serological study were well distributed across our study with samples available
from all five regions so it was possible to capture regional differences in pre-outbreak
community immunity.
Finally, the entomological department at the Ministry of Health recorded 49 individ-
ual events of vector population reduction interventions. The vast majority, 42 (86%)
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Figure 6.3: Map of study area and location of collected serological samples. Red dots, centroid
of a cluster of up to twenty-five participants in the original 2013 serological survey. A subset
of participants at each of these cluster locations were sampled in 2015 and in 2017. White
crosses show the largest health care centre in each of the five regions as in Figure 6.2
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Figure 6.4: Timing of vector control interventions during the 2017 DENV-2 outbreak. One
intervention was defined as reported by the Fijian MOH during the outbreak and could corre-
spond to an area sprayed with insecticide or targeted source reduction in a specific area
of these were chemical spraying and the remaining 7 were removal of breeding sites.
The first round of spraying was in February as a preventative measure to reduce the
likelihood of a large outbreak and was followed by a second round of chemical spraying
throughout March and April as cases increased quickly (Figure 6.4).
The sites of these interventions were well distributed across the study region. Chemical
spraying is designed to target areas with a high case load so a lot of the activity is in
Nausori, especially in the north around the Davuilevu housing estate, and in the area
immediately surrounding CWM hospital (Figure 6.5).
6.2.3 Model structure
I used a compartmental deterministic model introduced in Chapter 2. The model de-
fined the human population as either Susceptible, Exposed (pre-infectious), Infectious,
or Recovered (SEIR). The mosquito population followed a similar process without a
Recovered compartment because I assumed that mosquitoes did not recover from in-
fection. The full model was as follows:
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Figure 6.5: Map of study area and location of vector control interventions during the 2017
DENV-2 outbreak. Green dots, a vector control intervention implemented, either insecticide
spraying or source reduction in this area. White crosses show the largest health care centre in
each of the five regions as in Figure 6.2
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= βH(t)iM − αHEH (6.2)
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sM − (δ + αM) eM (6.7)
diM
dt
= αMeM − δiM (6.8)
Data were available on the size of the human population but not the mosquito popula-
tion so the human compartments were specified in terms of numbers and the mosquito
compartments in terms of proportions. The birth and death rates of mosquitoes was
assumed to be equal so the population density remained constant throughout the out-
break but the proportion susceptible was variable. The human population was assumed
to be constant throughout the outbreak with no deaths or births in this model.
Humans are assumed Susceptible (SH) until exposed to infection with DENV-2 when
they transition to a latent class (EH), then an infectious class (IH), and finally a recov-
ered and immune class (RH). Mosquitoes followed a similar process from susceptible
(sM), through latency (eM) to infectious (iM) where they remained until they died at
rate δ. The model uses six parameters in total: the force of infection from mosquitoes
to mosquitoes (βH(t)) and mosquitoes to humans (βM), the intrinsic (αH) and extrin-
sic incubation period (αM), the recovery from infection period in humans (γ), and the
birth rate of mosquitoes (δ) which was equal to the death rate to keep mosquito density
constant. The force of infection to humans varied over time due to seasonal variation
in transmission (details below). All other parameters in the model were constant over
time. The full model was defined as follows:
The next generation matrix for humans and vectors was defined as follows (Kucharski
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The effective reproduction number, R, was equal to the dominant eigenvalue of this
matrix. The basic reproduction, R0, was calculated by the same method, but assuming
that both humans and vectors were fully susceptible.
6.2.4 Climate and control effect on transmission
The effect of seasonal variation in temperature was introduced to the model directly
into the transmission rate as has previously been described in Chapters 2 and 5. The
transmission rate at time t was dependent on a baseline mosquito-to-human transmis-
sion rate βH and sinusoidal forcing defined by an amplitude (βamp) and a midpoint
(βmid) as given in Equation 6.10.
βH(t) = βH (1 + βamp sin (2π (t+ βmid))) (6.10)
Similarly, I modelled the ‘control effect’ – any additional reduction in transmission
during vector control intervention campaigns – as a direct effect on the transmission
rate. Unlike in Chapter 5 the transmission rate fixes at the reduced value for the
duration of this outbreak because the study period is short and a single season. As in
Chapter 5 the transmission rate could gradually reduce over time with the reduction
centred around time βcentre. The total reduction in transmission rate (βbase) was defined
as a proportion between 0 and 1. The steepness of the decline in transmission rate was
defined by the parameter βgrad. The ‘control effect’ on transmission was defined as
follows:
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The model fitting process I used has previously been described (Chapters 2 and 5)
(Kucharski et al., 2016, 2018). Briefly, the model was jointly fitted to case and serolog-
ical data using adaptive MCMC with a Metropolis-Hastings algorithm. I used adaptive
MCMC by adjusting the covariance matrix used to resample and obtain a target ac-
ceptance rate of 0.234 (Roberts and Rosenthal, 2009).
6.2.6 Assessing model forecasts performance
During the outbreak, I assessed model performance visually by comparing previous
forecasts with newly available data. When I performed a retrospective analysis of model
performance I used three metrics of forecast performance – calibration, sharpness and
bias (Funk et al., 2019). I judged our best performing forecast to be the one that
maximises the sharpness of predictive distributions subject to calibration (Gneiting,
2008). I therefore calculated the calibration of forecasts before assessing sharpness and
bias. I compared three types of prediction model to identify which component led to the
greatest improvement in forecast performance. I started with our null (‘näıve’) model
where I assumed that the entire population was susceptible to DENV-2 and fitted
to surveillance data only. I then fitted to our pre-outbreak DENV-2 seroprevalence
estimate as well as the surveillance data. Finally, I jointly fitted to both the 2017
DENV-2 epidemic and the 2013-14 DENV-3 epidemic.
Calibration
Calibration of forecasts is the ability of a forecast to correctly identify its own uncer-
tainty in making predictions. I used data up to a specific fixed point in the outbreak
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and then used these model fits to forecast at weekly horizons up to 12 weeks. For
each forecast horizon, at time t I took bootstrap samples of the estimated weekly inci-
dence from our a posteriori model fits and derived the empirical cumulative probability
distribution Pt. I then calculated the calibration at time t, ut, according to the formula:
ut = Pt(kt) + ν (Pt(kt)− Pt(kt − 1)) (6.12)
This estimates the density of the data point at time t from the empirical probability
distribution defined by simulations from the forecast. Where kt is the observed data
at time t, and ν is the standard uniform distribution. I took a random draw from
a uniform distribution between the probabilities at kt and kt − 1 to adjust for the
discretised cumulative probability distribution when handling count data. I calculated
ut for weekly forecast horizon from 1 to 12 weeks after the data used to fit the model.
I obtained a distribution of ut from a bootstrap sample from the posterior of model
forecasts. If a model is perfectly calibrated then the observed data at each time point
will look as if they came from Pt at that time point. Therefore, if Pt is the true
cumulative probability distribution, then ut is standard uniform (Czado et al., 2009). I
tested whether ut followed a standard uniform distribution using the Anderson-Darling
test of uniformities. I used the function ad.test from the package goftest to perform
the test. The p-value from this test was used as evidence of good or poor calibration. I
considered that there was no evidence to suggest a forecasting model was miscalibrated
if the p-value found was greater than a threshold of p ≥ 0.1, some evidence that it was
miscalibrated if 0.01 < p < 0.1, and good evidence that it was miscalibrated if p ≤ 0.01
(Funk et al., 2019).
Sharpness
After assessing the calibration of the models I wanted to find the model that maximised
sharpness and reduced bias. Sharpness is a data-independent measure and is the ability
of the model to generate predictions within a narrow range of possible outcomes. I eval-
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uated the sharpness at time t, by calculating the normalised median absolute deviation





where y is a variable with CDF Pt. The sharpest model would focus all forecasts on
one point and have S = 0, whereas a completely blurred forecast would have S −→∞.
Bias
I evaluated bias at time t as:
Bt(Pt, xt) = 1− (Pt(xt) + Pt(xt − 1)) (6.14)
Where xt is the observed data point at time t. The least biased model would have
Bt = 0, whereas a completely biased model would systematically over-predict (Bt = 1)
or under-predict (Bt = −1) the data.
6.3 Results
6.3.1 DENV-2 transmission was low and ended by August
2017 as forecast in real-time
There were 755 cases of DENV-2 confirmed by detection of RT-PCR, NS1 or IgM anti-
bodies in the medical subdivision of Suva and neighbouring Nausori between January
and September 2017 (Figure 6.6). The population of Suva, Nasinu and Nausori is esti-
mated as 243,795 (Fiji Bureau of Statistics, 2018a). The epidemic peaked in May with
61 confirmed cases in one week. 497 cases (65.8%) were positive for NS1 antigen and
258 (34.2%) were confirmed ELISA positive for anti-DENV IgM antibodies.
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Figure 6.6: Confirmed weekly DENV-2 cases during the 2017 epidemic
I arrived in Fiji on 1st May 2017, by which point data were available up to the end
of March. There were 223 confirmed cases (29.5% of the total outbreak) in the final
data set released after the outbreak. However, the real-time data used to forecast the
outbreak had a slightly higher incidence and more variable trajectory, a comparison of
the real-time and post-outbreak case data is shown in Figure 6.7. A combination of
testing capacity and repeated tests led to this discrepancy. Real-time data recorded
more suspected cases at that point of the outbreak with 299 suspected cases between
January and March 2017.
There was concern in early May 2017 that this outbreak could increase rapidly and
cause a similar disease burden as the DENV-3 outbreak in 2013-14. This concern was
valid especially when taking into account the serological data collected from Fiji. In
November 2015, sera collected from 390 participants estimated that DENV-2 seropreva-
lence was 15.3% (95% CI: 12.6–19%) so there was a large proportion of the population
susceptible to DENV-2. In November 2013, at the start of the DENV-3 outbreak, esti-
mated DENV-3 seroprevalence was 45.3% (95% CI: 40-51%), so population immunity
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Figure 6.7: Comparison of available DENV-2 data. Both lines show DENV-2 case data
during the 2017 epidemic. Red line and dots shows the epidemic case data that was available
in real-time. After the outbreak some data were revised and the final epidemic curve for
confirmed cases is shown with the black line
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Figure 6.8: DENV model predictions provided to Fiji MOH during the DENV-2 on 12th
May 2017. Left panel: black dots, DENV-3 2013-14 case data. Blue line and region, model
projections with median (blue line) 95% CrI (light region) and 50% CrI (dark region). Middle
panel: black dots, real time DENV-2 2017 case data up to 8th March 2017. Blue line and
region, model projection as in left panel with seasonal forcing and additional ‘control effect’.
Right panel: black dots, case data as in middle panel. Blue line and region, model projection
as in middle panel but without any ‘control effect’ (assumed to be 50% at time of analysis).
All model projections include seasonal forcing.
to DENV-2 in May 2017 was lower than DENV-3 immunity before a large outbreak in
November 2013.
Together with my supervisor, Dr. Adam Kucharski, who was in Fiji with me at the
time to set up the serological survey, we began modelling the outbreak by jointly fitting
the available data in 2017 and the whole 2013-14 DENV-3 outbreak. We assumed that
some of the drivers of transmission were constant across the two outbreaks, primarily
parameters controlling the effect of climate on DENV transmission. On 12th of May
2017 we presented projections of DENV forecasts to the Ministry of Health (Figure
6.8). We found good evidence that this outbreak was unlikely to grow rapidly, total
weekly cases were not likely to exceed 200, and that the outbreak would have ceased
by August. We found that, because of the decline in temperature in Fiji between April
and August (Figure 6.9) and the effect this had on DENV transmission in 2013-14,
continued circulation of DENV-2 beyond July was unlikely.
I also analysed the effect of control interventions in real-time on the assumption that in-
terventions in 2017 were similarly effective to those implemented in 2013-14. I assumed
that interventions reduced transmission by 50% and was able to show that the epidemic
would be shorter with a lower peak (Figure 6.8 middle panel) than if no interventions
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were applied (Figure 6.8 right panel). Even in the absence of interventions the 2017
outbreak was forecast to be smaller than the DENV-3 epidemic had been.













Figure 6.9: Average daily temperature in Suva, Fiji. Green line, daily temperature between
November 2013 and October 2014. Grey lines, average daily temperature in 2012-13, 2011-12
and 2010-11
6.3.2 The forecast could have been accurate only using data
up to March 2017
After the 2017 outbreak I was able to assess the performance of our forecast. Visually
comparing our forecast to the final data there was good agreement between the model
projections and the final epidemic (Figure 6.10). The projection made in May 2017 was
broadly accurate in terms of the number and timing of peak cases and duration of the
outbreak. Incident DENV-2 cases slowed rapidly in June as predicted. The epidemic
did have a longer tail than expected with cases reported as late as September 2017.
I wanted to analyse which aspect of our modelling approach led to the success of the
forecast. Then, using the best fitting model structure, I wanted to analyse how early in
the epidemic we could have made an accurate forecast on the trajectory of the epidemic.
I compared three versions of the same model for forecasting the epidemic and used data
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Figure 6.10: Comparison of real-time model forecasts with final outbreak data. (Joint work
with Dr. Adam Kucharski and this forecast was presented to public health officials on 12th May
2017). Top row, 2013-14 DENV-3 epidemic. Bottom row, 2017 DENV-2 epidemic. Black
dots, weekly case data. Blue line, median model projected cases. Blue region, 95% CrI (light
region) and 50% CrI (dark region). Red region, estimated seasonal forcing of transmission. In
this model we estimated that DENV transmission intensity peaked before temperature peaked
in Fiji. Red dots and lines, estimated seroprevalence and 95% CI from serological surveys
conducted in November 2013, November 2015 and June 2017 included in model fitting. Green
dot and lines, estimated seroprevalence and 95% CI presented for reference but not included in
model fitting. Orange line, median estimated seroprevalence from the model. Orange region,
95% CrI for estimated seroprevalence from the model
up to 8th March 2017 for all three models to forecast the epidemic. Firstly, a null (or
‘näıve’) model, as described in the methods section but assuming that we have no
information on prior immunity and the whole population is susceptible. This first
model was fitted to surveillance case data only. Secondly, the same model but fitted
to both surveillance case data and the estimated pre-outbreak DENV-2 seroprevalence
in Fiji. This should improve the estimate of the proportion of the population that
were susceptible to DENV-2 at the start of the outbreak. Finally, I fitted the model
to both 2017 DENV-2 cases and serological data and also jointly fitted this with the
2013-14 DENV-3 epidemic. For this third model I included pre- and post-outbreak
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seroprevalence estimates for DENV-3 but only pre-outbreak DENV-2 seroprevalence
when model fitting.
The results from the null model show a forecast of a very large outbreak with post-
outbreak seroprevalence above 80% (Figure 6.11A). In the second model, even with
a pre-outbreak seroprevalence estimate we would still project a large outbreak if we
only included 2017 data (Figure 6.11B). In this second model a smaller proportion
of the population can get infected compared to the null model because an estimated
proportion are immune before the outbreak begins. The increase in suspected cases
up to March 8th 2017 therefore suggests that the virus is more easily transmitted than
in the null model assuming total susceptibility. This higher estimated transmission
in the early stages of the outbreak then leads to an overestimate of the peak cases
in April in the forecast. Neither of these first two forecasts are particularly accurate
from a visual comparison to the data. In the final model however, by incorporating
information from the 2013-14 DENV-3 epidemic the forecast would accurately project
a small outbreak and accurately predict the peak cases, peak timing and timing of the
end of the outbreak (Figure 6.11C). I used an MCMC sampler where the total likelihood
for each iteration was the sum of the likelihood from the 2013-14 DENV-3 epidemic and
2017 DENV-2 epidemic. In this joint fitted model, information from both outbreaks
was therefore used to estimate parameters that were constant across both outbreaks,
such as the seasonality and baseline transmission rate.
Even from a visual comparison it is clear that the third model provided a more accu-
rate forecast. However I also used three metrics to compare the forecast performance:
calibration, sharpness and bias. I compared these metrics for the three models using
forecast horizons up to 12 weeks. I found that the forecast which jointly fitted to both
DENV outbreaks preformed much better. The näıve model and joint fitted models
were both well calibrated – p-values greater than 0.1 – up to approximately a 2 month
forecast horizon (Figure 6.11D). However, the joint fitted model was sharper, which
measures the ability of the model to generate predictions within a narrow range of
possible outcomes, with values closer to 0 across all forecast horizons (Figure 6.11E).
Finally, the joint fitted was the least biased forecast with values closer to 0 whereas both
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Figure 6.11: Assessment of model forecast performance using three models. A, a null model
assuming the whole population is susceptible to DENV-2 infection. B, model fitted to pre-
outbreak seroprevalence as well as surveillance data. C, Model jointly fitted to the 2017 DENV-
2 and 2013-14 DENV-3 epidemics including fitting to seroprevalence estimates. Red dots,
DENV-2 case data used in model fitting. Black line, complete 2017 DENV-3 epidemic case
data. Blue line, median model projected cases. Light region, 95% CrI. Darker region, 50%
CrI. Gradient of blue regions shows weekly projections from the end of the available case data
in model fitting up to the 12 week forecast horizon used in assessing model performance. D,
calibration - p values from a test of uniformity of the calibration at increasing forecast horizons
from 8th March (1-12 weeks). Lower p-value shows more evidence against the null hypothesis
that the model is well calibrated. E, sharpness - the ability of the model to generate predictions
within a narrow range of possible outcomes. Lower values are preferable. F, bias - unbiased
model with have a value of 0. D, E, and F. Black lines, null model. Red line, model including
pre-outbreak seroprevalence. Blue line, model jointly-fitted with DENV-3 2013-14 epidemic
of the simpler models systematically over-predicted the case burden (Figure 6.11F)
Having found that the joint-fitting model had superior forecast performance I wanted
to analyse the performance of this model with varying lead times for data availability.
My objective was to evaluate how early in the outbreak we could have provided a
reliable forecast of the 2017 DENV-2 outbreak. The epidemic take-off was slow in 2017.
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Two months after the first confirmed case, at the end of February, there were only 68
confirmed cases of DENV-2 (Figure 6.6). This slow emergence of the epidemic meant
that using data available up to February, we would have predicted that there would
likely be no epidemic (Figure 6.12A). In March the epidemic started to increase and
our forecast improved. Using data available up to 1st March 2017 we overestimated
the total size of the epidemic but accurately predicted that cases would decline by
July with good confidence (Figure 6.12B). As more data became available from April
through June, the overall conclusions of the forecasts did not change substantially but





























































Figure 6.12: Model forecast performance with increasing data used in model fitting. Model
forecasts used data up to 1st February 2017 (A) then 1st March (B), April (C), May (D),
June(E). Red line, DENV-2 case data used in model fitting. Black line, complete DENV-2
outbreak case data. Blue line, median model projection. Light region, 95% CrI. Dark region,
50% CrI
6.3.3 Summary of data available to assess interventions
When we were modelling the outbreak in real-time we provided two forecasts, one that
assumed no additional reduction in transmission due to interventions, and another that
assumed a 50% reduction (Figure 6.8). In the analysis of forecast performance I re-
moved any additional effect of interventions on transmission for simplicity. To better
analyse the role of public health interventions I collected detailed data on incidence,
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seroprevalence and entomological interventions during the DENV-2 outbreak from the
capital of Fiji, Suva, and neighbouring regions Nasinu and Nausori. I combined surveil-
lance and serological data with information on entomological interventions to model
outbreak dynamics in each of these five regions.
In follow-up serological studies conducted in November 2015 and June 2017 we were able
to recontact and recruit participants from all five regions for another sample collection.
In 2015 there were 153 samples collected from Suva, Nasinu and Nausori, and in 2017
we collected 123 samples. 82 participants were sampled in both years. Samples were
available at both time points from all regions. The sample size in Nasinu was the largest
in our study with 128 samples across both time-points, and it also saw a large estimated
increase in DENV-2 seroprevalence (as measured by MIA) between collection dates from
18% (95% CI: 11-29%) to 35% (95% CI: 22-49%). The seroprevalence pattern in CWM
is hard to estimate because only 6 samples were collected from this region in 2015 and
all were negative. Post-outbreak seroprevalence in CWM was comparable to the rest
of Suva. Estimates were also uncertain in Raiwaqa with the smallest sample size of 31
over both time periods (Table 6.1).
Table 6.1: Number of participants who were seropositive to DENV-2 as measured by MIA
in 2015 and 2017, divided by study area regions
2015 2017
Region Positive N % (95% CI) Positive N % (95% CI)
CWM 0 6 NA 4 17 24 (7.8–50)
Nasinu 14 76 18 (11–29) 18 52 35 (22–49)
Nuffield 3 28 11 (2.8–29) 4 15 27 (8.9–55)
Raiwaqa 4 15 27 (8.9–55) 4 16 25 (8.3–53)
Samabula 5 28 18 (6.8–38) 5 23 22 (8.3–44)
The location of cases in the data were defined according to the location of the health
centre/hospital where the case was reported. Unsurprisingly, most cases reported at the
largest hospital in Suva, CWM. The second largest case burden was in Nasinu/Nausori
and there were very few cases in Nuffield. In both Raiwaqa and Samabula, the more
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residential areas of Suva city, the case burden was small but the epidemic curve was
well defined in surveillance data. Overall, we had a detailed description of the outbreak
within each of the five study regions, allowing us to model the DENV-2 outbreak for
the area as a whole and in each of the five regions defined in this section (Figure 6.13).
6.3.4 Climate and herd immunity were not enough to recreate
epidemic dynamics
I modelled DENV transmission in Suva, Nasinu and Nausori by jointly fitting the
DENV transmission model to both 2017 DENV-2 surveillance and serological data,
and the 2013-14 DENV-3 outbreak. This model was able to reproduce the transmission
dynamics of DENV-2 in Suva, Nasinu and Nausori in 2017, and of DENV-3 in Central
Division in 2013-14 (Figure 6.14). For the 2017 DENV-2 outbreak the model captures
the dynamics of the outbreak well in terms of peak cases, peak timing and duration of
outbreak. The basic reproduction number (R0) was variable across the calendar year
because of the seasonal forcing in the model so I used the median R0 over one year
to compare values. Median R0 values were similar for both outbreaks, 1.4 (95% CrI:
0.93-1.78) for DENV-2 and 1.5 (95% CrI: 0.94-1.92) for DENV-3.
To capture any potential effect of vector control interventions the model included a
flexible function to capture any additional reduction in transmission separate from
immunity dynamics and seasonal forcing. The effect of interventions on transmission
was weaker in 2017 than it had been in 2013-2014 (Figure 6.14B and D). However, even
though our estimate for relative reduction in transmission was less precise in 2017 I still
found strong evidence of a non-zero effect. The estimated reduction in transmission
after interventions in 2017 was 36% (95% CrI: 31-42%). For the 2013-14 DENV-3
outbreak the estimated reduction in transmission from this model was 71% (95% CrI:
68-75%). The dynamics of the 2013-14 DENV-3 and 2017 DENV-2 epidemics were
different for several reasons. The DENV-3 epidemic was larger and peaked earlier
in the year and had a smaller susceptible population at the start off the outbreak.
This analysis suggests however that for both epidemics seasonal forcing in transmission
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Figure 6.13: Summary of all available data in each of the five study area regions. Black lines,
weekly reported cases of DENV-2 during the 2017 outbreak. Pink dots and lines, estimated
DENV-2 seroprevalence as measured by MIA in each region and 95% CI before the outbreak
(samples collected in November 2015) and at the tail end of the outbreak (June 2017). Green
lines indicate timing of vector control interventions in each region
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Figure 6.14: Impact of climate and control measures on DENV transmission during the
2017 DENV-2 outbreak (A, B) and 2013-14 DENV-3 outbreak (C, D), using a model that was
jointly fitted to both outbreaks. (A, C) Black lines, weekly reported DENV case totals. (A, C)
Blue line and region, median estimate from the jointly fitted model, 95% CrI (light region), and
50% CrI (dark region). (B, D) Green line and region, estimates of the effective reproduction
number (Rt). Pink line and region, estimated additional reduction in transmission potentially
as a result of vector control interventions which are shown with vertical pink lines
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intensity and increase in immunity during the outbreak were insufficient to fully explain
observed outbreak dynamics and an additional reduction in transmission better fits the
observed data.
I estimated the start of the reduction in transmission for the 2017 DENV-2 epidemic. I
put no constraints on this parameter because I wanted to analyse whether a reduction
in transmission coincided with the actual interventions over this period. I estimated
that the central point of the ‘control effect’ was 68 days (95% CrI: 56-87) after the
start of the outbreak. This means the estimated reduction in transmission in the model
is centred around early March 2017, which is between the two rounds of interventions
during the outbreak (Figure 6.14B). For the 2013-14 DENV-3 outbreak I limited the
start of any reduction in transmission to be after the clean-up campaign in March 2014
(Figure 6.14D).
I compared this model for Suva with another model without a ‘control effect’ using the
Deviance Information Criteria (DIC). A difference in DIC of >10 was considered as
evidence that the model with the lower DIC was better. A difference between 5 and
10 was considered borderline evidence and any difference less than 5 was considered
as no evidence that the models performed differently. The model without a ‘control
effect’ (Figure 6.15) had a higher DIC (1003) than the model with control (851). This
suggests that the inclusion of an additional reduction in transmission improved the
model fit. Without this additional ‘control effect’, the estimated peak of cases in Suva
in 2017 is later than the observed reported cases and the estimated seroprevalence
post-outbreak is greater than that observed in our study (Figure 6.15A). This model
comparison provides further evidence that, at a regional level, the additional reduction
in transmission on top of herd immunity and seasonal climate effects better captures
the observed transmission of the 2017 DENV-2 outbreak.
I estimated five parameters in the better performing model with a ‘control effect’ (Figure
6.14). I used multiple MCMC chains and all five parameter values converged such
that parameter estimates were normally distributed (Figure 6.16). From this model
I estimated that 14% (95% CrI: 9-19%) of Suva were DENV-2 immune at the start
of the outbreak, slightly lower than the estimate from serological data, 17% (95% CI:
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Figure 6.15: Estimated DENV transmission dynamics without any additional reduction in
transmission during the 2017 DENV-2 outbreak (A, B) and 2013-14 DENV-3 outbreak (C,
D), using a model that was jointly fitted to both outbreaks. (A, C) Black lines, weekly reported
DENV case totals. (A, C) Blue line and region, median estimate from the jointly fitted model,
95% CrI (light region), and 50% CrI (dark region). (B, D) Green line and region, estimates
of the effective reproduction number (Rt)
13-22%). I also estimated a lower reporting rate in 2017 of 1.8% (95% CrI: 1.2-2.5%)
compared to 2013-14 DENV-3, 24% (95% CrI: 17-40%).
6.3.5 There was no evidence that more interventions led to
different transmission dynamics between local regions
There was a lot of variability in the timing and intensity of vector control interventions
across the five regions of our study site. All regions were covered as part of the first
round of chemical spraying in February, but some were targeted more heavily than
others such as Raiwaqa which had 7 different spraying events before the end of February.
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Figure 6.16: Correlation between estimated parameters from full DENV transmission model.
The transmission rate was a global parameter (the same value for the 2017 DENV-2 and
2013-14 DENV-3 epidemic). All other parameters are from the 2017 DENV-2 model only.
Histograms show estimated parameter values
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By contrast, Nasinu saw more spraying in the second round in April compared to the
February interventions (Figure 6.4).
Due to these heterogeneous intervention strategies, I analysed whether different inter-
vention strategies were related to different transmission dynamics by running our model
in each of the five regions. Population data for each region were estimated from Fiji
census data collected in 2017. I fitted the model to outbreak data from the 2017 epi-
demic for each study region and the 2013-14 DENV-3 outbreak at the Division level
using an MCMC sampler. The likelihood for each step of the MCMC was the sum of
the likelihood for each study region and the DENV-3 outbreak.
I was able to recapture DENV transmission dynamics in all five regions in 2017 with
this model, as well as the 2013-14 DENV-3 epidemic (Figure 6.17). The model was
able to reproduce the observed temporal trend of cases and seroprevalence within each
of the five regions for the 2017 DENV-2 outbreak (Figure 6.17A-E), however estimates
were less precise than the previous model fitted to the region as a whole (Figure 6.14).
Results were more precise in locations with more data available such as CWM and
Nasinu. These results show that it was possible to recapture transmission dynamics in
smaller areas with our model which included seasonal forcing on DENV transmission
and a ‘control effect’ coinciding with interventions in each area.
The estimates for the effect of interventions on DENV transmission were imprecise.
Even with the combination of surveillance and serological data and jointly fitting the
2013-14 DENV-3 outbreak, there was not enough data to accurately characterise the
‘control effect’ in each region (Figure 6.18). There was a stronger signal for reduced
transmission in Nasinu (Figure 6.18B) and Raiwaqa (Figure 6.18D). In both these areas
I estimated a > 50% reduction in transmission when interventions were implemented.
There was no evidence of an additional reduction in transmission due to a ‘control
effect’ in CWM, the area with the most interventions and most cases. This could be
because CWM is the largest health centre in Suva and cases reported at this location
were from infections in other locations, so interventions in this area will have less of an
effect on reported cases in the area.
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F − 2013−14 DENV−3
Figure 6.17: Dynamics of DENV transmission in Central Division, Fiji. Transmission
dynamics in five regions of Suva during the 2017 DENV-2 epidemic (A-E), and the whole
region during the 2013-14 DENV-3 epidemic (F). Black lines, weekly reported DENV case
totals. Blue line and region, median estimate of reported cases from the model, 95% CrI (light
region), and 50% CrI (dark region). Red line and region, median and 95% CrI of estimated
of seroprevalence from the model. Red dots and vertical lines, estimated seroprevalence from
serological surveys conducted pre-outbreak and in June 2017
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Figure 6.18: Variable intervention strategies across the five regions which make up our
study area. Coloured regions and line show the 95% CrI and median estimate of the ‘control
effect’ (βbase in Equation 6.11). Transmission reduced relative to a baseline transmission
rate according to these functions in the model (a value of 0.5 is equivalent to a 50% lower
transmission rate at the corresponding time point). Vertical red lines show the number of
vector control interventions in each region
6.4 Discussion
In this study I analysed DENV outbreaks in 2013-14 and in 2017 by combining both
surveillance and serological data. The same model was used for two purposes; forecast-
ing outbreak dynamics in real-time and estimating the effect of interventions after the
outbreak. I found that we were able to accurately recreate outbreak dynamics in terms
of the number and timing of peak cases and the duration of the epidemic. As the 2017
outbreak emerged our model was able to accurately forecast the transmission dynamics
before the peak of the epidemic had occurred by jointly fitting to the early case data, an
estimate of pre-outbreak immunity and the full 2013-14 DENV-3 epidemic. This model
was able to help in outbreak response and could be used in the same way for future
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arbovirus outbreaks in Fiji. Additionally, using complete data after the DENV-2 out-
break I found that herd immunity and seasonal forcing of infection were not sufficient
to explain the size and timing of the outbreak for both of the 2013-14 or 2017 DENV
epidemics. I found evidence that an additional reduction in transmission was necessary
to accurately recapture the transmission dynamics of the outbreak. However, I was
unable to find conclusive results when analysing the relationship between interventions
and reductions in transmission across the Fijian capital city of Suva.
With a model that can characterise a DENV outbreak in Fiji I was able to predict
transmission dynamics accurately in real-time during the 2017 DENV-2 outbreak. The
DENV-2 outbreak started in January 2017 and the final cases were recorded in Septem-
ber with 755 confirmed cases in total. Our model was able to accurately predict the
scale and dynamics of the outbreak from as early as March 2017 when only 68 cases
had been reported. Our model results were used during the outbreak to inform the
response from the Ministry of Health to reduce uncertainty and fears that the outbreak
would grow to the scale of previous large DENV outbreaks in Fiji.
After the outbreak I found that the increase in herd immunity and the decrease in
transmission intensity as the temperature decreased in Fiji contributed to slowing the
spread of DENV-2. However, by including an additional reduction in transmission
in the model I was better able to recreate the 2017 DENV-2 transmission dynamics,
both in terms of the scale of the outbreak and the timing of the decline in confirmed
cases. These findings, combined with similar results from a modelling analysis of the
2013-14 DENV-3 outbreak, add to the very limited evidence base for the effectiveness of
public health interventions in Fiji during arbovirus outbreaks. For this study I collected
detailed data on incident cases, seroprevalence, and information on when and where
interventions on the adult vector population were implemented. Despite this amount of
data, I was unable to draw reliable conclusions when comparing transmission dynamics
in the different regions using our model. This study highlights how difficult it is to
accurately assess the effectiveness of interventions during an outbreak.
This study was heavily reliant on seroprevalence estimates in the Suva region, both
when assessing the performance of the real-time forecast and when evaluating the role
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of interventions in the outbreak. When looking at small regions within the Suva-Nausori
region sample sizes were small and as a result some of the estimates of seroprevalence
lack precision with wide confidence intervals. In addition, the timing of sera collection in
June 2017 is not ideal with an ongoing outbreak and our assay tested for the presence
of long term IgG antibodies against a variety of viruses. The potential for variable
antibody responses during an outbreak introducing uncertainty into our seroprevalence
estimates cannot be discounted. However, the model fitting should capture some of
this uncertainty since I included the seroprevalence estimates in our likelihood with a
binomial probability density. This means I was not reliant on a single point estimate
and more precise seroprevalence estimates – such as for the whole Suva-Nausori region
– will carry more weight in the model fitting than less precise estimates with wider
confidence intervals and less information.
Modelling during an outbreak is inherently limited by the rapid evolution of outbreaks.
People change their behaviours in response to an outbreak as they become aware of the
danger directly through public health campaigns or indirectly through news reports
(Bausch and Edmunds, 2018). This rapid evolution of outbreaks limits the conclusions
I could draw from this model of the 2017 DENV-2 outbreak. I concluded that the
outbreak was small – sera collected in June 2017 showed an estimated 28.9% (95% CI:
22-36.6%) of the population were seropositive – and that transmission slowed rapidly
in June 2017 (Figure 6.14). However, it is hard to separate the mechanisms by which
this was made possible. We know that herd immunity increased over the outbreak, that
transmission likely slowed as temperatures declined and that an additional reduction in
transmission best explains the observed dynamics. However, I was unable to separate
the effect of several simultaneous interventions such as chemical spraying, health seeking
behaviour in the community, people closing windows and wearing more insect repellent.
A key limitation is therefore that I am not inferring a causal relationship between
chemical spraying and a reduced burden of cases. Future research should be designed
proactively to assess the performance of different interventions before a DENV outbreak
in Fiji. This is especially important to get a baseline measure of effectiveness before
new interventions are introduced such as Wolbachia infected mosquitoes that cannot
transmit DENV when they bite a human (Lambrechts et al., 2015).
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In this study I chose a level of model simplicity that reflected the data we had avail-
able. I chose simple mechanisms to represent the effects of climate and interventions
in the transmission model. It is well established that there is a strong relationship be-
tween temperature and DENV transmission (Brady et al., 2014; Descloux et al., 2012).
In Suva, temperature typically fluctuates between a peak of 30°C and a low of 24°C
(Figure 6.9) and recent research showed that maximal DENV transmission from Aedes
aegypti occurs between 26-29°(Mordecai et al., 2017). As a result, I used a simple sine
wave to introduce seasonal forcing on DENV transmission. Similarly, because of the
lack of evidence on the effectiveness of interventions on DENV transmission in Fiji I
used a simple and flexible sigmoid function to capture any reduction in transmission
and did not specify which interventions these could be from. This function assumes
that any reduction occurs once, at a fixed rate to a diminished transmission rate from
which it does not recover during the outbreak. A more complex model which more
closely represents the reality of a mosquito-borne disease outbreak could deconstruct
the baseline transmission rate βH into component parts (Funk et al., 2016; Lourenço
et al., 2017; Pandey et al., 2013). However, I chose a more parsimonious approach
due to the lack of robust entomological data in Fiji which would have made estimating
more mosquito specific parameters a challenge. In both cases, these simpler mechanisms
seemed justified at the expense of realism. This was especially true since real-time fore-
cast results had to be communicated to an audience of decision makers mostly näıve to,
and occasionally sceptical of, the benefits of modelling disease outbreaks. In the case of
temperature and seasonal forcing, a more complex model incorporating daily changes
in temperature and humidity could have produced a more detailed mechanism but the
principle I wanted to capture was that transmission was not constant over the year
and this was achieved with the sine curve. Our work on the impact of interventions
demonstrates how hard the effectiveness of interventions is to measure at a population
level, let alone when trying to compare different strategies.
This study was unable to draw conclusions about differing levels of effectiveness from
heterogeneous intervention strategies in the Suva-Nausori region. The most likely lim-
itation in our data was the use of health care facility reporting as the location of a
case, not home address which was unavailable. As a result, the majority of cases (55%)
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were located in CWM however it seems unlikely that all cases reported at CWM were
infected in this region. This could potentially explain why I have a well-defined signal
for the additional reduction in transmission for the Suva-Nausori region as a whole but
not for individual regions within it. I was limited by ignoring the spatial component
of this outbreak and consequently our model assumed that the walls between the 5
defined regions were barriers that disease could not cross. While it seems likely that
infected mosquitoes would not travel far enough to blur these boundaries with a range
of 200m (Turell et al., 2005) it is likely that people – especially those seeking health
care – would travel out of their home region to report in a neighbouring region. This
highlights the need for more complete epidemiological data in routine surveillance, es-
pecially information on home residence and place of work or school so that it is possible
to more accurately infer the likely location of infection in future studies.
There are limitations in generalising the findings from this study and the approach
used. I clearly benefited from the availability of good quality representative serological
data. The study setting of Fiji, as an island state in the South Pacific with epidemic
outbreaks of arboviruses rather than ongoing endemic transmission, made characterising
population immunity simpler. The potential for cross-reaction in serological assays if
multiple virus were co-circulating at a high level would be greater in endemic regions.
This feature of distinct invasive outbreaks makes island states such as Fiji valuable for
research and hypothesis generation but limits the generalisability of conclusions from
such studies.
Assessing this study post-outbreak I identified an area of clear missed opportunity which
was to look at forecasting over a longer time period, even when the priority was the
short-term course of the 2017 outbreak. I had the model and the ability to test whether
re-emergence of DENV-2 was likely when temperatures increased. DENV transmission
did continue into 2018 (World Health Organisation, 2018), and our model could have
highlighted the risk of this happening which could have proved valuable. This highlights
the need to focus on the long-term, even when forecasting an outbreak and preoccupied
with the short-term predictions. As forecasting methods improve and the predictive
ability of modelling improves, we should answer more interesting questions in real-time.
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This study demonstrates the power of jointly fitting and combining data in model
fitting. In terms of real-time modelling, the forecasts produced if we fitted to 2017 real-
time data alone are much worse and estimate a larger outbreak. I included the 2013-14
outbreak in our model fitting and as a result borrowed information on certain common
parameters from these data. Even within a single outbreak, the value of including the
serological data is clear. An estimate of pre-outbreak population immunity sets realistic
initial conditions for the model. Estimating post-outbreak seroprevalence gives a strong
estimate of the size of the outbreak, which can improve parameter estimation in the
model. The joint fitting and combination of data in our model were essential in estab-
lishing an accurate and timely prediction of the outbreak and in untangling different
mechanisms that affected DENV transmission dynamics in post-outbreak analyses.
I collated a large amount of data for this study. I was able to estimate an additional
reduction in transmission when vector control interventions were implemented when
analysing Central Division. However, results on the effect of vector control interven-
tions at a finer spatial scale were inconclusive. There is very little evidence available
globally to demonstrate that current vector control tools such as fogging are effective
at reducing DENV incidence (Achee et al., 2015; Bowman et al., 2016; Heintze et al.,
2007). Guidelines are available to design a study to fill this evidence gap and suggest
that a cluster randomised control trial is an optimal study design (Wolbers et al., 2012).
These trials are expensive so I attempted to use modelling to analyse vector control
interventions in Fiji. This study demonstrates that even with good quality data from
multiple sources this is a very challenging application of modelling. The most notable
omission from my study was spatial data on home locations of reported cases. Recent
research has demonstrated that with fine scale spatial data on cases and interventions
it is possible to estimate the effect of interventions on local DENV transmission (Abdur
Rehman et al., 2020). Modelling will be a valuable tool in improving DENV control
(Ferguson, 2018) and it is important to test the effect of these interventions in real-
world settings. This study implies a baseline of data requirements to conduct such a
study. Data on seasonal factors, local immunity, infections, population size, and the
timing and location of interventions were insufficient to produce a reliable estimate of
the effect vector control. More accurate spatial data on the home location of cases is
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a necessity, information on work location and mobility for these individuals would be
beneficial. This is a large data burden but could still prove to be a more efficient route
to improving DENV control in Fiji compared to establishing a large trial.
Outbreak response can clearly benefit from having a good model prediction at the start
of the outbreak. In this study I demonstrated the value of embedding a modelling anal-
ysis in outbreak response to improve preparedness and most efficiently use resources.
Working closely with local health officials over the course of two DENV outbreaks in
2013-14 and 2017, we were able to collate good data and therefore predict the dynamics
of an emerging outbreak. The importance of evidence from a previous outbreak is clear
in this study so there are great benefits to be gained from making outbreak research
and previous forecasts accessible. Not only does this aid transparency but it has the
potential to improve future forecasting efforts.
Our study added to the very limited evidence base for the effectiveness of current
control measures in DENV. Especially in Fiji, there is a real question as to whether
these chemical spraying efforts provide value for money. Previous work had shown that
herd immunity and seasonal forcing alone could not recapture transmission dynamics in
the 2013-14 DENV-3 outbreak. Our results in this study corroborate the same finding
during the 2017 DENV-2 outbreak, adding to the evidence that interventions during
DENV outbreaks do help to reduce transmission. However, this remains indicative
and not proof of causality. Further, we do not know which intervention could reduce
transmission most effectively. In the short-term this supports current strategies for
outbreak control in Fiji. In the long-term, further study into current control strategies
should be conducted to differentiate the effects of different interventions on the vector
population and DENV transmission, especially as outbreaks become more frequent.
Through this study we have demonstrated the benefit of real-time modelling and the
effectiveness of combining data with a relatively simple model to predict outbreak dy-
namics. This study has also shown that vector control interventions are likely having
a negative effect on transmission in Fiji. In Fiji before this study there was extremely
limited information on the effectiveness of vector control and the trajectory of ongo-
ing outbreaks were not forecast. Through systematic incorporation of evidence from a
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previous outbreak and combination of multiple data sets, mathematical modelling can
help address both of these gaps.
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This research had two primary aims; the first was to improve the understanding of
population immune dynamics following arbovirus outbreaks. Secondly, to identify the
determinants of arbovirus transmission dynamics in island outbreaks. This aim led to
the following five objectives:
1. Conduct a serological survey in Fiji, resampling as many participants of previous
surveys in Central Division as possible
2. Analyse longitudinal serological data to determine the burden of ZIKV infection
in Fiji between 2013 and 2017
3. Evaluate the population level immune response to ZIKV from serological data
following outbreaks in Fiji and French Polynesia
4. Develop a mathematical model of arbovirus transmission and use it to explain
different transmission dynamics of recent arbovirus outbreaks in Fiji
5. Inform control strategies for DENV outbreaks in Fiji by estimating the effect of
vector control on DENV transmission
At the start of these studies Zika virus (ZIKV) was an emerging public health threat
and, in the absence of better information, the majority of mathematical models for
ZIKV transmission assumed that the virus acted similarly to dengue virus (DENV)
(Champagne et al., 2016; Ferguson et al., 2016; Funk et al., 2016; Kucharski et al.,
2016; Netto et al., 2017; O’Reilly et al., 2018). DENV and ZIKV share the same
primary vector (Musso and Gubler, 2016) and are antigenically similar (Priyamvada
et al., 2016). However, it was still unknown whether these viruses did result in simi-
lar immune dynamics in a population following an outbreak. Similarly, as arboviruses
including DENV, ZIKV and to a lesser degree chikungunya virus (CHIKV) began to
circulate more frequently in the Pacific over the past decade there was a pressing need
to understand the determinants of arbovirus outbreak dynamics. Outbreaks in the
region were often short, large, single-season epidemics (Cao-Lormeau et al., 2014b;
Dupont-Rouzeyrol et al., 2015; Lowe et al., 2018a; Roth et al., 2014), but there is in-
creasing evidence of persistent low level circulation over several years (Kama et al.,
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2019; Ruchusatsawat et al., 2019). The factors that determine these contrasting out-
break dynamics in Fiji and the wider Pacific are not well understood.
This doctoral project has demonstrated distinct differences in the immunological re-
sponse to outbreaks of both of these viruses in the Pacific. I found that ZIKV neutral-
ising responses waned in adults within two years of a ZIKV outbreak, whereas DENV
neutralising responses were maintained over the same time frame (Chapter 4). Overall,
I found a diverse range of outbreak dynamics across closely related arboviruses in the
same location which were revealed through a longitudinal seroepidemiological study
(Chapter 3).
The diverse range in dynamics on tropical islands were shown to be highly dependent
on the timing of the emergence of a virus. I developed a mathematical model that
showed that if ZIKV was introduced to Fiji earlier in the year then it could have caused
a large single season epidemic in Fiji, comparable to the 2013-14 DENV-3 epidemic
(Kucharski et al., 2018) or ZIKV outbreak in French Polynesia (Cao-Lormeau et al.,
2014b) (Chapter 5). Despite this range of outbreak dynamics, it was possible to reliably
and accurately forecast outbreaks in real-time by combining a mathematical model with
multiple data sources and knowledge from previous outbreaks (Chapter 6).
In Chapter 3 I presented an overview of a 2017 seroepidemiological data collection
study I led. My objective was to resample as many participants as possible from
previous serological surveys conducted in Fiji (Kama et al., 2019; Kucharski et al.,
2018; Lau et al., 2016; Watson et al., 2017). The study design was effective and we
successfully resampled 320 participants. Using these data I showed that seroprevalence
against DENV-1 was highest in Fiji, but that seroprevalence against ZIKV and CHIKV
remained low despite confirmed circulation of these viruses in 2016 (Kama et al., 2019).
By collating longitudinal samples between 2013 and 2017 from the same individuals
I was able to demonstrate the wide variety of serological dynamics in a population
against different circulating arboviruses during the study period. Seroprevalence by
MIA increased following outbreaks of CHIKV and DENV-2 between 2015 and 2017 but
seroprevalence declined for ZIKV despite recorded cases over the same period.
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This seroepidemiological study was designed to specifically focus on ZIKV seropreva-
lence in Fiji between 2013 and 2017 by analysing longitudinal serological data in Fiji to
determine the burden of ZIKV infections. Between 2013 and 2015 ZIKV seroprevalence
in Fiji had increased from 7% in 2013 to 22% in 2015 (Kama et al., 2019). In Chapter 3
I presented evidence that ZIKV seroprevalence as measured by MIA actually declined
in Fiji between 2015 and 2017 to 12.5%. The proportion of the Fijian population with
evidence of past ZIKV infection remained low, unlike other outbreaks of ZIKV in the
Pacific (Aubry et al., 2017a) and beyond (Flamand et al., 2019; Gallian et al., 2017;
Netto et al., 2017; Rodriguez-Barraquer et al., 2019; Zambrana et al., 2018). If the
three serological studies conducted in Fiji between 2013 and 2017 had been designed
as a cross-sectional studies then exploring the causes of this pattern of seroprevalence
would have been limited. Since both studies in 2015 and 2017 included the additional
complexity of re-contacting previous participants, I was able to analyse sera in the same
189 individuals in Fiji between 2013 and 2017.
Chapter 4 presented the results of an analysis of the three longitudinal serological
studies conducted in Fiji, combined with five cross-sectional serological surveys from
French Polynesia. The objective of this analysis was to evaluate the population level
immune response to ZIKV from serological data following outbreaks in both countries.
The main finding of this analysis was that seroprevalence declined in adults within
18 months of ZIKV transmission in each country. Seroprevalence in children in both
countries remained stable over the study period. A subset of samples collected in Fiji
were also tested for neutralising antibodies and we found that individual-level antibody
titres against ZIKV, as well as overall seroprevalence, decreased over time (Henderson
et al., 2020).
Chapter 5 presents the main mathematical model of arboviruses in this thesis. I used
the aforementioned serological data combined with surveillance and molecular data to
evaluate different transmission dynamics of recent arbovirus outbreaks in Fiji. In par-
ticular, I wanted to compare a large single-season epidemic of DENV-3 in 2013-14 with
the low level circulation of ZIKV between 2013 and 2017. I developed a mathematical
model that included information on seasonal variation in temperature, reduced trans-
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mission from a vector control campaign in March 2014 and estimated virus introduction
date from a phylogenetic analysis. I fitted this model to surveillance and serological
ZIKV data to evaluate the determinants of these diverse arbovirus outbreak dynamics.
I found that virus introduction date, combined with a strong seasonal forcing on trans-
mission, was sufficient to explain the diverse outbreak dynamics in Fiji. This analysis
can be used to define a period of high epidemic risk in Fiji.
In the final results chapter of this thesis, Chapter 6, I present results from a modelling
analysis of a DENV-2 outbreak in Fiji in 2017. The original objective of the study
presented in this chapter was to estimate the relative contribution of vector control in-
terventions during the outbreak on transmission. Previous research had found evidence
of reduced transmission intensity during a vector control campaign in Fiji in March
2014 (Kucharski et al., 2018). I aimed to take this research further by combining more
detailed information on the DENV-2 outbreak at a finer spatial resolution. I found ev-
idence that an additional reduction in transmission helped explain DENV-2 outbreak
dynamics in 2017 at a regional level but I found no evidence that stronger interventions
in local areas led to weaker transmission. This work added to the very limited evidence
base for vector control effectiveness in Fiji but more research is clearly needed to help
guide the most effective intervention strategy during arbovirus outbreaks.
While I was in Fiji during the 2017 seroepidemiological study the DENV-2 outbreak
was spreading and was a cause of concern for the Ministry of Health. I therefore used
this model of DENV transmission to provide real-time forecasts of the DENV outbreak
to help inform the public health intervention strategy used by the Ministry. After the
outbreak, I wanted to analyse how accurate this forecast was and how early in the
outbreak it would have provided a useful projection of the DENV outbreak dynamics.
The DENV-2 outbreak resulted in 755 confirmed cases between January and September
2017 in Suva, the capital of Fiji. In Chapter 6 I demonstrated that this model could
accurately predict the scale and dynamics of the DENV-2 outbreak from as early as
March 2017 when only 68 cases had been reported. I found that modelling could inform
and guide public policy during an outbreak, especially if the model is well calibrated




A major strength of this project is the serological data collected in Fiji between 2013
and 2017 and the fact that these data were population representative and collected
from the same individuals over time. The original study in 2013 collected a population
representative sample of individuals from Fiji. Most other ZIKV seroprevalence studies
are a result of convenience sampling which are more susceptible to biased estimates
(Gake et al., 2017; Gallian et al., 2017; Lozier et al., 2018; Netto et al., 2017). Through
systematic recontacting of participants in 2015 and 2017 we were able to maintain
the distribution in our sample in terms of key demographics, particularly age. As a
result I collated a longitudinal data set of population representative sera from the same
individuals with up to three measurements. The serological data strongly influenced the
size of the modelled outbreaks and without these data the plausible parameter space
in the model fitting would have been less constrained. The ZIKV model for example
would have estimated a larger ZIKV outbreak in a majority susceptible population
(Kucharski et al., 2016) and the DENV-2 estimates would have been less precise without
a baseline estimate of the proportion of residents of Suva that were immune at the start
of the outbreak. These longitudinal sera data were also combined with cross-sectional
serosurveys from French Polynesia to describe the population immune response to ZIKV
outbreaks in both countries. The data collected from French Polynesia were cross-
sectional so provided weaker evidence for the waning of ZIKV neutralising antibodies
over time, whereas the longitudinal data from Fiji facilitated analysis of changes in
neutralising antibody titres over time.
This project has shown how mathematical models can be used with multiple data
sources to infer underlying epidemiological and immunological dynamics, even in situ-
ations with imperfect data. The analyses in this thesis, especially in Chapter 5 about
outbreak dynamics of ZIKV in Fiji, are reliant on combining multiple data sets with a
mathematical model. Without this approach the potential to answer questions about
the diverse outbreak dynamics of ZIKV and DENV in Fiji would have been limited. For
example, I took two steps to facilitate this analysis and mitigate the limited available
surveillance data with just 16 cases of ZIKV confirmed in Central Division. Firstly
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I combined multiple data sets. The surveillance data suggested minimal ZIKV trans-
mission but serological data showed evidence of widespread ZIKV transmission, albeit
lower than other ZIKV outbreaks in the Pacific (Cao-Lormeau et al., 2014b; Duffy et al.,
2009; Funk et al., 2016). Combining these multiple data sources told us that a ZIKV
epidemic was likely missed in Fiji. Secondly, I used these multiple data sets in a math-
ematical model that explicitly modelled the mechanisms that affect arbovirus outbreak
dynamics. The results from this model showed evidence of when ZIKV infections, both
detected and undetected, spread most and defined a period of high epidemic risk in
Fiji. A theoretical model without data would have been able to propose hypotheses for
the diverse range of arbovirus dynamics in Fiji. However, the conclusions in this thesis
are drawn from models that were validated with real-world data. This project demon-
strates that even if one data source provides limited information, including another
data sources with a mathematical model can compensate for this.
The models used in this thesis have been used to evaluate outbreak dynamics, but
have also been empirically tested in real-time outbreak response. The aim of this
doctoral project was to better explain arbovirus outbreak dynamics in Fiji and the
wider Pacific. The test of my ability to characterise outbreak dynamics in Fiji was to
use the data in real-time to forecast the course of an arbovirus epidemic, which is what I
did during a DENV-2 outbreak in 2017 (Chapter 6). This demonstrated that this model
could provide valuable input in real-time, as well as used in post-outbreak analysis to
evaluate dynamics of the epidemic. I used the model to demonstrate that joint fitting
of the ongoing outbreak with a previous DENV outbreak was the key contributor to
successfully forecasting the outbreak. This leads to a clear recommendation that having
a well calibrated model for a particular disease can help forecast emerging outbreaks in
Fiji and beyond.
Finally, I have aimed to work in a transparent and reproducible manner throughout
this doctoral project. An attainable minimum standard in epidemiological research is
‘reproducibility’, whereby data and software are available to verify findings (Peng et al.,
2006). The gold standard for this is to make the data and code publicly available and
able to run the analysis on open source software (Peng, 2011). Data should be publicly
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available alongside analyses, while respecting the anonymity of study participants. De-
identified data from Fiji – all demographic and location data removed, except age –
have been made public when published (Henderson et al., 2020). This is not only
appropriate for validation of the findings in my research but maximises the value of
the data collected. Study participants in Fiji contributed a lot to our data collection
and if the data drawn from these studies are publicly available then this maximises
the potential usefulness of these data. I have benefited from publicly available ZIKV
sequences and it is possible that others will similarly benefit from the availability of the
data I have collected. Data and code have been made available on GitHub and all code
uses open source software R (R Development Core Team, 2011).
7.2 Limitations
The conclusions drawn in this thesis rely heavily on the quality of the serological data
collected in Fiji. Cross-reactivity of antibodies is a problem for all seroprevalence stud-
ies, especially studies of flaviviruses (Andrade and Harris, 2018; Beck et al., 2019; Keasey
et al., 2017; Mansfield et al., 2011). Serological cross-reaction of viruses imply the shar-
ing of closely related antigenic sites or epitopes (Calisher et al., 1989). As a result
of these close relationships antibodies acquired from natural infection with one virus
may bind to a different but related antigen in a serological test. This cross-reaction
can provide a false positive result and we assume that there has been more infection
with a particular virus in a population than actually occurred. The specificity of the
microsphere immunoassay (MIA) is greater than tests using enzyme linked immunosor-
bent assays (ELISAs) however cross-reaction is still a cause for concern (Beck et al.,
2015). This doctoral project consistently assumes that ZIKV circulated in Fiji between
2013 and 2015 because of an increase in seroprevalence (from MIA testing) from 7% to
22% (Kama et al., 2019). It is possible that the increased seroprevalence in 2015 was
a result of cross-reaction. This would imply that ZIKV seroprevalence did not wane
between 2015 and 2017, but that the assay results were more specific in 2017. However,
there were limited increases in DENV seroprevalence between 2013 and 2015, with the
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exception of DENV-3 because of a large outbreak (Chapter 3). Analysis of correla-
tion between changes in neutralisation titre between 2013 and 2015 in those initially
seronegative to any ZIKV or DENV showed no association between change in ZIKV
titre and any of the four DENV serotypes (Chapter 4). It is however unavoidable that
serological cross-reaction is a limitation for the analyses in this project. To account
for the problem when mathematical modelling I explicitly estimated the sensitivity
and specificity of the seroprevalence estimates in Chapter 5. Instead of comparing
the proportion infected in the model to the reported seroprevalence I calculated the
expected seroprevalence given the underlying “true” number of infections. Observed
seroprevalence was therefore compared to a proportion of those infected in the model
(sensitivity) plus a proportion of those not infected in the model (1 minus specificity.
From this model I estimated a false positive percentage and sensitivity of 6.3% (95%
CrI: 4.4–8.6%) and 79% (52–98%) for ZIKV. These results adjust for the inevitable un-
certainty in seroprevalence estimates when modelling arbovirus transmission dynamics
and were also consistent with the previously reported assay specificity and sensitivity
for ZIKV of 94.9% and 79.6% (Henderson et al., 2020). To validate results I have
analysed complimentary assays and examined seroprevalence trends within the same
participants. Through this work I am confident that the observed pattern of increasing
then decreasing ZIKV seroprevalence in Fiji is a result of real immunological dynamics
and not merely a function of the assays used.
A second problem with interpreting serological data is the uncertain relationship be-
tween a participant’s antibody response and how this correlates with protective im-
munity against that virus. A particular cutoff for positivity does not necessarily mean
that all those that test positive are immune and those that test negative are susceptible.
Therefore, relating a seroprevalence level in a population with immunity against that
virus is complicated. I observed a trend of declining seroprevalence as measured by
MIA in adults between 2015 and 2017 in Fiji but cannot conclude from this alone that
the majority of the population is susceptible to ZIKV infection. Collaborators in Tahiti
tested all 2017 samples with a plaque reduction neutralisation test (PRNT) so that we
could more directly relate our serological data to protective immunity. These results
showed that for ZIKV, neutralising antibodies (NAbs) declined between 2015 and 2017
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but that a significant proportion of the population still had high levels of NAbs in 2017
(log titre ≥ 2). Work on DENV suggests that there is a relationship with NAbs and
immunity with DENV (Katzelnick et al., 2016). We found that ZIKV NAbs waned
in adults between 2015 and 2017 but were still able to neutralise ZIKV. I therefore
included waning detectable ZIKV antibodies (from the recovered compartment) in my
model of ZIKV transmission but did not allow for reinfection within the study period
(Chapter 5). It is important to acknowledge the uncertainty in the connection between
seroprevalence and immunity. I have been careful throughout this thesis not to imply
that the low ZIKV seroprevalence in Fiji in 2017 implies that the close to 90% of the
country are susceptible to ZIKV infection. However, this is more of a limitation in how
far results can be extrapolated, not in the finding itself.
An additional limitation to the findings of this thesis is that more advanced methods
exist to analyse serological data than have been used in this project. Data augmentation
can be used to obtain probabilistic assessments of changes in titre values and whether
they are caused by actual infection or assay variability. This has been done effectively
in DENV serology using a haemagglutination-inhibition (HI) assay on blood samples
from a school-based cohort of 3,451 participants (Salje et al., 2018). It has previously
been shown that there is good agreement between HI assay titre values and PRNT
(Venturi et al., 2006). The seroprevalence estimates from MIA in this study did not
allow for this extended analysis because titre values were not stable enough. The process
used in the MIA results in an immunofluorescent (IF) reading even if there is no sera
in the well during the test. This IF measure is referred to as the ‘background’ and a
participant’s MIA value is their IF reading for a particular minus this background value.
This control step is essential to ensure that the IF reading for a particular virus is the
result of actual antibody binding not inflated or deflated because of the plate being
tested. However, this does mean that values are not stable and can be negative, which
when log transformed can lead to a loss of data. This issue makes comparisons of values
between samples much harder than handling titre values that are discretised, such as
PRNT. Our PRNT data was however limited by a smaller sample size than the MIA
data. In 2015 a subset of samples were tested with PRNT, mostly those positive by
MIA, so the longitudinal PRNT sample was too small to be robust enough to estimate
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infection times. Another limitation in both MIA and PRNT assays is the batch effect
where non-biological factors affect the data from these assays. Our data were sampled
at two different time-points as samples from 2013 and 2015 were analysed together, then
2017 samples were analysed two years later. These separate analyses could also have
introduced random error into our results that were not associated with the outbreak
dynamics.
A final major limitation in the serological survey data is potential sampling bias through
loss to follow-up over the five-year study period. The original study in 2013 was well
designed to be population representative however successfully resampling an individual
in follow-up studies was not completely random. Some demographic groups and loca-
tions in Fiji were going to be more difficult to resample in the 2017 survey. It is possible
therefore that trends in seroprevalence were a result of changing samples rather than
underlying transmission dynamics. I was conscious of this potential problem through-
out and when collecting 2017 samples I tracked the spatial and age distribution as data
were collected to try and collect as balanced a sample as possible. Even after this, it
is possible to calculate adjusted seroprevalence if a particular variable is of concern.
For example the unadjusted estimated ZIKV seroprevalence in 2017 was 12.5% (95%
CI: 9.1-16.6%) and, using weights from the 2013 survey, the estimated age-adjusted
seroprevalence was 12.1% (95% CI: 8.7-16.7%). We can repeat this process for rural-
ity, of particular interest in this study given the urban mosquito vector for ZIKV and
DENV. Estimated ZIKV seroprevalence in 2017 adjusted for rurality (using the distri-
bution from the 2013 sample) was 12.3% (95% CI: 8.8-16.8%). Doubtless the follow-up
surveys were not as representative of the population as the 2013 survey, but there was
no evidence that this bias was significant enough to change the findings of this study.
Where possible, as an additional step to mitigate this bias, I used a constant sample
over time of those participants sampled at each survey.
In addition to the limitations with the data in this thesis, there were limitations in
the modelling in this project. The major modelling analysis in this thesis analysed the
dynamics of unobserved ZIKV transmission in Fiji before cases were recorded in July
2015. This analysis rested on the assumption that there was one single introduction
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event. From this modelling I concluded that ZIKV was likely introduced in late 2014
and conclusions about waning ZIKV seroprevalence in Chapter 4 are affected by this
conclusion. There is evidence elsewhere that there were multiple introductions of ZIKV
(Griffin et al., 2019; Grubaugh et al., 2017, 2019), including in island settings (Black
et al., 2017). In Fiji, the three ZIKV sequences isolated in Central Division did not
form a distinct cluster in phylogenetic analysis (Kama et al., 2019). It is therefore
possible that there were multiple introduction events; an earlier one that failed to seed
a large outbreak, and a later one that led to the observed cases between 2015 and 2017.
However, there is clear evidence of a close relationship between two sequences isolated
in 2015 and 2016 in Central Division, consistent with persistence of the virus in the
same location. Separate introduction of the virus from the same location could also
explain this clustering. However there was further evidence that ZIKV spread at a low
level for multiple years in seroprevalence data between 2013 and 2015 which suggests
there was widespread transmission. To capture some of the uncertainty about the intro-
duction dynamics, I modelled ZIKV introductions as a flexible and continuous process
rather than relying on a single instantaneous introduction of infected individuals. This
function could capture the flow of infections to the model over several months, but
not several years. I concluded that there was sufficient evidence in the molecular and
serological data that ZIKV circulated at a low level after a single introduction event
and this is further supported by my modelling analysis, which fits the data well (Chap-
ter 5). All conclusions in this project about ZIKV transmission dynamics in Fiji rely
on the explicit assumption that there was one introduction event that seeded ZIKV
transmission in Fiji.
In the introduction to this thesis I outlined the trade-off at the heart of any modelling
strategy between transparency and detail. The models used in Chapters 5 and 6 were
designed to find a balance in this trade-off, but as a result they could also be criticised
for being both too complex or too simple. The finding with greatest direct impact from
these models was likely the ability to predict the course of an epidemic in real time in
2017, which could have been possible with a simpler model. There is a lot of research
into predicting DENV outbreaks from historic DENV incidence and climate data using
statistical models (Descloux et al., 2012; Hii et al., 2012; Johansson et al., 2016, 2019;
286
Mathematical Modelling of Arbovirus Outbreak Dynamics in Fiji and the Wider Pacific
Lowe et al., 2018b). These have proven very effective at predicting the burden and
timing of DENV outbreaks. It is fair to ask if the additional complexity I included
– building a compartmental model – was justified? While statistical models can be
very accurate for predicting case burden one of the aims of this research project was to
evaluate the determinants of different transmission dynamics. This meant that these
different drivers needed to be explicitly modelled. A key strength of this project was the
ability to actually estimate the contribution of different mechanisms, not just provide
approximate scenario analyses. For example, to estimate the relative contribution of a
targeted vector control campaign I needed to model this mechanism. I was also not able
to rely fully on one reliable source of data. I needed to combine multiple data sources
to model these outbreaks. Both the model design and model fitting process had to be
flexible enough to accommodate this, which is why I opted for a more complex model
structure.
The models used in this thesis were therefore complex enough to capture the mecha-
nisms of transmission but were still simple compartmental models. The simplicity in
the models did rely on several assumptions about outbreak dynamics, especially con-
cerning the mosquito population. I assumed that the mosquito population and biting
rate were constant and that mosquitoes and humans mixed homogeneously. More ex-
plicit modelling of the mosquito population, and interaction with humans, could have
improved model realism (Hladish et al., 2016). Modelling human behaviour is crucial
when modelling other diseases, especially respiratory infections (Danon et al., 2009;
Mossong et al., 2008; Munday et al., 2018; Read et al., 2014) and human movement
has an impact on arbovirus transmission as well, even at fine geographic scales (Adams
and Kapan, 2009; Salje et al., 2012). At larger spatial scales, movement of people glob-
ally could impact transmission dynamics (Brockmann and Helbing, 2013; Colizza et al.,
2006; Semenza et al., 2014; Tian et al., 2017). It is the omission of these spatial com-
ponents that likely limited the conclusions drawn from the modelling of vector control
effects on DENV-2 transmission in 2017 (Chapter 6). I could also have directly mod-
elled the impact of secondary DENV infections on the severity of infection and therefore
the probability of being recorded as a case of ZIKV or DENV (Andrade et al., 2019;
Cummings et al., 2005; Esteva and Vargas, 2003; Recker et al., 2009; Wikramaratna
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et al., 2010). However, I judged this to be an inefficient complication of the models
given the limited amount of available surveillance case data for DENV-2 in 2017 and
ZIKV between 2013 and 2017.
As explained above, designing the models used in this project inherently involved a
trade-off between detail and transparency. I believe these models present the best
balance to meet the objectives set out at the start of the project. The complexity was
needed to evaluate determinants of transmission dynamics. The simplicity of models
was mostly a result of data availability. This simplicity also helped when communicating
results with Ministry of Health officials in Fiji. It was important to be able to explain
why DENV-2 transmission was likely to be low in 2017 compared to DENV-3 in 2013-
14. By directly modelling the effect of seasonal forcing on transmission I could provide
projections and the rationale behind them.
A final limitation is how generalisable these findings are. One of the principal findings
of this work is that outbreak dynamics are heavily dependent on setting, population
immunity and the timing of the outbreak. Island outbreaks are an ideal study site
for modelling arbovirus transmission dynamics because of their unique isolation, small
population size and well characterised outbreak history. My work is not the first to
demonstrate the importance of setting on outbreak dynamics of DENV and ZIKV
(Funk et al., 2016). This project aimed to better understand island outbreak dynamics.
Further work is needed to extend these methods to other settings where the immunolog-
ical profile of the population is more complex, viruses transmit endemically or multiple
viruses transmit simultaneously.
7.3 Implications and future work
Long term immune dynamics for ZIKV
The first aim of this doctoral project was to improve understanding of population
immune dynamics following arbovirus outbreaks. The data I collected in Fiji provided
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early evidence that ZIKV-specific antibodies and ZIKV neutralising antibodies wane
in adults after a ZIKV epidemic. A recent study in Salvador, northeastern Brazil,
similarly found a rapid decline in ZIKV NS1 antigen-specific antibodies (Moreira-Soto
et al., 2020). This is important because this trend could continue to be observed in
other locations, particularly in the Americas where there were large ZIKV outbreaks
several years later than in Fiji and the wider Pacific. However, my results show that
seroprevalence estimates collected shortly after a ZIKV outbreak may underestimate
the true burden of ZIKV infection. If researchers then fit models to post-outbreak
seroprevalence data then this could lead to false conclusions about ZIKV dynamics.
These findings should also help dispel the notion that ZIKV “could be considered as a
fifth member of the DENV serocomplex” (Dejnirattisai et al., 2016). Despite similarities
between the two viruses ZIKV immunity following infection does not necessarily act in
the same way as DENV.
This doctoral project has demonstrated the advantage of collecting longitudinal sero-
logical data but more studies are needed to fully understand the immune response to
ZIKV, especially in the presence of co-circulating flaviviruses. I presented an indication
that waning ZIKV NAbs could be related to prior DENV exposure in Chapters 3 and
4. However, these results were inconclusive and further research is needed into this
area. Do those with more prior flavivirus infections lose ZIKV neutralising antibodies
faster? Does the reduction in quantity of NAbs affect immunity, or are the remaining
antibodies sufficient to protect from infection and disease? These were not questions I
was able to answer with the data collected in this study but carry large implications
on the likelihood and dynamic of future arbovirus outbreaks.
Efficiently combining data sources with mathematical modelling
Another novel aspect of this research is the framework I developed to include multiple
data sets and models into a model of ZIKV transmission dynamics in Fiji. Combining
multiple data sets in a model is not new (Birrell et al., 2011; Goubar et al., 2008;
Presanis et al., 2014; Sweeting et al., 2008; Welton and Ades, 2005) nor is the ability to
model outbreak dynamics from molecular data (Faria et al., 2016; Grenfell et al., 2004;
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Grubaugh et al., 2019; Jombart et al., 2014; Koelle et al., 2006, 2010; Ratmann et al.,
2012). However, conclusions on outbreak dynamics drawn from phylogenetic analysis
can have a wide range of uncertainty. For example, in the analysis of molecular data
in Chapter 5 the estimated time of ZIKV introduction to Fiji spanned a wide period.
Therefore, I developed a framework that could incorporate the uncertainty from the
phylogenetic analysis in an outbreak dynamic mathematical model as prior information.
Without this phylogenetic analysis, it was more difficult to differentiate between an early
ZIKV introduction with longer circulation at a lower level, or a later shorter epidemic.
By providing more information on the introduction time I was able to demonstrate clear
support for a later introduction of ZIKV to Fiji and demonstrate the marked effect that
virus introduction timing could have on transmission dynamics. This also demonstrated
the flexibility of mathematical models and the ability to combine multiple data sets.
Combining data was essential to this project but there is a lot of methodological work
that could be done into ensuring this process is efficient. Throughout this project I have
combined the log likelihood of surveillance and serological data when fitting models to
data. However, the contribution to the likelihood from seroprevalence data is much less
than the contribution from a time series of surveillance case data. A potential area of
future study would be whether this method is creating unbalanced contributions from
each of the data sets and whether a more efficient method is available. It would also
be interesting to investigate how best to fit a model to surveillance data when the start
time is of particular interest and is estimated in the model. We know that transmission
spreads before cases are reported, especially for novel infections. However, a model with
an earlier introduction date will be penalised more heavily than a later introduction,
since the model will estimate infections when no cases were reported. A method that
can test the effect of this potential bias and adjust for it could be valuable. Combining
data with mathematical models clearly has great potential but there are elements of
the process that would benefit through validation with simulation studies.
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Real-time modelling of arbovirus outbreaks
The importance of modelling in public health is growing, especially in outbreak response
(Bausch and Edmunds, 2018). In this project I have demonstrated how a relatively
simple model was able to make an important contribution to outbreak response to a
DENV-2 epidemic in Fiji. The fear at the onset of the epidemic was that the peak
would be as large as the 2013-14 DENV-3 epidemic. Using a simple model I was able to
provide evidence that transmission of the DENV-2 outbreak would likely be lower due
to seasonal forcing of DENV transmission in Fiji. This was a model simple enough for
me to run in the first year of my PhD and was able to support the government response
to an outbreak. The most important factor in the accuracy of the model predictions,
as demonstrated in Chapter 6, was the joint fitting with a previous DENV epidemic. I
think it is clear that if outbreak dynamics can be well characterised with a simple model
this can greatly improve real-time modelling accuracy if a new, comparable outbreak
emerges.
The biggest potential improvement to real-time modelling in Fiji and the wider Pacific
would be to better categorise the cycling of viruses in the region. I have said many times
throughout this thesis that arbovirus outbreaks in Fiji are becoming more common.
I have presented details of four outbreaks in Fiji between 2013 and 2017. Previous
perceived wisdom suggested for DENV there was a 4-5 year gap between outbreaks,
then a 12 year period before re-emergence of the same serotype (Cao-Lormeau et al.,
2014a). The question remains, is this pattern changing in the region? This is hard to say
but local data availability is improving which could help investigate this. Work has been
done in French Polynesia to characterise historic DENV infections since 1970 (Teissier
et al., 2020). The ability of collaborators at Institut Louis Malardé to diagnose viruses
from blood stored on filter paper from the region means there is an increasing data base
for circulating viruses in the Pacific (Aubry et al., 2012). This is already being used to
identify potential future outbreaks such as DENV-2 in French Polynesia, a prediction
in 2017 (Aubry et al., 2017b) that came to fruition in 2019 (Aubry et al., 2019). This
doctoral project has demonstrated the potential for combining multiple data sets with
mathematical modelling. It may be possible to learn how these arboviruses spread and
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interact with each other if novel data sets can be included in models for a variety of
locations across the Pacific.
7.4 Concluding remarks
I aimed to improve understanding of underlying serological dynamics and explain ar-
bovirus outbreak dynamics in Fiji and the wider Pacific using mathematical modelling.
There is much more to discover in this field, especially about how flavivirus infections
interact and affect the long-term immune response. It is clear from this analysis of sero-
logical data collected in Fiji and the wider Pacific that these interactions are complex
and that ZIKV does not necessarily cause the same long-term immune response in a
population following an outbreak as DENV. It is also evident from modelling transmis-
sion of these viruses that we can characterise outbreaks well enough to predict their
future dynamics in real-time, but that they are sensitive to a variety of factors that can
shape outbreak dynamics. A change as simple as the month of virus introduction could
have had a dramatic effect on the ensuing ZIKV outbreak dynamics in Fiji. Given
the uncertainty surrounding DENV and ZIKV transmission globally, island outbreaks
– combined with mathematical models – present a unique opportunity to gain insights
into these diseases.
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(Selecting individuals both agreeing further sample testing and further contact)  
Participant ID FJD CT££££  
 
First name:______________________ Family Name : ________________________________ Age: __________ 
 
Part	B:	Visit	record	sheet	






Circle:	1=yes 0=no, -1=don’t know, -2=refused 
 
Have	you	visited	a	doctor	with	a	fever	in	the	last	2	years?	
Circle:	1=yes 0=no, -1=don’t know, -2=refused 
 
Have	you	had	a	rash	in	the	last	2	years?		
Circle:	1=yes 0=no, -1=don’t know, -2=refused 
 
Have	you	visited	a	doctor	with	a	rash	in	the	last	2	years?	












When? Year	(-1=don’t know)	 	 	 	
Month,	if	known	(-1=don’t know)	 	 	 	
Did	the	doctor	suspect	it	was	zika?		
1=yes,   0=no,   -1=don’t know,   -2=refused	
	 	 	
Did	the	doctor	suspect	it	was	dengue	
fever?	1=yes,   0=no,   -1=don’t know,   -2=refused	
	 	 	
Did	the	doctor	do	a	blood	test	for	zika?	 	 	 	
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1=yes,   0=no,   -1=don’t know,   -2=refused	
Did	the	doctor	do	a	blood	test	for	dengue	
fever?	1=yes,   0=no,   -1=don’t know,   -2=refused	
	 	 	
Was	the	blood	test	positive	for	zika?				
1=yes 0=no, -1=don’t know, -2=refused	
	 	 	
Was	the	blood	test	positive	for	dengue	
fever?			1=yes 0=no, -1=don’t know, -2=refused	
	 	 	
Were	you	hospitalised?						1=yes 0=no	 	 	 	
	
Have	any	household	members	visited	a	doctor	with	a	fever	and	rash	in	the	last	2	years?	
Circle:	1=yes 0=no, -1=don’t know, -2=refused 
	
If	YES,	give	details	of	most	recent	episode	(for	up	to	3	household	members)	
	 Member	1	 Member	2	 Member	3	
That	person’s	age	now	 	 	 	
When? Year	(-1=don’t know) 	 	 	
Month,	if	known	(-1=don’t know)	 	 	 	
Did	the	doctor	suspect	it	was	zika?		




1=yes,   0=no,   -1=don’t know,   -2=refused	
	 	 	
Did	the	doctor	do	a	blood	test	for	zika?	




1=yes,   0=no,   -1=don’t know,   -2=refused	
	 	 	
Was	the	blood	test	positive	for	zika?				
1=yes 0=no, -1=don’t know, -2=refused	
	 	 	
Was	the	blood	test	positive	for	dengue	







Item	 Yes	 No	 Could	not	find	
out	
Mosquitoes	 	 	 	
Used	car	tires	 	 	 	
Open	water	containers	(e.g.	vase,	bucket,	basin,	oil	 	 	 	
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GPS coordinates of 1= front door of house,   2= community centroid, 
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